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ABSTRACT 
CD4+ T-cells play a pivotal role within the immune response, and multiple studies have 
highlighted their importance in anti-tumour immunity. TCR gene transfer is a successful 
method of specifically redirecting T-cell specificity. We have therefore investigated the anti-
tumour potential of EBV-specific MHC class II restricted T-cells, generated by this approach. 
We have identified and cloned a DR52b-restricted TCR, specific for an EBNA2 derived 
peptide (PRS), which is expressed in Post-Transplant Lymphoproliferative Disease (PTLD) 
and some other EBV-associated malignancies.  
We have shown that the TCR is functional in both CD4+ and CD8+ T-cells, with transduced 
T-cells specifically recognising the PRS-peptide with a high avidity. Transduced T-cells have 
been shown to proliferate, produce multiple cytokines and have direct cytotoxic capacity in 
response to physiological levels of EBNA2 processed and presented by EBV-infected B-cells. 
Additionally to this direct response, CD4+ T-cells retain helper functions. Importantly, 
transduced T-cells have shown hints of tumour control in vivo.  
Results from this study highlight that TCR gene transfer with EBV-specific MHC class II-
restricted TCRs can generate polyclonal T-cells with functional capacity against virus-
infected cells. PRS specific TCR gene transfer may thus be useful in rapid generation of T-
cells for treatment of PTLD. Given the importance of CD4+ T-cells for anti-tumour 
responses, this study also highlights the potential for using TCR gene transfer to target these 
cells towards other MHC class II-positive tumours.  
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CHAPTER 1 
1 INTRODUCTION 
That the immune system is naturally capable of recognising and eliminating tumours was first 
proposed  just over 100 years ago by Paul Ehrlich [1].  From this evolved the cancer 
immunosurveillance hypothesis in 1957, when Burnett and Thomas identified spontaneous 
regression of syngeneically transplanted tumours in mice [2]. This hypothesis stated that the 
immune system could destroy cancer cells, providing they displayed an altered antigenic 
repertoire.  Then followed the notion that the immune system can be enhanced to improve the 
anti-cancer response. In fact, William Coley first attempted to treat malignancies using the 
immune system in 1893 by stimulating the host’s immune system after observing cancer 
regression in a patient who experienced multiple bacterial infections [3]. Immunotherapy for 
cancer is now a rapidly growing area of clinical research, with numerous reports of successful 
trials of immunotherapy in multiple cancer types. This growth is due to the technological 
advancements within immunology and molecular biology fields. Indeed, highlighting the 
success of this area was the declaration by the journal Science that Cancer Immunotherapy 
was the Breakthrough of the Year 2013. 
1.1 The Human Immune System 
As immunotherapies are based upon the immune system, we must have knowledge of this 
system prior to designing an effective immunotherapy. The immune system comprises the 
innate and adaptive systems and these will be discussed individually below. 
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1.1.1 Innate Immunity 
The purpose of the innate response is to respond rapidly to invading pathogens. There are 
multiple components of the innate immune response, including epithelial barriers, anti-
microbial substances and blood proteins, such as the complement system. Additionally, the 
innate immune response includes phagocytic leukocytes such as eosonophils, neutrophils, 
basophils and macrophages, dendritic cells (DCs) and the cytotoxic leukocytes natural killer 
(NK) cells [4].  These ‘first-on-scene’ cells respond quickly to shared features of pathogens 
(pathogen associated molecular patterns; PAMPs) or damaged self-cells (danger associated 
molecular patterns; DAMPs) [5]. Innate cells recognise these PAMPs and DAMPs through 
pattern recognition receptors such as Toll Like Receptors, and upon receptor binding, innate 
cells are stimulated to phagocytose or lyse target T-cells and pathogens and to activate an 
inflammatory response [6]. Phagocytic leukocytes phagocytose pathogens as well as infected 
or damaged cells. DCs process and present antigenic material to adaptive immune cells (see 
below), priming them for response [7]. NK cells recognise signals associated with aberrant 
cells such as MHC class I down-regulation and up-regulation of MHC class I chain related 
(MIC) molecules MICA and MICB. They respond by killing target T-cells and releasing 
cytokines [8].  
1.1.2 Adaptive Immunity 
The innate response is stimulated almost instantly after pathogenic infection.  Whilst 
responding directly to the pathogen, this response also activates the adaptive immune 
response. This allows both systems to work in synergy to respond effectively to primary 
infection and to protect the body from subsequent invasions. Adaptive immune cells include 
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B- and T-cells. Each cell is tailored to target a specific antigen and thus for an effective 
response to be generated, the B- and T-cells which recognise the antigens present must first 
undergo activation and clonal expansion. Therefore the adaptive response is a delayed one. 
Once activated, these cells directly kill or induce the killing of infected cells. Target specific 
B-cells produce and secrete antibodies and cytokines in response to infection. Antibodies 
function by binding to their targets and inducing phagocytosis of the target T-cell and by 
antibody dependent cell-mediated cytotoxicity (ADCC).   Following adaptive responses to 
infection, a proportion of B- and T- cells will differentiate into memory cells. Memory cells 
are maintained at a higher precursor frequency than their original parent clone and are able to 
function more rapidly upon re-encounter with target antigens. As such they provide a more 
rapid and magnified immune response upon secondary exposure to that antigen. As this thesis 
focuses on T-cell-based therapies for cancer, I shall focus on this immune cell type herein.  
1.1.3  T-cells 
1.1.4  T-cell receptors 
T-cells recognise processed target antigens presented at the cell surface in Major 
Histocompatability Complex (MHC) molecules through their T-cell Receptors (TCRs). They 
respond by killing the cells and/or producing cytokines to activate a broad immune response. 
As T-cells recognise targets solely through their TCRs, the generation of TCRs is a critical 
step in T-cell development.  
There are two main subtypes of T-cells, distinguished by the type of TCR genes expressed. T-
cells can express TCRs generated from gamma and delta (γδ), or alpha and beta (αβ) TCR 
genes. All TCR chains are generated through a series of somatic gene rearrangements. The α 
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chain genes are generated by the rearrangement of DNA at the TCRα loci, which contain 
multiple variable (V), joining (J) and constant (C) gene segments. The TCRβ loci consists of 
these V, J and C gene segments but also has multiple diversity (D) gene segments, which 
increase the heterogeneity of the TCRβ chains (Figure 1.1) [9]. Somatic rearrangement results 
in the joining of one of each gene segment to form complete α and β chain genes.  The 
number of V, J, D and C gene segments make TCRs highly heterogeneous. Random 
nucleotide insertion or mutation between the V, D and J gene segments further increases this 
heterogeneity. The most variable regions in the TCR chains are referred to as 
complementarity determining regions (CDRs 1, 2 and 3), with CDR3 being the most variable 
of all. It is these variable regions that determine the antigenic specificity of the TCR [10].   
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Figure 1.1 TCR gene rearrangement.  
Alpha and Beta TCR genes are somatically rearranged in the thymus. Taken from The 
Immune System, 3ed. (© Garland Science 2009). 
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Each TCR has six highly variable CDRs located in the membrane-distal area of the TCR, 
where it interacts with peptide presented in MHC (p-MHC). TCRs also have more conserved 
areas, which form interactions with the MHC – which in humans is also termed Human 
Leukocyte Antigen (HLA) (Figure 1.2) [11]. 
 
Figure 1.2 Diagram of TCR p-MHC interaction.  
The alpha and beta chain of the TCR bind to the p-MHC complex, with the CDRs making the 
most interactions. A) Schematic view of alpha and beta TCR chains with colour coded CDRs 
B) illustration of how the TCR binds to p-MHC. The colours are in accordance to A). 
Adapted from [12] 
 
CHAPTER 1  Introduction 
30 
 
TCR heterogeneity theoretically allows for the generation of  approximately 1018 unique 
TCRs [13]. However, this is an overestimation, as some gene segments are not found in 
combination with each other. Furthermore, the number of TCRs in any one human is lower 
than this as the majority of TCRs are unable to pass successfully through central and 
peripheral tolerance (described below). Therefore, it is estimated that the average number of 
unique TCRs in one individual is 25x106 [14]. This large TCR repertoire enables recognition 
of a vast number of epitopes, allowing the host to respond to the array of foreign pathogens 
and antigens encountered through the course of life.  
1.1.5 TCR subtypes 
Of the two main subtypes of T-cells, γδ TCRs recognise non-peptide targets such as 
pyrophosphate antigens and lipids, and reside mainly in tissues such as the gut and skin [15]. 
As many γδ TCR targets are expressed on tumour cells, this subset is under investigation for 
its immunotherapeutic potential. The majority of TCRs expressed on T-cells in the peripheral 
blood are generated from α and β TCR genes, and recognise peptides presented on MHC. A 
small proportion of αβ TCRs recognise glycolipids presented through MHC-like CD1 
proteins, or bacterial metabolites, presented through MHC-related protein 1 (MR1) [16-18]. 
This thesis focuses on αβ TCRs which recognise peptide presented in MHC complexes, and 
therefore this will be explained in greater detail.  
1.1.6 Antigen presentation 
Antigen Presenting Cells (APCs) and target T-cells present antigen through MHC. Every 
individual inherits up to fourteen MHC (HLA) genes. HLA alleles are highly polymorphic, 
with approximately 9500 MHC class I alleles and 3000 MHC class II alleles identified as of 
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April 2015 (see http://hla.alleles.org/).  Each allele can present a range of peptides, providing 
the peptides are the correct size and sequence to bind the peptide binding groove. The number 
of potential antigens that could be presented through MHC class I or MHC class II greatly 
exceeds the number of TCRs in the human repertoire. Therefore, T-cells have evolved to be 
able to recognise multiple peptides of similar shapes, due to TCR flexibility [19]. This cross 
reactivity allows high coverage of potential non-self antigens [13].  
1.1.7 MHC class I antigen presentation 
MHC class I genes are ubiquitously expressed in nucleated cells and present endogenous 
antigen to CD8+ T-cells. Endogenous proteins are degraded in the cytoplasm by proteasomes 
and transported into the endoplasmic reticulum (ER) by the transporter associated with 
antigen presentation (TAP) protein. Here the chaperone protein tapasin directs peptides into 
the MHC class I peptide binding grove. This p-MHC complex can then be transported to the 
cell surface.  
It is also possible for MHC class  I to present exogenous antigen acquired by the cell to CD8+ 
T-cells through cross priming [20].  
1.1.8 MHC class II presentation of exogenous antigen 
MHC class II alleles are constitutively expressed on professional APCs (DCs, monocytes and 
B-cells), thymic epithelium and activated T-cells, and can be expressed on other cell types 
when stimulated by interferon gamma (IFNγ) [21, 22]. In general, MHC class II presents 
exogenous antigen to CD4+ T-cells.  
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Through endocytosis, macropinocytosis and phagocytosis, proteins are taken up by APCs and 
enter cytosolic vesicles. Here, proteins are degraded into peptides by proteinases.  
MHC complexes are translated in the endoplasmic reticulum (ER) and transported into the 
golgi by the aid of the chaperone protein, invariant chain (Ii). This binds to the MHC complex 
in the peptide binding groove in order to prevent MHC associations with peptides present in 
the ER [23]. From the golgi, they are sorted into endosomes and lysosomes which contain the 
degraded exogenous proteins [24]. Ii is then proteolytically degraded, leaving a small 
fragment (The Ii-derived class II invariant chain peptide (CLIP)) in the peptide binding 
groove [25]. This is removed in conditions of low pH by the class II -like chaperone HLA-
DM. DM facilitates peptide exchange by stabilising the empty MHC class II complex [26]. 
Depending on their amino acid sequence, peptides are then able to bind to the MHC class II 
peptide-binding groove, and p-MHC complexes are transported to the cell surface for 
interaction with CD4+ T-cells (Figure 1.3). 
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Figure 1.3 Exogenous antigen is processed and presented to CD4+ T-cells in MHC 
class II complexes. 
MHC class II is assembled in the ER and translocates through the Golgi to endosomes 
containing exogenous proteins. Here, Invariant chain is removed from the peptide binding 
groove and replaced by foreign peptides. The peptide-MHC complex is directed to the 
plasma membrane for surface expression.  Figure taken from [27]. 
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1.1.9 MHC class II presentation of endogenous antigen 
In some cases, endogenous antigen derived from  nuclear or cytoplasmic proteins can also be 
processed for presentation to CD4+ T-cells through MHC class II [28]. In fact, up to 20% of 
antigens presented in MHC class II are derived from endogenous proteins [29]. Cells that 
express MHC class II can thus directly present endogenous proteins to CD4+ T-cells, 
providing these proteins enter the MHC class II processing pathway.  
Endogenous antigens derived from self, tumour and viral proteins have been shown to access 
this pathway through different mechanisms. Firstly, endogenous proteins that naturally reside 
in the ER can be identified in MHC class II complexes [30]. Autophagy is another mechanism 
that results in MHC class II presentation of endogenous cytoplasmic (and less efficiently 
nuclear) antigens [29, 31-33]. Autophagy is the process of the cell sequestering part of it’s 
cytoplasm in vesicles. These fuse to lysosomes, thereby transferring cellular contents to the 
same location as MHC class II [33]. Additionally, plasma membrane proteins that are 
internalised from the cell surface can enter endosomes. Here they are degraded and resulting 
peptides can bind to MHC class II [34]. Finally, if the infected or diseased cell is an APC, it 
can phagocytose neighbouring infected or diseased cells, or indeed uptake released antigen. 
This intercellular antigen transfer allows for cross presentation of antigens to CD4+ T-cells 
[35]. 
1.1.10 T-cell development 
Before T-cells can respond to cells presenting their cognate p-MHC complexes, they must 
develop into functional naïve cells. T-cells are derived from hematopoietic progenitor cells 
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(HPCs). These cells are produced in the bone marrow and those which migrate to the thymus 
undergo T-cell maturation to develop into mature, naïve T-cells.  
Through T-cell maturation T-cells differentiate into one of two lineages, and are distinguished 
by the presence of co-receptors CD4 and CD8. Following their identification, these subsets 
were attributed different functional characteristics. However following further investigation it 
is now clear that CD4+ and CD8+ T-cells are capable of producing similar functional 
responses, albeit with different efficiencies. Following priming by DCs (discussed below), 
CD8+ T-cells recognise target T-cells presenting antigen. This stimulates a cytotoxic effector 
response, resulting in target T-cell killing. CD4+ T-cells recognise APCs presenting cognate 
antigen and respond by producing cytokines to provide “help” to CD8+ T-cells and other 
arms of the adaptive and innate immune system. CD8+ T-cells have classically been 
considered the T-cell subset that mediates anti-tumour responses. However the role of CD4+ 
T-cells in this setting, and indeed the role of individual CD4+ subtypes, has been shown to be 
much more significant than originally considered.   
During T-cell maturation, hematopoietic precursors enter the thymus and develop as they pass 
through the outer cortex, inner cortex and finally into the medulla [36]. T-cell maturation 
involves the expression of genes required for function such as TCR and co-receptor genes, 
and selection of those T-cells which are both functional and not auto-reactive. 
Initially in T-cell maturation, no CD4 or CD8 co-stimulatory molecules are expressed (double 
negative T-cells). Expression of CD4 and CD8 ensues  and these double positive T-cells  
interact with thymic cortical epithelial cells (TECs) which express self-antigens through  
MHC class I and II [37]. TECs express the transcription factor AIRE. This transcription factor 
induces the expression of genes which are normally expressed in a tissue dependent manner, 
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to ensure that mature T-cells are tolerant to antigens they will contact throughout the body 
[38].  Maturation into CD8 or CD4 single positive T-cells depends on whether the cells 
recognise antigens presented in MHC class I or II complexes, respectively. Through the 
process of positive selection, all T-cells which bind to MHC class I or II receive a survival 
signal. T-cells which do not bind receive no such signal and enter apoptosis [39].  Single 
positive T-cells are next subjected to negative selection in the medulla. Here, CD4+ or CD8+ 
T-cells interact with thymic epithelial cells expressing self-antigen. Any T-cells which bind to 
self-antigens with a high avidity receive an apoptosis signal and are deleted, or mature into 
regulatory T-cells (Tregs) [40].  Cells that survive both rounds of selection in the thymus 
leave the thymus to circulate the periphery as mature, naïve T-cells. Here, T-cells are 
subjected to peripheral tolerance. If a T-cell recognises a self-antigen that is not expressed in 
the thymus, in the absence of co-stimulation it will become tolerised and thus unable to 
respond to the presenting cell [41].  
1.1.11 T-cell target priming 
Naïve T-cells are primed for action upon encounter with professional APCs – such as DCs.  
DCs uptake antigen in infected tissues and migrate to lymph nodes. Here, they present antigen 
to naïve T-cells and provide the co-stimulation required for T-cell activation (see below). 
Primed CD8+ T-cells will then mature into effector cells and leave the lymph nodes to 
encounter and respond to target T-cells. Primed naïve CD4+  T-cells will differentiate into 
different T-cell subsets with different effector functions, depending upon the surrounding 
environment at the time of activation (Figure 1.4) [42]. This differentiation drives T-cells to 
perform a diverse array of immunological functions. As well as inducing differentiation, T-
cell priming results in up-regulation of activation markers and an enhanced potential for 
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cytokine production and proliferation in CD4+ and CD8+ T-cells [43]. Together, this ensures 
that T-cells are ready to respond following further encounters with their cognate antigen.  
 
Figure 1.4. CD4+ T-cell subtypes.  
Naive T-cells differentiate into different T-cell subtypes depending on the conditions in which 
they were primed. Different cytokines drive the activation of different transcription factors, 
which are responsible for the gene expression changes that drive T-cell differentiation. T-cell 
subtypes have differing effector functions. Adapted from [44]. 
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1.1.12 T-cell activation 
When T-cells form interactions with target T-cells presenting their cognate antigen after being 
primed for response, they become activated to respond.  
T-cell activation involves a huge number of proteins translocating to the area of the plasma 
membrane which is closest to the target T-cell to form an immunosynapse. These proteins 
work in synergy in the T-cell/target T-cell immunosynapse, to allow for recognition and 
response to antigen (Figure 1.5). The most central region of the immunosynapse contains 
TCR complexes. These complexes consist of TCRs and CD3 co-receptor proteins, which are 
essential for T-cell activation. Additionally, co-receptors CD4 and CD8 form part of the TCR 
complex. When a TCR interacts with its target p-MHC complex, the CD4 or CD8 co-receptor 
will interact with the MHC allele, in order to potentiate antigen driven stimulation by 
stabilising interactions and recruiting signalling molecules [45].  
For T-cell responses, TCRs need to bind to specific p-MHC complexes and co-stimulation 
must be present. Co-stimulation is required to enhance cytokine production in response to T-
cell activation, increase proliferation and prevent anergy (which will render the cell 
unresponsive to secondary antigen encounters) [46, 47]. CD28 is a potent co-stimulatory 
molecule. It is expressed on T-cells and binds to CD80 or CD86 on target T-cells. Binding 
results in downstream T-cell signalling pathways to enhance T-cell activation [48]. Activated 
T-cells then upregulate surface expression of the co-inhibitory molecule cytotoxic T-
lymphocyte associated protein 4 (CTLA-4). CTLA-4 is a CD28 homologue that binds to 
CD80 and CD86 with a tenfold higher affinity than CD28, and signals to inhibit T-cell 
activation [49]. This provides a negative feedback loop to prevent over-activation. Whilst 
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there are other co-stimulatory molecules, they are beyond the scope of this thesis and will not 
be discussed here. 
Providing the TCR is specific for the p-MHC complex bound and the T-cell receives co-
stimulation, cytoskeletal rearrangements allow for the directed translocation of multiple 
signalling molecules required for cell-cell adhesion and T-cell activation. This results in a 
supra-molecular activation complex (SMAC), in which numerous TCRs and costimulatory 
molecules reside [50]. When TCRs bind to their target p-MHC, conformational changes in 
CD3 result in the phosphorylation of CD3 immunoreceptor tyrosine based activation motifs 
(ITAMs). These phosphorylated regions provide docking and interaction sites for downstream 
src-related signalling molecules Lck and Fyn. These molecules activate the protein tyrosine 
kinase ZAP-70, in order to amplify the signalling response [51]. These interactions lead to the 
activation of a wide variety of downstream pathways, including the Extracellular Signal 
Regulated Kinase (ERK) and c-Jun N-terminal Kinase (JNK) pathways [51]. Additionally, 
signalling leads to calcium influx which, with the signalling pathways, results in the 
translocation of transcription factors such as Nuclear Factor kappa-light-chain-enhancer of 
activated B-cells (NFκB) and Nuclear Factor of Activated T-Cells (NFAT) to the nucleus. 
These transcription factors initialise transcription of many T-cell activation related genes. 
This regulates effector functions such as proliferation, differentiation and cytokine production 
etc. [52].  
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Figure 1.5. T-cell activation.  
TCRs, in combination with CD3 molecules, drive signalling through the T-cell to activate 
numerous downstream signalling pathways and calcium influx, leading to changes in gene 
expression (adapted from [53]). 
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1.2 CD4+ T-cells and cancer  
This thesis explores the potential of MHC class II restricted TCRs for the treatment of cancer. 
Whereas this T-cell subset was initially thought to only provide helper functions to other 
immune cells, there is now ample evidence that these cells are also capable of direct cytotoxic 
responses towards their targets, which include tumour antigens. Here I will consider these 
functions in relation to cancer immunology.  
1.2.1 Immune surveillance and defence against cancer 
The interplay between the immune system and cancer has been summarised in the 
immunoediting model. This model takes into consideration the paradoxical effects that the 
immune system has on tumour development. The immune response both sculpts tumour 
development by pressuring tumour cells to be less immunogenic, and prevents tumour 
development by killing tumour cells [54]. The three processes of immunoediting are described 
with three E’s: elimination, equilibrium and escape.     
Elimination is the immune mediated destruction of tumour cells. Both innate and adaptive 
arms of the immune system work in synergy to destroy transformed cells which are 
recognised due to tumour associated antigens being displayed on the cell surface. Pivotal 
work in this field was performed after the generation of Recombination Activating Gene 
(RAG) knock-out mice. As the RAG gene is responsible for the activation of TCR and B-cell 
Receptor (BCR) recombination, these mice lack T- and B-cells [55]. RAG-/- mice injected 
with chemical carcinogens form tumours faster that their wild type controls. This suggests 
that in the wild type mice, lymphoid cells are controlling tumour outgrowth, with the absence 
of clinical symptoms [56]. Spontaneously developed tumours are similarly eliminated by wild 
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type mice more efficiently than RAG-/- mice. If elimination of the cancerous cell(s) isn’t 
complete, the second stage of immune editing begins, and equilibrium is established between 
the immune system and the cancer. 
In this stage, the immune system continues to attack the genetically unsTable pre-malignant 
cells, driving selection of immune-resistant cells. Immune resistance is achieved by either 
reducing immunogenicity (immune evasion) or suppressing immune responses (immune 
suppression). Immune evasion often involves the reduction of cell surface MHC class I or II, 
thereby limiting antigen presentation [57, 58]. Additionally, malignant cells can have 
deregulated antigen processing and presentation pathways, again, limiting the presentation of 
antigen to immune cells. Alternatively, the reduction or cessation of mutated protein synthesis 
will prevent mutated peptides being presented to the immune system (epitope loss) [59]. 
Malignant cells have a multitude of mechanisms to suppress the immune response, and indeed 
the microenvironment is also often immunosuppressive. Malignant cells can express 
inhibitory molecules such as PDL1, and secrete molecules such as kynurenines, which can 
induce Th1 T-cell apoptosis [60, 61]. This selection of immune resistant cells highlights the 
dual effects of the immune response; it is able to both eliminate cancerous cells, yet shape 
them to avoid detection and develop into malignant disease.   
Finally, if transformed cells are able to successfully evade the immune response, they will 
escape, proliferate uncontrollably and form tumours.  
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1.2.2 CD4+ Helper functions in cancer 
Many groups have demonstrated that CD4+ T-cells are capable of orchestrating anti-tumour 
immunity through the production of a range of cytokines (reviewed in [62]). These cytokines 
are T-cell lineage dependent and have pleotropic effects within the immune response. 
Important for anti-tumour immunity are the cytokines produced by the CD4+ Th1 T-cell 
subtype, namely IFNγ, Tumour Necrosis Factor alpha (TNFα) and IL2.  
One such example of immune modulation by cytokine production is the induction of tumour 
specific cytotoxic T-lymphocyte (CTL) responses, shown in mice by Nishimura et al. [63]. 
Here they show that Th1 T-cells are effective at eradicating tumours by stimulating CD8+ T-
cells through the production of IFNγ. Others have identified the ability of tumour-specific 
CD4+ T-cells to aid CTL recruitment, survival and proliferation; responses driven by specific 
chemokines and cytokines [64].   
CD4+ T-cells have also been shown to indirectly stimulate CTLs via conditioning or 
“licensing” of DCs [65-68]. Activated CD4+ T-cells express CD40L, which binds to CD40 on 
immature DCs to drive their maturation [69]. Mature DCs are better equipped to activate 
CD8+ T-cells, as they have upregulated surface expression of CD80 and CD86 [70].  
Another example of immune modulation by CD4+ T-cells has been described by Perez-Diez 
et al. The group investigated monoclonal tumour-specific CD4+ T-cell responses in vivo. 
Results show that these cells were more efficient at clearing tumours than their CD8+ 
counterparts. As this effect is retained in MHC class II negative tumours, they suggest that 
here the CD4+ T-cells could function indirectly by maturing DCs and recruiting macrophages 
and natural killer (NK) cells [71].   
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Further evidence for the anti-tumour response of CD4+ T-cells is highlighted in mouse 
models and human trials. For example, Muranski et al. have shown that Th17+ T-cells are 
capable of eradicating established melanoma in mouse models – a result that was dependent 
upon the production of IFNγ [72]. Interestingly, Frankel et al. have described CD4+ T-cells as 
being as effective at tumour clearance as CD8+ T-cells, when transduced with the same, 
HLA-A2-restricted, CD4/CD8 independent, TCR [73]. As they have a reduced ability to lyse 
tumour cells when compared to tumour specific CD8+ T-cells, they suggest that the indirect 
helper effects contribute to the tumour control [72, 73].   
1.2.3  CD4+ Effector Functions 
In addition to this classic, indirect CD4+ T-cell response, recent studies have highlighted the 
direct effects that CD4+ T-cells can have on tumour clearance. This direct cytotoxicity has 
previously been attributed to an artefact of in vitro culture. However, studies investigating 
CD4+ T-cell cytotoxic responses ex vivo have validated this effector function [74, 75].   
In a mouse model designed by Xie et al., MHC class II restricted transgenic T-cells specific 
for a melanoma specific antigen, tyrosinase, were adoptively transferred into tumour bearing 
mice. Regression was noted independently of vaccination, NK, NK-T, B or CD8+ T-cells. As 
Fas Ligand (FasL) and granzyme B were upregulated in the transgenic T-cells, the mechanism 
of killing was suggested to be through this pathway [76].  
Human CD4+ T-cell anti-tumour responses have also been studied closely over the past 
decade. 
Firstly, an increase in the frequency of tumour infiltrating CD4+ T-cells in patients with 
Diffuse Large B-cell Lymphoma (DLBCL) has been positively correlated with an improved 
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prognosis, highlighting the importance of this T-cell subset in anti-tumour immunity [77]. 
Additionally, CD4+ T-cells have been successfully isolated from the peripheral blood of 
patients with B-cell Chronic Lymphocytic Leukaemia (CLL) and shown to be cytotoxic 
towards CLL cells in vitro [78].   
Adoptive T-cell therapy is further highlighting the importance of CD4+ T-cells in tumour 
clearance. Dudley et al. have identified the CD4+ T-cell influence in tumour infiltrating 
lymphocyte (TIL) transfer, as patients receiving both CD4+ and CD8+ T-cells showed greater 
tumour responses overall [79]. Consequently, a number of groups have looked at transfusion 
of tumour reactive CD4+ T-cells alone. Both Hunder et al. and Tran et al. have demonstrated 
that in case studies, CD4+ TIL therapy is effective in the treatment of metastatic melanoma 
and metastatic cholangiocarcinoma, respectively [80, 81]. 
1.3 Immunotherapy overview 
It is clear that the immune system can target cancer, and also that the immune system does not 
always do so effectively, as cancer is common, worldwide disease. How to best harness anti-
tumour immune responses for cancer therapy is a question that is currently being investigated 
by researchers worldwide.  
There is now a huge focus on immunotherapy. Immunotherapy is a term which describes the 
generation, activation or enhancement of a desired immune response in order to treat disease. 
There are multiple forms of immunotherapy including vaccines, immune checkpoint blockade 
inhibition and adoptive therapy.  
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1.3.1 Vaccines 
Vaccines enhance the immune response towards specified antigens. There are many different 
types of vaccines currently being used clinically. Vaccines can include whole proteins, 
peptides, RNA or DNA. Clinical success with vaccines has to date been seen when vaccines 
are used prophylactically. Remarkably, by prophylactically treating smallpox we have 
managed to eradicate this disease from the world [82]. In terms of vaccinating against specific 
cancers, many challenges have hindered success in this field, including tumour driven 
immunosuppression and immune evasion. There are now prophylactic vaccines for the 
prevention of Human Papilloma Virus (HPV) associated cervical cancer.  Prophylactic 
vaccines against other cancers such as breast cancer are currently under development [83]. 
Therapeutic cancer vaccines are currently being developed. For example, an EBV vaccine for 
the treatment of EBV associated malignancies and vaccines to treat glioblastoma are now in 
clinical trials [84-86].   
1.3.2 Checkpoint Blockade Inhibitors 
Checkpoint blockade inhibitors activate immune cells which may otherwise have been 
inactive, by removing the ‘brake’. When immune cells (specifically, T-cells), interact with 
their target they are activated to respond. Part of this activation includes a negative feedback 
loop, resulting in the expression of inhibitory signalling molecules such as CTLA-4, which 
leads to T-cell anergy, preventing T-cell proliferation and response [87]. CTLA-4 can be 
blocked by the monoclonal antibody Ipilimumab. This has shown clinical successes in the 
treatment of metastatic melanoma, increasing patient survival for 4 months when compared to 
a vaccine [88]. Whilst this effect may seem limited, it is the first treatment to ever show an 
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improved patient survival in a randomised trial for metastatic melanoma [88]. Ipilimumab is 
currently being tested for the treatment of other tumours such as non small cell lung cancer 
and metastatic prostate cancer [89, 90].  
The Programmed Cell Death 1 (PD1) – Programmed Cell Death Ligand 1 (PD-L1) signalling 
pathway is another pathway which will inhibit T-cell responses; proliferation, survival and 
effector functions are all impaired after PD1-PD-L1 signalling [91]. PD1 is a receptor that is 
expressed on activated T-cells and often, tumours will express its ligand, PD-L1 [91]. 
Interaction of the receptor and its ligand can be blocked by antibodies against either molecule. 
These have shown to have great anti-tumour effects clinically, with anti-PD1 or anti-PD-L1 
antibodies being approved for an increasing number of tumours every year [92]. 
1.3.3 Adoptive Therapy 
Adoptive therapy is an arm of immunotherapy which refers specifically to the transfer of 
antigen specific immune cells (autologous or non autologous) into a patient, in order to 
achieve a desired response. This can activate and enhance responses by culturing immune 
cells in the absence of the immunosuppressive microenvironment. Additionally, adoptive 
therapy can generate novel immune responses, by genetically engineering immune cells to 
redirect their specificity. 
1.3.4 Donor Lymphocyte Infusion 
Donor Lymphocyte Infusion (DLI) involves the transfer of T-cells from a donor to a recipient. 
This occurs following HSCT which is used to treat cancers of the hematopoietic system. Prior 
to transplant the patient’s immune system is ablated using total body irradiation and 
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chemotherapeutic agents such as cyclophosphamide to remove cancer cells [93]. 
Reconstitution of the donor derived immune system in these patients is slow. Neutrophils 
recover after 14-30 days depending on the type of HSCT (peripheral blood, bone marrow or 
cord blood derived stem cells). T- and NK-cells recover fully after 100 days and B-cells can 
take up to two years to recover [94]. Therefore, immune control of cancer relapses is limited. 
Here, DLIs are administered to increase the number of lymphocytes that will attack the 
tumour. DLIs are efficient at clearing recipient derived tumours as they are seen as ‘non-self’ 
and so destroyed [95]. The caveat to this therapy is that graft versus host disease (GvHD) is 
common.  
1.3.5 Tumour Infiltrating Lymphocytes 
Adoptive therapy with tumour infiltrating lymphocytes (TILs) requires isolation of TILs from 
a tumour biopsy, in vitro expansion and re-infusion into the patient. This therapy is 
autologous and thus removes the risk of GvHD. It can generate a range of T-cell specificities, 
reducing the risk of tumour escape by epitope loss. Unfortunately, the long expansion period 
of around 4-16 weeks is a major drawback in this therapy because cells can become exhausted 
with such expansions and patients treated by such therapy (most often metastatic melanoma 
patients) require rapid treatment; however shorter protocols are being developed. [79, 96]. 
TILs are found primarily in highly immunogenic tumours such as melanoma and thus 
isolation from less immunogenic tumours will prove difficult [97]. Additionally, TILs can 
only be generated if it is possible to biopsy the tumour. Despite these drawbacks, the therapy 
has seen clinical success in the setting of melanoma. Rosenberg et al. have reported a 72%  
object response rate when total body irradiation was used as a preconditioning regimen and 
complete remission was observed in 22% (20/93) of patients [98].  
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1.3.6 Cytotoxic T-Lymphocyte Infusion 
Like TIL therapy, cytotoxic T-lymphocyte (CTL) infusion also requires the expansion of 
tumour specific T-cells. Here, T-cells are isolated from patient peripheral blood mononuclear 
cells (PBMCs), and target-specific T-cells are selectively expanded and infused into the 
patient. Alternatively, in HSCT, donor CTLs can be isolated and expanded. In one study 
treating melanoma patients, partial responses were reported in 8 of 20 patients treated [99].  
Additionally, CTL infusion has been used to treat Hodgkin and non Hodgkin lymphoma, with 
responses seen in 13 of 21 relapsing patients, of which 11 responses were complete [100].  
These trials did not see GvHD – a toxicity considered to be reduced in comparison to DLI due 
to the selective expansion of target specific T-cells, however GvHD will remain a safety 
concern when administering donor derived T-cells into immunocompromised patients [101].  
1.4 Genetic Engineering of T-cells 
It is not possible to isolate and expand naturally occurring tumour reactive T-cells from every 
patient, due to their low frequencies or absence. Genetic engineering of T-cells to redirect 
their specificity has been shown to be clinically effective and would allow for the treatment of 
patients who do not possess tumour reactive T-cells. Additionally, genetic engineering of T-
cells bypasses the need for long T-cell expansions; it allows for the rapid production of many 
specific T-cells. Finally, these T-cells can be patient derived. The use of autologous T-cells 
reduces the complications associated with allogeneic T-cells, including rejection of the 
adoptively transferred cells and GvHD. 
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1.4.1 Chimeric Antigen Receptors 
The first of these genetic engineering approaches is the use of chimeric antigen receptors 
(CARs). CARs are generated from the antigen specific fragment of an antibody (single chain 
variable fragment, ScFv), linked to a constructed signalling domain. T-cells transduced with 
this construct express it on their surface and bind to their cognate antigen with the high 
affinity of an antibody. What’s more, CARs are not MHC restricted, and so any patient 
expressing the target antigen on their tumour cells could potentially be treated. Upon antigen 
binding, signalling through the CAR activates a T-cell response. To date, there have been 
numerous generations of CARs (Figure 1.6), which include various signalling domains from 
different co-stimulatory molecules [102-104] [105-107]. It is not yet known which 
combination of co-stimulatory molecules is optimal due to a lack of direct comparisons, and it 
is likely to change depending on the ligand being targeted.  
 
Figure 1.6. Generations of CAR constructs. 
Three generations of CARs have been developed which include a range of signalling 
molecules. First generation CARs typically signal though CD3ζ whilst second and third 
generation CARs incorporate additional signalling domains  (adapted from [108]).   
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Clinical trials that target Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic 
Leukaemia (CLL) with second generation CD19 specific CARs have proven remarkably 
effective. Carl June’s group have shown that these transduced cells are predominantly safe, 
persist, and have impressive anti-tumour effects [109]. Indeed, in a trial treating 30 ALL 
patients, 90% of patients entered complete remission [110]. However, the strength of this 
therapy has also been witnessed in adverse effects and patient mortality using CARs directed 
towards other targets. When T-cells have been administered to patients with large tumours, 
copious amounts of cytokines have been produced during the rapid tumour lysis. This is 
known as a cytokine storm and can be toxic [111]. Furthermore, CAR transduced T-cells 
specific for targets that are present at low levels in normal tissues yet upregulated in cancer 
have attacked the normal tissues. In rare cases this on target off tumour toxicities has resulted 
in the death of the patient [109, 112].  
1.5 T-cell Receptor Gene Transfer 
Following initial successes of adoptive cell transfer with TILs and CTLs, there has been much 
interest in using TCR gene transfer as a therapeutic approach to target tumours. TCR gene 
transfer is a method of genetically engineering T-cells to bestow upon them a specific 
reactivity.  T-cells with defined specificities are isolated, and the genes which encode their 
TCRs are cloned into retroviral or lentiviral constructs. These constructs are subsequently 
transduced into activated T-cells, which will then express the specific TCR (Figure 1.7). 
Unlike CARs, TCRs are HLA-restricted. Consequently the patient can only be treated if they 
express the HLA allele that the transduced TCR is restricted by.  However, TCRs have a 
wider peptide repertoire than CARs since unlike CARs they can recognise not only surface 
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antigens, but antigens derived from any compartment of the target T-cell, although this is 
dependent on a functioning MHC processing pathway.  
 
 
Figure 1.7. TCR gene transfer.  
Polyclonal T-cells are redirected towards new antigen specificity by TCR gene transfer 
(adapted from [113]).  
 
1.5.1 History of TCR gene transfer 
The first demonstration of redirecting T-cell specificity was seen in 1986, when Dembic et al. 
transferred TCR genes from one CTL to another, successfully redirecting it’s specificity 
[114]. Since then, there have been numerous clinical trials and much preclinical research into 
TCR gene transfer.  
Using a TCR specific for a HLA A2 restricted melanin antigen, Clay et al. acknowledged the 
redirection and anti tumour activity of TCR transduced cells in vitro [115]. Kessel et al. 
subsequently demonstrated that redirected T-cells can function in vivo [116] . Work within 
this field then bloomed, with multiple clinical trials currently on-going.  The first clinical trial 
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for TCR transfer involved the transfer of a TCR specific for a Melan-A (MART1) antigen 
(DMF4) for patients with melanoma. Early results showed an overall response rate in 2/15 
(13%) of patients [117].  Subsequent trials with higher affinity TCRs and improved 
transduction efficiencies have resulted in improved responses. By using the DMF5 MART1 
specific TCR, which has a 100 fold increase in avidity compared to DMF4, a 30% response 
rate was observed (6/20 melanoma patients) [118]. The disadvantage of this TCR is its on 
target side effects, as non-tumour cells which express this antigen at low levels were 
destroyed, resulting in toxicities. These on target side effects highlight the potential of TCR 
transfer as an effective cancer therapy, providing conditions are optimised to increase 
efficiency and reduce toxicities.  
1.6 TCR Gene Transfer Optimisation 
1.6.1 Mispairing 
When exogenous TCR alpha and beta chains are introduced into T-cells, they are theoretically 
able to pair with endogenous TCR chains. This mispairing results  in TCRs with unknown 
specificity – a risk that has been shown to be associated with lethal GvHD in vivo, at least in 
mice [119].  Additionally, mispairing TCR chains will reduce the amount of fully formed 
exogenous TCRs at the cell surface, thereby reducing T-cell sensitivity. Due to these 
disadvantages, a number of groups have developed ways to reduce this mispairing.  
Creating an additional disulphide bond between the alpha and beta TCR chains has been 
shown to aid pairing between exogenous TCR chains, thereby increasing the surface 
expression of the exogenous TCR [120].  
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Another method used to improve TCR chain pairing is to use mouse constant domains, with 
the V, D and J domains remaining human [121, 122]. By using this technique, surface 
expression of exogenous TCR can be increased by more than two fold [122].Due to concerns 
that  this technique would result in loss of TCR-transduced cells in the host, as human anti-
mouse immune responses develop,  some groups choose to utilise minimal murine constant 
domains. These would retain TCR pairing yet be less likely to stimulate an anti-mouse 
response [123].  
Recent work has focused on preventing TCR mispairing by removing the endogenous TCR 
altogether. This not only increases the safety profile of the therapy, but also improves TCR 
expression at the cell surface, as the introduced TCR will no longer have to compete with the 
endogenous TCR for CD3 binding, which is required for surface expression [124]. There are 
multiple methods in place to remove the endogenous TCR. Zinc finger domains have been 
utilised to disrupt the expression of endogenous alpha and beta chains [125]. Whilst this 
method is effective, it considerably increases the amount of time the T-cells are in vitro, the 
complexity of the protocol and the cost, which is a clear disadvantage for this therapy. RNA 
interference molecules (RNAi) have been used to remove the endogenous TCR [126]. RNAi 
silences transcription of the endogenous TCR genes and results in equal surface expression of 
the exogenous alpha and beta chain, suggesting improved pairing [126.]. Finally, others have 
transduced hematopoietic stem cells (HSCs), which do not express endogenous TCRs. This 
technique has shown to generate functional T-cells [127]. However, the added complexity of 
obtaining these cells complicates this protocol for widespread clinical use. 
Although TCR mispairing remains a safety concern,  no lethal toxicities due to mispairing 
have been identified clinically to date in the human setting [128].   
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1.6.2 Increasing surface TCR 
Along with ensuring correct pairing, techniques are commonly employed to increase surface 
expression of the TCR. Firstly, codon optimisation is frequently used to improve translation 
of TCR messenger ribonucleic acid (mRNA). Codon optimisation is the process of changing 
nucleotides by site directed mutagenesis to other nucleotides without altering the resulting 
amino acid sequence, in order to improve translation efficacy. This is possible because triplet 
codons are degenerate; multiple triplet codons can result in the incorporation of the same 
amino acid. Some triplet codons are more easily translated by ribosomes and so if the DNA 
sequence is altered to include the better translated triplet codons, translation as a whole is 
more efficient. This method was originally used in TCR gene transfer by Scholten et al. and 
resulted in substantially increased surface expression of the exogenous TCR [129].  
TCRs must bind to CD3 for surface expression. The competition for CD3 can be removed 
either through deleting the endogenous TCR as described above, or by the addition of more 
CD3. Ahmadi et al. have investigated the co-transduction of CD3 and TCR genes, and show 
that this enhances both TCR surface expression and T-cell function [130].  
1.6.3 Transduction vehicle 
To date most of the preclinical and clinical studies of TCR gene transfers use a retrovirus or a 
lentivirus system to transduce TCR genes into cells. 
Retroviruses integrate non-specifically into the host cell genome, often close to transcription 
start sites [131].  Although this could theoretically result in integration next to oncogenes and 
drive tumour development, this has not been seen clinically, and patients who were treated 
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with retroviral constructs over 12 years ago have not developed retroviral driven tumours 
[132, 133]. Lentiviruses are considered ‘safer’ than retrovirus as they have a more selective 
integration site, and will often integrate within active transcription units [134]. However the 
transposon/transposase system may be used in the future, and prove to be safer. 
Transposon/transposase systems have been shown to only integrate into a few sites in the 
genome and are unlikely to integrate into transcriptionally active genes [135, 136]. The SB 
system has been developed for clinical use and tested in a phase I/II clinical trial to transduce 
a CD19 CAR into T-cells [137]. The SB system likely requires further optimisation before it 
will be used commonly within the field, as currently transduction is inefficient. In a second 
CD19 CAR trial which used SB to transduce cord blood cells, 4 cycles of electroporation of 
the transposon and transposase was typically required to generate enough transduced T-cells 
for clinical use, which took 28 days [138].   
1.6.4 Clinical Results 
There have been numerous TCR gene transfer therapies in the clinic, with a range of epitopes 
being targeted. To date, these therapies have been studied in most depth in metastatic 
melanoma and lymphomas. Synovial cell carcinoma, myeloma and chronic lymphocytic 
leukaemia have also been treated clinically [117, 139-144].   
In general terms, responses are varied and toxicities are common, highlighting the 
requirement to identify tumour specific antigens. The first clinical trial in 2006 showed 
modest tumour regression, with 2/15 patients with metastatic melanoma achieving an 
objective response [117]. Since this time, TCR gene transfer has been optimised (as discussed 
above), and now we are seeing trials with greater responses. A trial by Robbins et al. in 2011 
achieved responses in 4/6 patients with synovial cell carcinoma and 5/11 patients with 
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melanoma. However, as TCR gene transfer is being optimised and thus becoming more 
potent, more toxicity is occurring, highlighting the strength of this therapy. In 2015, van den 
Berg et al. reported a mortality in a patient treated with a MHC class I restricted TCR specific 
for MART1 [112]. Toxicities were determined to be due to cytokine release syndrome, 
highlighting the potency of this TCR. Additionally, in 2013, a trial was performed to treat 
patients with myeloma and melanoma with an affinity enhanced TCR targeting MAGE A3. 
Following infusion of these affinity enhanced TCR transduced T-cells into two patients, the 
patients developed cardiogenic shock which led to their death and termination of the trial 
[144]. In depth investigation revealed that the TCR was cross reactive to a protein (titin) 
which is present on beating cardiomyocytes. This cross reactivity was not noticed prior to the 
trial as titin is not expressed on cardiomyocytes in vitro unless grown as beating 
cardiomyocyte cultures. This trial highlights the requirement for safety measures within this 
therapy, and many methods to increase safety have been developed, including the use of 
suicide genes to provide control over harmful T-cell responses [145].  
1.6.5 Suicide Genes 
The administration of T-cells for therapeutic intervention differs from the administration of 
molecular drugs as T-cells are able to expand in vivo and persist for years [132, 133]. These 
reasons are what make adoptive T-cell therapy of cancer so exciting; one cell product could 
expand or decrease depending on the target availability and immune memory can be 
generated for the prevention of tumour relapse. On the other hand, expansion and persistence 
of infused T-cells could be lethal if the T-cells administered have unexpected toxicities.  As 
shown in the pre- and post-clinical evaluation of the titin cross reactive TCR, the specificity 
of genetically engineered T-cells cannot always be completely defined in vitro. Regardless of 
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the in vitro safety profile of the TCRs, suicide genes could be transduced into the T-cells to 
give clinicians some control over toxicities. Suicide genes can be activated to kill the 
transduced T-cells if unwanted toxicities are witnessed. Examples of such suicide genes 
include the Herpes Simplex Virus Thymidine Kinase (HSV TK) gene and the inducible 
caspase-9 safety switch. The HSV TK phosphorylates the nucleoside analogue ganciclovir. 
The phosphorylated from of ganciclovir is incorporated into DNA and prevents DNA 
replication, ultimately resulting in cell death [146]. This suicide gene is consequently 
inducible; it only functions after the administration of ganciclovir. HSV TK has been used in 
clinical trials and shown to be safe, however when transduced into T-cells for DLI, not all T-
cells were killed and thus its efficacy is limited [147, 148].  The caspase-9 safety switch is 
made of a human caspase-9 linked to the human FK506 binding protein (FKBP). This is 
transduced into T-cells. A synthetic molecule which induces dimerisation of the caspase-9 
molecules can be administered if ablation of genetically engineered T-cells is required. 
Dimerised caspase-9 is active and causes a caspase cascade and consequential apoptosis of 
99% of the transduced cells [149]. This safety switch has been tested in a clinical trial where 
it was transduced into donor T-cells prior to HSCT. When a patient developed GvHD the 
small molecule was administered. This resulted in elimination of 85-95% of infused T-cells 
within 30 minutes and rapid resolution of GvHD [150]. As well as being very efficient, this 
caspase-9 safety switch has other benefits over the HSV TK gene transduction. As it is made 
of human genes, T-cells transduced with it will not be targeted for destruction by the host’s 
immune system (as has been shown in the HSV TK system) [151]. Secondly, the pro-drug is 
non-toxic, unlike ganciclovir, which is an antiviral used for the treatment of CMV infections 
and is associated neutropenia [152].
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First 
Author  
Target 
Tumour  
Target 
Epitope  
MHC  T-cell 
Subtype  
Patients  Results  Toxicities  Other Notes  
Morgan 
(2006) 
[98] 
Melanoma  MART-
1 
I  Total 
PBMC  
15  2 objective regressions  No toxicities 
attributed to 
engineered T-cells 
TIL derived 
TCR 
Johnson 
(2009) 
[117] 
melanoma  MART-
1  
I  Total 
PBMC  
20 (DMF5) 
16 (GP100)  
30% (DMF5) and 19% 
(GP100) objective 
response  
Vitiligo and 
melanocytes 
destruction in 
majority of patients. 
Hearing loss  
DMF5 TCR 
from TIL 
GP100 from 
HLA Tg mice 
Parkhurst  
(2011) 
[118]  
 
Metastatic 
colorectal 
cancer  
 CEA  
 
I   3  1 objective response  Severe transient 
inflammatory colitis  
Murine TCR (tg 
mouse)  
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First 
Author  
Target 
Tumour  
Target 
Epitope  
MHC  T-cell 
Subtype  
Patients  Results  Toxicities  Other Notes  
Robbins 
(2011) 
[119] 
Metastatic 
Melanoma 
Synovial 
Cell 
Carcinoma  
NY-
ESO1  
I  Total 
PBMC  
SCC – 6 
Melanoma - 
11  
SCC  - 4 responders 
Melanoma – 5 
responders  
Transient neutropenia 
and 
thrombocytopenia in 
response to 
lymphodepleting 
regimen and high 
dose IL2 infusion  
Patient 
derived TCR, 
Two amino 
acid 
substitutions 
in CDR3  
Seaman 
(2012) 
[120]  
 
Progressive 
Metastatic 
Melanoma  
 
MART-
1  
GP100 
  
I   MART-1 - 
18 
GP100 - 14  
 25% transient hearing 
loss due to 
autoimmune attack of 
melanocytes  
MART-1 from 
Tg mice, 
GP100 from 
TIL   
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First 
Author 
Target 
Tumour 
Target 
Epitope 
MHC  T-cell 
Subtype 
Patients Results Toxicities Other Notes 
Morgan  
(2013) 
[121] 
Multiple 
epithelial 
tumours  
MAGE-
A3  
I  Total 
PBMC  
9  5 patients showed 
clinical regression  
3 mental status 
changes, 2 deaths - 
cross reacted to mage 
A12 found in brain  
HLA transgenic 
mouse and site 
directed 
mutagenesis  
Linette 
(2013) 
[122] 
Myeloma 
and 
Melanoma  
MAGE-
A3  
I  CD25 and 
monocyt
e 
depleted 
PBMC  
2  N/A  Both patients died 
from myocardial 
infarction and 
myonecrosis 
Recognistion of 
unrelated peptide  
Affinity 
enhanced TCR  
Table 1.1 Table of TCR Gene Transfer Clinical Trials to date.
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1.7 Epstein Barr Virus 
EBV is a 172 Kb double stranded linear DNA gamma herpes virus that infects around 90% of 
the world’s population [153]. This genetically sTable virus is usually transmitted by salivary 
exchange. Infection generally occurs asymptomatically in childhood, although in the western 
world it is often delayed until adolescence. Infection results in Infectious Mononucleosis (IM)  
in up to 77% of adolescents, however this frequency is much lower when children are infected 
[154, 155]. The acute infection is eventually brought under control by the immune system 
[153]. The virus enters latency and persists as a lifelong infection.  
1.7.1 Life Cycle and Gene Expression 
EBV naturally infects B cells that are transitioning through the oropharyngeal epithelium. 
Through the viral glycoproteins gp350 and gp42, EBV binds to the chemokine receptor 
CD21, and MHC class II respectively, on the surface of B-cells. This is thought to happen in 
the oropharynx during viral infection of the host [156-158]. From here, the virus can infect 
epithelial cells in the oropharynx and replicate, causing cell lysis and virion release [159]. The 
released virions can infect naive B-cells by CD21 mediated endocytosis [160]. Upon infection 
the virus adopts a largely latent state with the expression of nine growth transforming “latent” 
viral proteins (these proteins are listed in Table 1.1), in a state known as latency III [161]. The 
rich array of immunogenic lytic and latent antigens present during acute infection drives a 
strong T-cell response which eventually brings the primary infection under control. However, 
some infected cells escape elimination and viral gene expression is completely shut down 
(latency 0) [162]. These resting memory B-cells circulate the blood indefinitely, avoiding 
immune recognition [3]. They undergo periodic lytic reactivation when circulating through 
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the oropharynx to produce new virus progeny for transmission and infection of new B cells 
[163]. EBV DNA is not integrated into the cell DNA; it is maintained in an episomal manner 
[164]. Host cell DNA polymerases replicate EBV DNA, which is spread equally into daughter 
cells before B-cells divide [165].  
 
Figure 1.8 EBV life cycle and immune response.  
EBV primarily infects epithelial cells. Here EBV replicates to produce new virions for oral 
transmission and infection of B-cells. EBV infected B-cells switch to latency 0 in response to 
NK, CD4+ and CD8+ T-cell pressure. EBV lytic gene expression occurs in infected memory 
B-cells to allow for virus transmission. Taken from [166]. 
 
The EBV lytic replicative cycle produces new virus particles for the spread of infection. Lytic 
cycle leads to cell lysis and thus the release of newly made EBV virions, allowing for the 
infection of more naive B-cells [167]. Expression of lytic genes is driven by the immediate 
CHAPTER 1  Introduction 
64 
 
early (IE) lytic protein, the transcription factor BZLF1. Lytic gene expression is staggered 
into immediate early, early and late gene expression. In these stages, different lytic genes are 
expressed, with the total number of lytic genes exceeding 80. A constant low level of viral 
shedding in the throat of healthy carriers suggests that a small proportion of the virus enters 
lytic cycle at any given time, probably due to antigenic stimulation of B-cells (Figure 1.8) 
[153].  
 
Programme Tumour association Gene expression 
Latency III PTLD 
AIDs related lymphoma 
DLBCL 
EBNA-LP, EBNA1, EBNA2, EBNA3a, 
EBNA3b, EBNA3C, LMP1, LMP2A, 
LMP2B, BHRF1, BARTs, EBERs. 
Latency II Hodgkin’s Lymphoma 
DLBCL 
NPC 
T/NK cell lymphoma 
Gastric Carcinoma 
EBNA1, LMP1, LMP2, EBERs 
Latency I Burkitt’s Lymphoma 
T/NK cell lymphoma 
Gastric Carcinoma 
EBERs and EBNA1  
Table 1.2 EBV gene expression profiles in tumours. 
EBV is associated with the tumours described in this Table and expressed most commonly a 
latency I, II or III gene programme. 
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1.7.2 Gene Function 
EBV has growth transforming potential through the coordinated actions of the latent proteins, 
which can be seen in vitro as the outgrowth of latency III positive lymphoblastoid cell lines 
(LCLs) upon infection of B cells with EBV.  However, some tumours display more restricted 
patterns of EBV gene expression (Table 1.1).  Here, cellular changes in tumours with more 
complex aetiologies can compensate for some transforming functions.  
EBV nuclear antigen (EBNA) 1 is a nuclear protein which binds to both viral and host DNA 
during mitosis to ensure the viral episomes get integrated into the daughter B-cells [168]. It 
has been proposed to prevent apoptosis in BL [169]. EBNA1 also acts as a transcription 
factor, negatively regulating itself and positively regulating LMP1 and Cp promoters [168, 
170]. EBNA2 is a transcription factor which leads to transcription of all latent genes and thus 
has a transforming role. This transforming role can be shown by rescuing the transformation 
ability of EBNA2 mutants with wild type EBNA2 [171]. It can bind to c-myc to activate it 
and drive cell proliferation and additionally has partial homology to NOTCH, allowing it to 
block cell differentiation and so maintain a proliferating state [171]. EBNA3 proteins are 
transcriptional regulators for viral and host genes [172]. Both EBNA3a and 3c are essential 
for in vitro transformation [173]. EBNA-LP can bind to pRb and p53 although the functional 
significance of these interactions is so far unclear [174]. However it is required for LCL 
outgrowth and has been proposed to be a transcriptional activator [168]. LMP1 is a major 
transforming protein, indispensable for B-cell transformation [171]. It acts as a ligand 
independent, constitutively active CD40 homologue and signals via cell signalling molecules 
to activate MAPK, NFkB and PI3K pathways[175]. In this manner it increases expression of 
cytokines and antiapoptotic proteins, aiding cell growth and survival [176]. LMP2 aids B-cell 
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survival by signalling in a similar manner to BCR signalling, activating both PI3K and 
MAPK pathways [171]. By sequestering the binding proteins required for BCR signalling it 
inhibits this pathway and so prevents B-cell differentiation, helping to maintain a latently 
infected B-cell pool [177]. EBV encoded RNAs (EBERs) are non-polyadenylated RNA 
structures which are suggested to inhibit RNA-dependent protein kinase (PKR) activation. 
PKR activation facilitates the anti-EBV effect of IFNs and so by inhibiting this kinase, the 
immune response to EBV is diminished, enhancing viral persistence [171, 178]. Finally,  
BamHI A rightward transcripts (BARTs) have no known function yet are expressed in healthy 
carriers and in tumours and therefore are thought to have a role in viral persistence [171]. As 
the tumorigenic properties of lytic genes are less clear, they will not be discussed here. 
1.7.3 EBV tumour association 
It is estimated that 200,000 cases of EBV-associated cancer occur annually [179]. EBV has 
been detected in multiple different B-cell tumours including; Hodgkin’s Lymphoma (HL), 
Burkitt’s lymphoma (BL), PTLD, DLBCL of the Elderly and AIDs-related lymphoma. These 
tumours express different EBV gene expression profiles, as can be seen in Table 1.1. EBV has 
further been identified in some epithelial cancers  such as nasopharyngeal carcinoma and in 
T-cell lymphomas [171]. The role of EBV in tumourigenesis has been debated due to cases of 
apparently EBV negative HL and BL. However, tumours negative for EBER expression (a 
common marker used to identify EBV infection) can test positive for EBV DNA [180]. A ‘hit 
and run’ hypothesis has been suggested in which EBV was originally in the B-cell but was 
lost when it was no longer needed; e.g. when the cell had undergone enough genome damage 
to be tumorigenic [177].  
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1.7.4 Immune Response to EBV 
Patients diagnosed with IM have proved invaluable for investigating the immune response to 
EBV. Peripheral blood samples taken from donors with IM have shown an increase in NK 
cell numbers, when compared to healthy donors [181]. The NK cells that proliferate in 
response to EBV infection are CD56dim and CD16-, which in vitro are most efficient at 
responding to lytically infected cells [181]. These NK cells persist for several months after 
infection [182]. In vitro studies of innate immune responses to EBV have shown that 
monocytes and DCs can also respond to this virus [183]. 
Adaptive immune cells also respond to EBV, and together with innate cells drive EBV 
latency 0, as infected cells which express EBV genes are cleared. B-cells respond to EBV 
infection by producing antibodies. IgG antibodies are initially detected following primary 
EBV infection against EBNA2 and these subsequently decline [166]. One way in which EBV 
serostatus is determined in healthy people is to test for the presence of IgG against VCA and 
EBNA1, as these are maintained in the B-cell pool following primary infection [166, 184]. 
Both CD4+ and CD8+ EBV specific T-cells proliferate in IM, with clinical symptoms 
coinciding with CD8+ T-cell expansion [154]. Indeed, in children where primary EBV 
infection does not result in IM, the total number of peripheral blood CD8+ T-cells are not 
significantly changed to those of healthy controls [185]. This suggests the clinical symptoms 
of IM are a result of CD8+ T-cell expansion. Huge numbers of CD8+ T-cells can be identified 
in IM patients, and up to 40% of peripheral blood CD8+ T-cells can be specific for single 
EBV derived lytic antigens [153]. Immunodominance is observed within the CD8+ T-cell 
response to EBV, with the majority of peripheral blood derived CD8+ T-cells being specific 
for lytic antigens.  Responses against IE antigens are the most prevalent, followed by E and 
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then L. Responses against latent antigens are observed in the blood from IM patients, albeit at 
lower frequencies. Up to 5% of total peripheral CD8+ T-cells can be specific for latent 
antigens. As acute infection is cleared, the EBV specific CD8+ effector cells undergo 
apoptosis. IM is a self-limiting disease, with the protraction of EBV specific CD8+ T-cells 
correlating positively with reduced symptoms. The overall number of CD8+ T-cells 
eventually reaches that of a healthy EBV carrier. A small proportion of memory CD8+ T-cells 
specific for EBV remain to control persistent infection.  
The investigation of the CD4+ T-cell response to primary EBV infection has met several 
challenges. These included the lower frequency of EBV specific CD4+ T-cells in the 
peripheral blood compared to that of the CD8+ T-cell counterpart, the lack of peptide-MHC 
multimers and the scarcity of knowledge of specific CD4+ T-cell specificities. Technological 
advancements – in particular the production of peptide-MHC multimers, has recently helped 
to overcome these challenges. 
The CD4+ T-cell response to primary EBV infection differs to that of the CD8+ T-cells, as 
specific T-cell expansion is less pronounced [154, 186]. Proliferation of EBV specific CD4+ 
T-cells is observed in IM, with the most frequent T-cells recognising latent-derived antigens 
[187]. The response is spread throughout all latent genes (with the exception of EBNA1) and 
as such, no immunodominance is observed. T-cells specific to any one epitope can be found 
to constitute up to 1% of total CD4+ T-cells in the peripheral blood, with these frequencies 
after primary infection returning to levels seen in healthy EBV carriers [187]. The EBV 
specific memory CD4+ T-cell repertoire contains T-cells specific for antigens derived from 
latent and lytic proteins. This breadth of specificities is larger than that observed in memory 
CD8+ T-cells [153]. 
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EBV specific CD4+ T-cells have been isolated from healthy EBV seropositive donors and 
shown to be able to produce multiple cytokines and also be directly cytotoxic towards EBV 
infected B-cells (LCLs) in vitro.  Long et al. have described CD4+ T-cell clones specific for  
12 latent antigens from 4 proteins, and 12 lytic antigens from 8 proteins, that are capable of 
producing cytokines and having direct effector roles [188, 189].  
Direct effector CD4+ T-cell responses are possible here as the infected cell type expresses 
MHC class II. Endogenous viral antigens have been shown to enter the MHC class II 
processing pathway through multiple mechanisms. EBV proteins including EBNA2, 
EBNA3a, b and c enter the MHC class II processing pathway by intercellular antigen transfer 
to neighbouring cells, thus effectively acting as exogenous antigens [35, 190]. Antigens from 
these proteins are not thought to be processed via intracellular routes, as overexpression of 
antigen using vaccinia vectors and inhibiting autophagy do not increase CD4+ T-cell 
responses [35]. 
Other EBV proteins such as EBNA1 have been shown to enter the MHC class II processing 
pathway through intracellular routes. Intercellular routes have been dismissed through antigen 
transfer assays which co-culture antigen negative, HLA restricted recipient cells with antigen 
positive, HLA unrestricted donor cells. Some EBNA1 antigens have been proven to be 
presented through MHC class II as a consequence of autophagy [33, 191]. Interestingly, other 
EBNA1 epitopes that CD4+ T-cell clones can directly recognise enter MHC class II 
processing pathways by undetermined routes.  
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1.8 Post Transplant Lymphoproliferative Disease 
The EBV associated malignancy we are particularly interested in here is PTLD. PTLD is a 
life threatening disease that occurs in roughly 1%-11% of patients following hematopoietic 
stem cell transplant (HSCT), and between 1 and 20% in solid organ transplants (SOTs) [192, 
193]. 90% of PTLDs are EBV positive, as EBV is able to expand infected B-cells 
uncontrollably in the absence of immune pressure [194, 195]. The clinical symptoms of EBV-
positive PTLD are diverse, and patients often present with symptoms similar to those of IM. 
PTLD is a heterogeneous disease. The World Health Organisation (WHO) has classified 
PTLD into four subgroups; early lesions, polymorphic, monomorphic, lymphomatous and 
Hodgkin lymphoma-like [196]. Cho et al. have characterised the EBV DNA in transplant 
patients and have identified that the peak EBV-DNA level is able to predict PTLD 
development [197]. Indeed, EBV load in patient blood is closely monitored post-transplant 
and patients are treated if this starts to rise [198]. 
1.8.1 Incidence and risk factors 
A number of factors are associated with an increased risk of developing PTLD, accounting for 
the range in incidence. These include the type of organ transplanted, with lung, heart, liver 
and kidney transplants being associated with the lowest risk (1-10%) and the small bowel 
being associated with the highest risk (20%) [192].The amount of transferred lymphoid tissue 
is dependent upon the type of organ transplanted, and has been shown to influence PTLD 
[199] . The EBV sero-status of both transplant donor and recipient has a large influence in the 
development of PTLD, with EBV seronegative recipients and seropositive donors being at 
highest risk [200]. For this reason, there is a high incidence of PTLD within young children, 
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who are more likely to be EBV seronegative. Additionally, young children have been shown 
to be at higher risk of developing PTLD, regardless of prior EBV status, along with patients 
over the age of 60 [201, 202]. The type and intensity of immune conditioning prior to 
treatment also influences PTLD development, with more immune suppression leading to a 
greater risk of developing PTLD [202].  As SOT transplants remain on some level of 
immunosuppression throughout life, PTLD can develop at any point after transplant, and has 
been reported up to 14 years post-transplant [203]. Additional factors influence the risk of 
PTLD development following HSCT, with the greatest being the type of preconditioning. The 
incidence of PTLD increased with the introduction of T-cell depleted grafts, which was 
introduced in order to avoid GvHD [204]. This puts recipients at higher risk of developing 
PTLD of donor origin because of the lack of T-cells to control the infection. Finally, HLA 
mismatch can influence PTLD development. If the PTLD arises from the recipient and 
antigens are being expressed through HLA alleles that are not common between the donor and 
recipient, donor T-cells may not be able to control the lymphoproliferation completely. 
Together, these risk factors have a cumulative effect on the development of PTLD.  
1.8.2 Clinical symptoms and morphology 
As a heterogeneous disease, PTLD has many clinical and morphological manifestations.  
Depending on the time of PTLD onset, lesions may contain monomorphic or polymorphic 
cells. These cells may be monoclonal or polyclonal. Clinical symptoms are diverse, often 
including fever, sweats, malaise, weight loss, enlarged tonsils, cervical lymphadenopathy, 
organ dysfunction and infectious complications [192]. The median onset of PTLD is 6 
months, yet it has been reported to arise from one week to over ten years after transplant 
[205].  
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Early-onset PTLD arises most commonly in HSCT patients, who are severely 
immunocompromised, within one year of receiving the transplant. These lesions are often 
polyclonal and polymorphic. Early-onset PTLD has a high association with EBV, with many 
cases expressing a latency III gene expression profile [206, 207]. Therefore, LCLs are a good 
model of PTLD. Indeed, they have been used extensively as a model of PTLD when 
investigating PTLD treatment options.   
Patients who received SOT also most commonly develop PTLD within a year, as this is when 
immunodeficiency is greatest, although continuing immunosuppression means that PTLD 
may develop after a year (late-onset) [166]. In these conditions, EBV is able to transform B-
cells. However, due to immune pressure (albeit limited compared to immunocompetent 
people) EBV gene expression is often restricted to avoid detection, and the tumours often 
carry cellular mutations such as p53, RAS or c-Myc. Hodgkin’s like lymphoma PTLD 
expressing a latency II profile is common in PTLD following SOT. Lesions are often 
monoclonal and monomorphic. Further, EBV is less frequently associated with late-onset 
PTLD, with only 66% of cases being EBV positive [208]. One hypothesis for the 
development of EBV negative PTLD is that the lesions were originally EBV positive, driving 
B-cells to proliferate. This increased proliferation drives cellular mutations of tumour 
suppressors and oncogenes. Supporting this theory, late-onset PTLDs have been associated 
with mutations in RAS, p53, c-myc and BCL-6 [209, 210].  
1.9 Treatment of Post-Transplant Lymphoproliferative Disease 
PTLD is associated with a high mortality rate. Despite the range of treatments available, over 
30% of patients with refractory disease die from PTLD [211, 212].  The main treatments for 
CHAPTER 1  Introduction 
73 
 
PTLD include depletion of CD20 positive B-cells by the chimeric monoclonal antibody 
Rituximab, and reducing immunosuppression with anti-viral therapy.  
Rituximab has been used against both HSCT- and SOT-derived PTLD, with varying 
responses. Phase II trials using Rituximab as a single agent to treat PTLD after SOT have 
shown response rates between 42%-70% [213, 214]. This range of response is likely due to 
time of diagnosis and type of organs transplanted.  
However, these patients often relapse, and the mortality rate associated with this treatment is 
50-80%, with the average survival time being 35 months [204, 215]. Furthermore, rituximab 
is associated with a diverse range of side effects, including: immediate hypersensitivity to the 
infusion, nausea, vomiting, fever and chills, systemic effects of tumour degradation, 
neutropenia, and profound B lymphocyte depletion with increased susceptibility for 
cytomegalovirus (CMV) reactivation. This clearly highlights the need for more effective and 
less toxic therapies. 
Reduction in immunotherapy is commonly used as treatment for PTLD following SOT. In 
HSCT patients whose immune system has been fully ablated, reducing immunosuppression is 
often ineffective, as reconstitution of the donor derived immune system is not increased. 
Reduction in immunosuppression in 67 SOT patients resulted in 45% of patients responding, 
however half of these relapsed [216]. Treatment led to graft rejection in 32% of these patients, 
highlighting the limitations of this therapy. Nevertheless, reduction in immunosuppression has 
clear benefit to some PTLD patients – namely those that develop early-onset PTLD following 
SOT. Reducing immunosuppression in early-onset PTLD (less than one year after transplant) 
gives response rates of 80%, yet responses in late-onset PTLD are as low as 6% [217]. This 
difference is likely due somewhat to the different EBV gene expression in early- and late-
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onset PTLD. As early-onset PTLD commonly presents with a latency III profile, reducing 
immunosuppression allows the immune system to target immunodominant viral antigens. 
Later stage PTLD, with limited EBV gene expression, has reduced immunogenicity. This 
suggests that treating PTLD in a stratified manner, according to the time of disease onset, and 
type of transplant, could have beneficial effects in the clinic. 
There are other treatments for PTLD, including, radiotherapy, cytokine therapy and surgery. 
Chemotherapy combined with Rituximab has shown to increase the overall response to 
therapy; however it is associated with treatment related toxicity. In a retrospective study of 35 
patients, overall response was increased by 6% when patients received Rituximab and 
chemotherapy rather than Rituximab alone. Nevertheless, 26% of patients receiving 
chemotherapy died of toxicity [218]. Chemotherapy is often used to treat PTLD patients after 
SOT but not after HSCT as these patients have already been treated with extensive 
chemotherapy and thus treatment related toxicity would likely be high [219]. 
EBV-associated tumours can also be targeted specifically due to the presence of the EBV 
genome, however identifying a clear way to deliver EBV specific drugs to their target T-cells 
has been challenging. Ghosh et al. have performed a phase I/II trial, in which they combined 
lytic inducers with anti-viral drugs. Anti-viral drugs such as acyclovir are phosphorylated by 
viral derived kinases. Phosphorylated acyclovir is a competitive nucleoside analogue that gets 
incorporated into viral DNA during replication and from here inhibits viral DNA polymerase 
activity [220]. Therefore anti-viral drugs are only toxic to lytically replicating virus. 
Consequently, increasing the frequency of lytic replication in infected cells should increase 
the therapeutic effect. They found this combination to be effective, with 10 of 15 patients 
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showing anti-tumour responses. However, toxicity due to rapid tumour cell lysis occurred in 
three patients [221].  
1.9.1 Immunotherapy to treat PTLD 
EBV-related tumours can be treated with immunotherapy because they express viral antigens 
and so can be targeted specifically. PTLD in particular is a target of immunotherapy, as it 
occurs in an immunocompromised host and expresses viral target antigens. As such, there are 
numerous epitopes that could be targeted. 
1.9.2 DLI and CTL Infusion 
DLI has been clinically utilised for relapse following HSCT in multiple haematological 
diseases and for the treatment of PTLD [222]. DLI can abolish PTLD, however not without 
considerable risk of developing GvHD due to mismatched HLA alleles [101, 223, 224]. A 
safer form of DLI has been developed; donor derived EBV-specific CTLs. 
CTLs are expanded in vitro by reactivation of PBMCs using donor-derived LCLs or specific 
EBV peptides. Reactivated T-cells can therefore be polyclonal for a variety of EBV epitopes, 
increasing the immune response. Toxicity is reduced as selecting for EBV-specific CTLs 
reduces the risk of GvHD. Adoptively transferred EBV specific CTLs can survive in vivo (8 
years), proliferate, and reduce EBV load in 20% of patients who have EBV reactivation 
following transplant [225, 226]. Furthermore, when used as a prophylactic treatment, EBV-
specific T-cell infusions resulted in 0/58 post-transplant patients developing PTLD, compared 
to 11.5% of (historical) control patients [192, 227]. In a fifteen year summary of all EBV-
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CTL infusions for the treatment of PTLD, 67% of patients who had received a HSCT and 
51% of patients who had received a SOT responded [228].  
One major drawback of EBV-CTL therapy is the production time. To stimulate and expand 
enough CTLs for clinical relevance takes between three to four months, as LCLs need to be 
generated and then used to expand EBV-specific T-cells to clinically relevant numbers. To 
overcome this, third party EBV-CTL bio-banks have been established, which eliminate this 
lag to treatment [229, 230]. The third party EBV-CTLs were used in a phase II trial to treat 
patients following SOT, as donor blood is often unavailable. They have shown that after six 
weeks 52% of patients respond, in a poor prognosis group unresponsive to conventional 
treatments. CTLs were selected on a best HLA match basis and patients receiving closer HLA 
matches had stronger responses.  At a T-cell infusion rate of 2 million T-cells per kg, once a 
week for four weeks, no toxicity was noted [229]. Despite these advances, 48% of patients do 
not respond to this therapy. Efforts are thus on-going to increase the cure rate following 
PTLD. One such effort includes the use of genetic engineering of EBV-CTLs to render them 
resistant to immune suppressive drugs. Ricciardelli et al. have developed calcineurin resistant 
EBV-CTLs, which allow them to persist in the face of drug-induced immune suppression, 
such is the case for SOT patients [231]. CTLs engineered with this construct survived better 
than control CTLs when tested against human EBV positive B-cell lymphomas in the 
presence of steroids in vivo. Furthermore, tumour bearing mice that were treated with these 
engineered T-cells had significantly improved survival than mice treated with control EBV-
CTLs [232].  
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1.9.3 TCR Gene Transfer for Treatment of PTLD 
TCR gene transfer for the treatment of PTLD has not yet been fully explored. Limited MHC 
class I restricted EBV specific TCRs for the treatment of a range of EBV associated 
malignancies have been isolated. Whilst these may be useful in the treatment of PTLD they 
have not been tested in such setting to date. Of the studies performed, early studies 
investigating EBV specific TCR transduced T-cells showed limited efficacy.  In 2001, 
Orentas et al. isolated a class I restricted LMP2 specific TCR for the treatment of EBV 
positive malignancies which express a latency II gene programme. Through in vitro functional 
studies the group demonstrated limited IFNγ production in response to peptide exposed target 
T-cells [233]. Furthermore, Jurgens et al. have isolated TCRs restricted through HLA A2, 
A23, and A24, specific for LMP2. T-cells transduced with these TCRs were able to lyse a 
proportion of LCLs in vitro, albeit only at high effector: target ratios and again, only when 
targets were pre-exposed to peptide [234]. Recent studies have showed more convincing anti-
tumour responses, with Zheng et al. demonstrating the efficacy of LMP2 TCR gene transfer 
therapy. Here the TCR was restricted through the HLA allele A11 which is common in the 
Chinese population, in order to treat a large proportion of nasopharyngeal carcinoma patients. 
Transduction with this TCR led to proliferation, cytokine release and cytotoxicity to target T-
cells both in vitro and in vivo [235].  
Despite the proven importance of CD4+ T-cells in anti-tumour immunity, this T-cell subset 
has not been fully explored in the context of TCR gene transfer. Specifically, CD4+ T-cells 
have been suggested to enhance T-cell responses towards PTLD, and yet MHC class II 
restricted TCRs specific for EBV antigens have not been isolated [229, 236]. LMP2 specific 
MHC class I restricted TCRs have been transduced into CD4+ T-cells and shown to be 
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functional; transduced T-cells have shown tumour protection in vivo [235, 237]. However, to 
our knowledge, there has not been an MHC class II restricted gene transfer therapy that 
targets an EBV epitope.  
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1.10 Scope of thesis 
This thesis focuses on the generation of an MHC class II restricted TCR gene transfer therapy 
for the treatment of PTLD and other EBV associated malignancies which express EBNA2. 
These include AIDs related lymphomas and DLBCLs. MHC class I restricted TCR gene 
transfer has been studied in depth but to date, reports on the feasibility and efficacy of MHC 
class II restricted TCR gene transfer are more limited.  
As CD4+ T-cells respond to tumours in multiple ways, including producing cytokines to 
orchestrate both the adaptive and innate immune response, and directly recognising and 
killing tumour cells, I have isolated an MHC class II specific TCR, and transduced this into 
both CD4+ and CD8+ T-cells.   By generating tumour specific MHC class II restricted T-cells 
we can improve the immune response to tumours through CD4+ T-cell activation. 
Furthermore, some tumours evade immune responses by down-regulating MHC class I, and 
therefore targeting MHC class II restricted epitopes increases our range of potential targets 
[238, 239]. We aim to isolate CD4+ T-cells which, through a range of in vitro studies, show 
therapeutic potential. We plan to clone TCRs from these cells intro retroviral constructs to 
allow for the transduction of healthy donor T-cells. Transduced T-cells will be subjected to a 
range of in vitro and in vivo assays to establish their therapeutic potential. Finally, we aim to 
explore EBV protein expression in PTLD to determine if there are any other EBV proteins 
which would make good targets for TCR gene transfer therapy for the treatment of this 
disease.
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     CHAPTER 2 
2 Materials and Methods 
2.1 Tissue culture  
2.1.1 Culture mediums 
Standard Culture Media: RPMI 1640 media (Sigma) supplemented with 2 mM L-
glutamine (Gibco), 100 IU/ml penicillin (Gibco), 100 μg/ml streptomycin (Gibco) and 10% 
fetal bovine serum (FBS) (Biosera) 
T-cell media: standard culture media supplemented with 1% pooled human serum (TCS 
Biosciences) and 100U/ml Proleukin (IL2) (Novartis). 
CD4 cloning media: standard culture media supplemented with 1% HuS, 50U/ml IL2 and 
30% filtered supernatant harvested from the Monkey Leukocyte Antigen 144 (MLA 144) cell 
line. 
Phoenix media: DMEM (Sigma) supplemented with 10% FCS, 2mM L-glutamine, 
100IU/ml penicillin and 100µg/ml streptomycin. 
Burkitt’s media: RPMI 1640 media supplemented with 10% B-cell serum (Life 
Technologies), 1% pyruvate (Sigma), 0.1% alpha-TG (Sigma), 2mM L-glutamine, 100IU/ml 
penicillin and 100µg/ml streptomycin. 
Freezing media: RPMI 1640 containing 2mM L-glutamine, 20% FBS and 10% DMSO 
(Fischer Scientific). 
SOC: SOB (Becton Dickinson) media, supplemented with 2% filter sterilised 20% glucose. 
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MLA 144: Supernatant from the Monkey Leukocyte Antigen 144 cell line (lymphosarcoma) 
cultured for 2 weeks in standard media was filtered through 0.45µM filters and stocks frozen 
at -20 °C.  
MACs buffer: PBS with 0.5% Bovine Serum Albumin (BSA) and 2.5mM 
Ethylenediaminetetraacetic acid (EDTA). 
TAE: 1x TAE made up from 50x TAE Ultra Pure buffer (Geneflow) in deionised H2O. 
Coating buffer: 10x stock was made of 1.36g Sodium Carbonate (Sigma), 7.35g 
Potassium bicarbonate (Sigma) and 100ml H2O. The buffer was adjusted to pH9.2 with 1M 
HCL (Sigma) or 1M NaOH (Sigma). 
Blocking buffer: 5g of BSA (Sigma) and 250µl of tween (Fischer Scientific) was 
added to 500ml of PBS (Thermo Scientific). 
2.1.2 Generation and maintenance of LCLs 
Lymphoblastoid cell lines (LCLs) were generated by in vitro transformation of B cells with 
EBV. To generate LCL, 4ml supernatant from virus producer lines (B95.8 or Ag876 EBV 
strains) was spun at 509 x g for 5 min to pellet cell debris. Supernatant was then filtered 
through a 0.45µm syringe filter and combined with 0.5ml FBS (Biosera) and used to re-
suspend 5-10 million pelleted PBMCs. After an overnight incubation at 37 °C 5% CO2, 
PBMC/virus mix was spun at 800 x g for 5 min. Supernatant was discarded and PBMCs 
resuspended in 2ml culture media supplemented with 1µg/ml cyclosporin A (Sandoz) in a 24 
well plate. Cells were split when they had proliferated sufficiently and maintained in culture 
media. 
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The LCLs used were either generated for this study or had been previously made during 
earlier work and stored in liquid nitrogen. Frozen cell lines were thawed as described below. 
2.1.3 Cryopreservation 
For cryopreservation, cells were centrifuged at 800 g x 5 min to obtain a viable pellet. Cells 
were resuspended in freezing media and transferred to a sterile 1.8ml cryovial (Thermo 
Scientific, Nunc). They were immediately transferred to a -80 °C freezer in a ‘Mr Frosty’ – a 
container containing isopropanol that is designed to lower the temperature of vials contained 
therein at a rate of -1 °C/min. When at -80 °C, cells were transferred to liquid nitrogen for 
long term storage.  
2.1.4 Cell restoration 
Cells were removed from nitrogen into a 37 °C water bath to thaw. Immediately after 
thawing, cells were suspended into their relevant media and washed twice via centrifugation 
to remove freezing media. Cells were then transferred to an appropriate culture flask or plate 
and incubated at 37 °C and 5% CO2.  
For T-cell clones, one million cells were recovered from nitrogen as above and resuspended 
into a well of a 24-well plate. The well contained 1 million allogeneic PBMCs from three 
donors that had been Phytohemagglutinin (PHA) (Life Technologies)-treated (10µg/ml) 
overnight and 1x105 HLA matched LCLs pre-exposed to cognate peptide (Alta Biosciences). 
Both PBMCs and LCL had been previously irradiated at 4000 rads.  
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2.1.5 Mycoplasma testing 
Cell lines were routinely tested for the presence of mycoplasma. 200µl of cell supernatant 
was centrifuged at 800 x g for 5 min. Of this, 15µl was added to a 96 well optiplate, with 
15µl room temperature mycoalert reagent (Cambrex) and mixed by pipetting. This was 
counted on TopCount NXTTM  microplate scintillation and luminescence counter (Perkin 
Elmer) for 1 second per well. Subsequently, 15µl of mycoalert substrate was added and the 
count was repeated. If the second count was greater than the first the culture being tested was 
mycoplasma positive and good laboratory practise was used to control the infection.  
2.1.6 Maintenance of adherent cell lines 
Phoenix cells were maintained in appropriate media. When cells reached between 75% and 
100% confluencey, they were split. To split adherent cells, media was removed and cells 
were washed with PBS. 0.05% trypsin (Gibco) diluted in PBS was added to the cells. They 
were then incubated until they entered suspension. The trypsinisation reaction was then 
inhibited from proceeding further by the addition of appropriate media containing serum. The 
cells were subsequently counted and seeded at lower density.  
2.2 Cloning EBV-specific T-cells 
2.2.1 Donors & Consent 
All blood donors used throughout this thesis were healthy volunteers who had provided 
written informed consent to participate in the study. The work was carried out under ethical 
approval by the South Birmingham Local Research Ethics Committee (07/Q2702/24). 
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2.2.2 Isolation of CD4+ T-cells from healthy donors 
Peripheral blood mononuclear cells (PBMCs) from blood of consenting, healthy EBV carriers 
with known HLA types were isolated by density centrifugation using Lymphoprep (Axis-
Shield). Blood was mixed with RPMI at a 1:1 ratio and layered onto lymphoprep. This was 
centrifuged at 800 x g for 30 min (no brake), and the mononuclear cells were isolated from 
the interface of plasma and lymphoprep. The harvested PBMCs were centrifuged in RPMI at 
800 x g for 10 min (low brake), then washed again with RPMI but centrifuged at 600 x g for 
10 min (low brake). A third wash in RPMI was conducted at 400 x g for 5 min (high brake) 
and resuspsended in culture media.   CD8+ cells were subsequently depleted using CD8+ 
dynabeads (Invitrogen) according to the manufacturer’s instructions. 
2.2.3 Reactivation of PRS specific CD4 T-cells and T-cell cloning 
CD8-depleted PBMCs were stimulated by addition of 5µM epitope peptide (either the 
EBNA2 derived peptide, “PRS” (PRSTVFYNIPPMPLPPSQL) or the BZLF1 derived 
peptide, “LTA” (LTAYHVSTAPTGSW)) for one hour. The cells were subsequently washed 
in standard media to remove the peptide and cultured in a 24-well plate at 1x106 cells/ml. 
One week later, the PBMCs were harvested and restimulated for three hours with 5µM of the 
same epitope peptide.  Responding cells were isolated using an IFNγ secretion assay 
(Miltenyi Biotec) according to the manufacturer’s instructions. Captured cells were plated out 
at 0.3 and 3 cells per well of 96-well plates in a limiting dilution cloning protocol as 
previously described [240].  From 2 weeks, Growing microcultures were screened for 
response to peptide by IFNγ ELISA from plates where less than a third of wells had growing 
cells. 
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2.2.4 Expansion of T-cell cultures 
PRS-specific T-cell cultures were expanded from 200 µl volumes into 2ml CD4 cloning 
media containing 105 peptide-pulsed γ-irradiated (4000 rads) LCLs and 106 γ-irradiated (4000 
rads) phytohemagglutinin-treated (10µg/ml) mixed allogeneic buffy coat feeder cells 
(Birmingham National Blood Service). 
2.2.5 Maintenance of T-cells  
T-cell clones were maintained in CD4 cloning media. Clones were fed twice a week, or when 
the media appeared exhausted. When cells reached 1 million per ml, cells were split into two 
wells. Clones were maintained by the addition of 1 million irradiated (4000 rads) healthy 
donor PBMCs from three donors every two weeks or when necessary. 
Transduced T-cells were maintained in T-cell media. Media was changed every three to four 
days. Cells were split when they reached between one and two million cells per ml.  
2.3 Functional analysis T-cell clones 
2.3.1 IFNγ ELISA 
Standard ELISAs involved pre-exposing LCLs to 5µg peptide or DMSO (unless otherwise 
stated) for 90 min and washing three times with standard media. LCLs and T-cells were co-
cultured overnight at ratios stated at 37 °C 5% CO2. The following day, the level of IFNγ 
released into the supernatant by responding T-cells was determined using the Thermo 
Scientific IFNγ ELISA protocol. Here, primary IFNγ antibody was diluted 1 in 1351 with 
ELISA coating buffer and 50 µl was added to each well of a 96 well Maxisorp plate (Nunc). 
The plate was incubated at 4°C overnight and blocked with 200µl blocking buffer the 
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following day. This was washed off with PBS and 100µl of test supernatant or IFNγ standard 
was added. IFNγ standard was made by double dilutions of IFNγ from 20,000 pg/ml to 
0pg/ml in RPMI. After two hour incubation at room temperature, the wash was repeated and 
the secondary, biotin labelled IFNγ antibody was added to each well (50µl of a 1 in 1351 
dilution in blocking buffer). This was incubated at room temperature for one hour and then 
the plate was washed in PBS. 50µl of Extravidin (Sigma)  was then added to each well and 
the plate incubated at room temperature for half an hour. Following this, the plate was 
washed and 50µl of TMB (Life Technologies) was added to each well. When the standard 
had developed, 50µl of 1M HCL was added to each well and the plates were read on the 
Biorad iMark microplate reader.  
For peptide titrations, target LCLs were exposed to ten-fold dilutions of peptide, ranging 
from 5µM to 5pM and incubated at 37oC/5%CO2 for 90 min re-suspending cells every 20-
30mins. Peptide exposed LCLs were washed five times at 400 x g for 5 min in LCL media 
prior to use.  
Where CD4 and CD8 T-cells were analysed separately, the relevant subsets were isolated 
through negative selection using CD4 or CD8 dynabeads (Dynal), as per the manufacturer’s 
instructions. After depletions, a sample of each cell population was stained with both anti-
CD4 and CD8 antibodies to assess purity.  
2.3.2 MHC class II Tetramer staining 
1x106 T-cells were washed in 500µl HuS. 0.5µl relevant HLA class II tetramer /peptide 
(made by Eddie James, Benaroya Research Institute, Seattle) was added in 100µl HuS and 
cells incubated for 2 hours at 37°C in the dark with frequent re-suspension [187]. After three 
washes in cold MACs buffer, cells were stained with anti-CD4 and anti-CD8 antibodies 
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conjugated to various fluorophores (see Table x) for 20 min at 4°C. After washing, cells were 
fixed in 500µl 2% paraformaldehyde (PFA – Fischer Scientific) before analysis on an Epics 
flow cytometer (Beckman Coulter). All data were processed using Flowjo software 
(TreeStar) version 7.6.5.   
2.4 Construction of retroviral plasmid 
2.4.1 RNA extraction from T-cell clones 
RNA was isolated from PRS and LTA-specific T-cell clones following the RNAeasy minikit 
protocol (Qiagen), as per the manufacturer’s instructions. RNA was either used immediately 
or stored at -80 °C. 
2.4.2 Rapid Amplification of cDNA ends 
TCR alpha and beta genes were amplified using gene specific primers, following the 
SMARTer RACE cDNA Amplification Kit and Advantage 2 PCR kits (Clontech) according 
to recommended protocols. 
Alpha primer: 5’-TAG GCA GAC AGA CTT GTC ACT GGA TT-3’  
Beta primer: 5’-CGA CCT CCT TCC CAT TCA CCC AC-3’ 
Cycling parameters for the PCR reaction were as follows: 5 cycles of 94 degrees 5 sec, 72 
degrees 3 min. 5 cycles of 94 degrees 5 sec, 68 degrees 10 sec, 72 degrees 3 min. 27 cycles of 
94 degrees 5 sec, 65 degrees 10 sec, 72 degrees 3 min, 4 degree hold.   
Resulting DNA was ran on a 1% ultra pure agarose (Invitrogen) gel. Bands of the correct size 
(600-800 bp) were cut out and DNA was isolated using the Qiagen Gel Extraction kit and 
corresponding protocol.  
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2.4.3 DNA cloning  
The Alpha and beta TCR gene sequences were cloned into TOPO TA vectors (Invitrogen) in 
accordance with the manufacturer’s instructions. 4.5µl of DNA was added to 0.5µl of the 
TOPO vector. This was incubated on at room temperature for 20 min and then put on ice. 1µl 
of this mixture was added to 50µl of competent cells on ice and left for 20 min. Following 
this the cells were heat shocked at 42 °C for 30 seconds and then put back on ice for 2 min. 
After the addition of 250µl SOC media the mixtures were shaken in a 37 °C incubator for one 
hour. This was then spread onto pre-warmed agar + 100µg/ml ampicillin (Roche) plates 
which were incubated at 37 °C overnight.  The following day, individual colonies were 
picked and added to 50µl H2O and re-plated onto a new agar plate with 100µg/ml ampicillin. 
The bacteria in H2O was heated to 100 °C for 10 min. 5µl of this was added to a PCR 
mastermix to determine which colonies were successfully transformed with the TOPO vector 
by amplifying DNA from M13 primers. The PCR mixture contained 5µl DNA, 1x PCR 
buffer with Mg2+, 200µM dNTPs, 0.5mM M13 forward and 0.5mM M13 reverse primers,  1 
unit of granzyme. 
Fast Start Taq and was made up to 10µl with H2O. The PCR cycles used were as follows: 94 
°C 5 min, 40 cycles of 94 °C 20 sec, 50 °C 30 sec, 72 °C 1 min, then 72 °C for 7 min and a 
4°C hold. The agar plate with the re-plated bacteria was incubated at 37 °C 5% CO2 for 16 
hours and then kept at 4 °C. 
PCR reactions were run on a 1% agarose gel (Invitrogen) and colonies which gave bands at 
the expected size of 800 bp were re-picked.  These were amplified in 5ml LB broth + 
100µg/ml ampicillin for 16 hours in a 37 °C shaking incubator. DNA from these cultures was 
subsequently isolated using the Qiaprep Mini Prep kit and corresponding protocols.  
CHAPTER 2  Materials and Methods 
89 
 
 
2.4.4 DNA sequencing 
10µl reactions with 1-10 ng of DNA and 3.2 pg of M13 forward or reverse primer were sent 
to the functional genomics laboratory at Birmingham University for sequencing. Here they 
were supplemented with 0.5µl Big Dye and amplified by PCR reaction (96 °C  for 1 min 
followed by 25 cycles of 96 °C for 10 sec, 50 °C for 5 sec, 60 °C 4 min) ran on the capillary 
sequencer ABI 3730.  
2.4.5 Vector assembly  
The TCR sequence was constructed by PCR with DNA overlap extension using NEB 
Phusion High Fidelity Polymerase. Both alpha and beta variable fragments were linked to the 
previously codon optimised alpha and beta constant fragments. These full length alpha and 
beta sequences were assembled into a single gene construct separated by a 2A linker from 
porcine Teschovirus.  
Cycle parameters: 98°C 30 sec, 35 cycles of 98°C 5 sec, *°C 20 sec, 72°C 15 sec. Then 72°C 
5min, 4° hold.  
*primers variable beta, constant beta at 66°C, variable alpha and constant alpha at 68°C. 
This was then inserted into an MP71 retroviral vector (provided by C. Baum, Hannover, 
Germany) using BamH1 and Not1 restriction sites and the Quick Ligation (NEB) kit 
according to the manufacturer’s instructions (see Figure 3.10 for cloning strategy). Vectors 
were subsequently amplified through bacterial transformation, as described in DNA cloning. 
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2.4.6 Transformation 
TOP 10 (Invitrogen) competent cells were transformed with the MP71-TCR vector by heat 
shock. Briefly, competent cells were thawed on ice and DNA (100pg-10ng) was added for 
half an hour. The competent cells were then given a 30 second heat shock at 42 °C and 
returned to ice. After the addition of 250µl SOC media, cells were incubated in a shaking 
incubator at 37 °C for one hour, before being plated out on agar plates containing 100µg/ml 
ampicillin and incubated overnight. The following day, individual colonies were picked to 
grow up in LB broth with ampicillin for 16 hours. 
Vector DNA was obtained through a mini prep (Qiagen) and the MP71 vector constructs 
were analysed by restriction enzyme digestion (BamH1 and Not1, NEB) and DNA 
sequencing. 
2.4.7 Restriction enzyme digests 
For vector construction, 1µg of DNA was digested with 10 units (1µl) of relevant restriction 
enzyme, in the appropriate buffer, in a reaction volume of 25-50µl for one hour at 37 °C.  
Following digestion of the vector for insertion of the TCR alpha and beta chain sequences, 
the vector DNA was treated with 10µl Calf Intestinal Phosphatase (NEB) for one hour at 37 
°C immediately after the digest, to prevent vector re-ligation.  
Digested DNA was subsequently run on an agarose gel (0.5-2% ultra pure agarose 
(Invitrogen) depending on DNA size), in 1xTAE buffer with 1/1000 dilution of sybr green 
(Invitrogen) at 100V. 
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If the DNA was to be extracted from gel, the DNA band would be cut out and DNA isolated 
with a gel extraction kit (Clontech), as per manufacturer’s instructions. 
2.4.8 Vector amplification 
TCR-MP71 vectors were transformed into One Shot® TOP10 chemically competent E-coli 
cells (life technologies), as described in section 2.4.3. Colonies were picked the from agar + 
100µg/ml ampicillin plates the following day and cultured in 5ml LB broth + 100µg/ml 
ampicillin for 16 hours. DNA was extracted for sequencing from 1ml of this culture by 
Qiagen Mini Prep as per manufacturer’s instructions. Cultures which contained the TCR-
MP71 DNA were amplified by being added to 300ml of LB broth + 100µg/ml ampicillin and 
incubated at 37 °C overnight. DNA was isolated using the endo-free maxi prep kit (Qiagen) 
as per manufacturer’s instructions. 
2.5 Transduction 
Recombinant retrovirus was generated using the Phoenix A packaging cell line (Nolan 
Laboratory, Stanford University, Stanford, CA). Phoenix cells cultured in phoenix media and seeded on 
day 0 to reach 50 – 80% confluence on day 1.  Phoenix cells were then transfected in 
penicillin- and streptomycin- free media with the appropriate vector using fugene (Promega), 
as per manufacturer’s instructions. PBMCs were stimulated on day 1 with 300U/ml IL2, 
30ng/ml anti-CD3 (OKT3, eBioscience) and 30ng/ml anti-CD28. On day 2, media on the 
phoenix cells was replaced with fresh media. On day 3, PBMCs were transduced with 
recombinant retrovirus harvested in the supernatant from the phoenix cells as previously 
described [241]. Briefly, non-tissue culture treated plates were coated for three hours in 
retronectin (30µg/ml) (Takara) then blocked using 3% w/v BSA in PBS. After three washes 
with PBS, viral supernatant was applied and plates spun for 2 hours at 2000 x g at 37°C. The 
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plate was washed once with PBS, PBMCs added in TCM and spun down at 800 x g for 5 
min. The TCM was changed the following day and T-cells analysed for transduction two 
days later. 
2.6 Functional analysis of transduced cells 
2.6.1 Flow cytometry  
1x105 cells were resuspended in 40µl PBS and stained with 1.5µl of a 1in100 dilution of 
LIVE/DEAD® Fixable Violet Dead Cell Stain Kit (Life technologies) in the dark at room 
temperature for 20 min. After one wash in MACs buffer, cells were surface stained with 
appropriate antibodies (see Table 2.3) in 100µl MACs buffer and placed on ice in dark for 30 
min.  Cells were washed three times in cold MACs buffer and analysed on the Epics flow 
cytometer (Beckman Coulter) or BD LSR II flow cytometer. All data were processed using 
Flowjo software (TreeStar) version 7.6.5.   
2.6.2 Intracellular Cytokine Staining (ICS) 
1x106 T-cells were either co-cultured with 5x105 peptide pulsed LCLs or unmanipulated 
LCLs for an hour in TCM, or left unstimulated. Cultures were then washed twice at 400 x g 
for 5 min before being resuspended in 1ml TCM containing 10µg/ml Brefeldin A (BFA, 
Sigma) and plated out into a 48 well plate. Plates were incubated overnight at 37°C. The 
following day, cultures were washed in MACs buffer at 800 x g for 5 min, the supernatant 
discarded and anti-CD4 and anti-CD8 antibodies (see Table 2.10) were added to the residual 
buffer of relevant tubes.  Cultures were incubated for 20 min at 4° in the dark.  After washing 
in MACs buffer, all cells were resuspended in 100µl 4% PFA and incubated at 25°C for 15 
minutes in the dark. Following a wash in PBS, 100µl 0.5% saponin (sigma) was added to 
each tube and tubes were then incubated at 25°C for 5 minutes in the dark. Intracellular 
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antibodies were then added and after 30 minutes incubation at 25°C in the dark, cells were 
washed, resuspended in MACs buffer and analysed by flow cytometry as above.  
 
Figure 2.1 Gating strategy used to determine which T-cells produce one, two and three 
cytokines. Cells were gated on single cells by gating out doublets using FSC-H amd 
FSC-A. Lymphocyes were gated using FSC/SSC. Live cells were gated using 
LIVE/DEAD® Fixable Violet Dead Cell Stain and CD4+ or CD8+.  
Gate 1 was drawn and subsequent gating is drawn from gate 1 quadrants. Gates which 
contain cells which produce one, two or three cytokines are indicated by the red labels. 
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2.6.3 CD107a analysis 
T-cells were co-cultured with HLA DR52b-matched LCLs pre-exposed to 5µg/ml peptide or 
DMSO at a 4:1 target: effector ratios.  Also in the culture was 0.25µg of FITC-conjugated 
anti-CD107a (BD Biosciences) and 1x Monensin (Sigma). After 6, 12 and 24 hour 
incubations cells were washed in MACS buffer and stained with a viability dye as described 
above, followed by anti-CD4 and CD8 antibodies. Samples were analysed on the BD LSR II 
Flow Cytometer. All data were processed using Flowjo software (TreeStar) version 7.6.5. 
2.6.4 Proliferation 
Autologous LCLs were irradiated at 4000 rads then exposed to 5µg/ml PRS or DMSO for 90 
min and washed twice in culture media. T-cells were labelled with 1µM CFSE (Invitrogen) 
and co-cultured with  DMSO and peptide exposed LCL for 5 days at a responder: stimulator 
ratio of 1:10. On day 5, surface staining for CD4 and/or CD8 was performed (see above) and 
samples analysed as described above. 
2.6.5 DC maturation assay 
Autologous immature DCs (iDCs) were isolated from PBMCs by leaving PBMCs 
undisturbed in a flask for 2 hours, after which non adherent cells were removed. The adherent 
cells were differentiated into immature-DCs by culturing in standard culture media 
supplemented with 50ng/ml IL4, 50ng/ml GMCSF (Peprotech) for 5 days. On day 5, iDCs 
were exposed to epitope peptide or not for 90 min and co-cultured for two days with T-cells 
at a 1:1 T-cell: DC ratio, in TCM supplemented with 10U/ml IL2.  iDCs in TCM + 10U/ml 
IL2 acted as the negative control, and iDCs matured by culture in TCM with 10U/ml IL2 and 
10ng/ml IL1β, 100ng/ml IL6, 20ng/ml TNFα, 50ng/ml IL4, 50ng/ml GMCSF (peprotech) were 
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the positive control. On day 7, cultures were analysed by flow cytometry for live cells using 
the LIVE/DEAD® Fixable Violet Dead Cell Stain Kit (Life technologies) , and for the 
surface expression of CD3, CD83, HLA DR, CD86 and CD40 (for antibodies, see Table 2.3). 
2.6.6 Chromium Release Assay 
LCL Targets were labelled with 50µCi  51Cr (Perkin Elmer) for two hours whilst being 
exposed to 5µg/ml peptide or not. After washing with culture media, targets were co-cultured 
with T-cells in triplicate wells of a 96-well V-bottom plate at defined effector: target ratios as 
described in the results. The percentage of 51Cr released into the culture supernatant after 5 
and/or 12 hours incubation was measured using the Cobra II Gamma Counter (Packard). 
Percent specific lysis was calculated as follows: (target release-spontaneous 
release)/(maximum release - spontaneous release)*100. 
2.6.7 Outgrowth assay 
For outgrowth assays, autologous LCLs were exposed to 5µg/ml peptide or not for 90 min. 
LCLs were then washed five times in culture media and plated out in a sterile 96 well U 
bottom plate at doubling dilutions from 1x105 to 97 LCLs per well. 1x105 T-cells were 
subsequently washed and added to wells containing the LCL. Control wells were also set up 
containing LCL or T-cells alone and all cells were then incubated at 37 °C 5% CO2 for four 
weeks. Media was changed weekly. The outgrowth of LCL cells was assessed at 4 weeks 
visually. 
2.7 In vivo 
All work was carried out under a Home Office approved Project and Personal Licence.  
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2.7.1 Generation of Luciferase transduced LCLs 
The pMSCV luciferase plasmid contained a puromycin resistance gene. This was amplified in 
Phoenix A cells and harvested as described above. 2ml Retronectin (30µg/ml) was added to 
the wells of 6 well non tissue culture treated plates and these were left at 4 °C overnight. The 
following day, the wells were blocked with 2.5ml of 2% BSA for 30 min. After three washes 
in PBS, 2ml supernatant harvested from the Phoenix A cells was added to each well and the 
plates were centrifuged at 2000 x g for 2 hr at 37 °C. LCLs were seeded at a concentration of 
3x106/ml in standard culture media, and added to retrovirus coated plates. These were 
centrifuged at 800 x g for 4 min and then incubated at 37 °C 5% CO2.  
After four days incubation, standard culture media was  supplemented with 1µg/ml 
puromcyin (Sigma), to select transduced LCLs.  
2.7.2 Injection of LCLs  
LCLs were washed in PBS and resuspended in PBS at the required concentration. Cells were 
kept on ice and 200µl was injected, subcutaneously into the flank or intraperitoneally, into 
mice. For subcutaneous injection, mice were anaesthetised and shaved prior to injection.  
2.7.3 Injection of T-cells 
T-cells were washed and resuspended in RPMI at the required concentration. Cells were kept 
on ice and a maximum of 200µl was injected intravenously into the mouse tail vein. 
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2.7.4 Injection of Decitabine 
0.25mg/kg decitabine was injected into mice once on day 0 and twice on days 1, 2 and 3, 
intraperitoneally. 
2.7.5 Peritoneal Wash 
LCLs were retrieved from culled mice by intraperitoneal washing. 5ml PBS was injected into 
the mouse peritoneum. The peritoneum was subsequently massaged to dislodge LCLs and the 
PBS was isolated by syringe.  
2.7.6 In vivo monitoring 
Mice were monitored three times a week for tumour size by caliper (for subcutaneous 
tumours) and once a week by bioluminescence imaging (IVIS Spectrum, Caliper Life 
Sciences) ( for IP tumours). For IVIS imaging, mice were injected with 10µl luciferin per 
gram of body weight. After five minutes, mice were anaesthetised with Isoflurane and 
imaged.  
Mice were monitored three times a week for signs of distress including weight loss, lethargy, 
ruffled fur, disinterest in surroundings, body condition, changes in colour of feet and ears, 
bulging cheeks. Mice were culled by a schedule 1 method when showing signs of distress or 
at experimental end points. 
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2.8 Immunohistochemistry 
2.8.1 TPA induction of Akata cells  
EBV positive Akata cells were thawed and cultured in Burkitt’s media, at 1x106/ml. To 
induce Akata cells into lytic cycle, cells were seeded at 0.5x10x106/ml in a 24 well plate to 
which 20µg/ml Tetradecanoyl Phorbol Acetate (TPA) (New England Biolabs) and 3µl/ml of 
1M Sodium Butyrate (Sigma) were added. After incubation at 37 °C overnight at 5% CO2, 
cells were washed and plated out at 2x106 per well of a 6 well plate, in 6ml Burkitt’s media. 
After 48 hours incubation, cells were spun down onto microslides using the cytospin 
preparation method.  
2.8.2 Cytospin preparation 
2x106 cells were spun onto each X-tra adhesive microslide (Suripath Europe) in cytospin 
preparation. Cells were resuspended in PBS and fixed with 4%  formaldehyde (Sigma 
Aldrich). Slides were assembled into cytoclips (Thermo Fisher Scientific) and covered with 
filter cards (Thermo Fisher Scientific). Plastic Cytofunnel disposable sample chambers 
(Thermo Fisher Scientific) were placed on top of the filter before the metal clamp was closed. 
These coverslips were then placed into the cytospin 3 cytocentrifuge (Shandon) before cells 
were added via the funnel. Cells were spun onto the slides at 400 x g for 5 min and then air 
dried for 30 min. The slides of were either stained immediately or stored at -20°C until use.  
2.8.3 Immunohistochemistry staining 
Immunohistochemistry was performed on paraffin embedded tissue sections and cytospun 
cells. With ethical approval, PTLD biopsies were obtained from Human Biomaterials 
Resource Centre (HBRC) at the University of Birmingham and Nottingham Tissue Biobanks. 
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Paraffin embedded samples were de-waxed in histoclear (National Diagnostics) for 10 min 
and dehydrated in industrial methylated spirits for 5 min (Sigma Aldrich). Hereafter, the 
same methods were applied to cytospins and fixed tissue samples. Endogenous peroxide 
activity was blocked with 0.3% H202 (Sigma Aldrich) for 15 min, followed by antigen 
retrieval as described: Citrate buffer (1.26g sodium citrate and 0.25g citric acid in 1L distilled 
water pH 6.0) was boiled in an 800 watt microwave for 10 min at high power and then slides 
were added. These were microwaved for 10 min at medium power, 10 min at low power, and 
then left at room temperature or 4°C until cool.  After washing for 5 min in water, circles 
were drawn around the samples using an ImmEdge Hydrophobic Barrier Pen (Vector 
Laboratories Ltd) to prevent dispersion of antibodies. Slides were conditioned with PBS-
Tween 20 (0.1%) (PBST) for 5 min before blocking with 5x Casein blocking solution (Vector 
Laboratories Ltd). Primary antibodies were added and left at 4 °C overnight (see Table for 
list of antibodies and dilutions). The following day, slides were washed with PBST (3 x 3 in)  
before the addition of the secondary antibodies, and incubated at room temperature for 30 
min. After three more washes with PBST, DAB substrate was added (ImmPACT DAB 
Substrate System, Vector Laboratories) for between 1-5 min for visualisation. Slides were 
washed in water for 5 min then stained by Mayer’s haematoxylin  (Sigma Aldrich) for 1 min. 
Slides were washed in warm water for 5 min before being placed in IMS for 15 min and 
histoclear for 10 min. DPX mounting solution (Sigma Aldrich) was utilised to attach cover 
slips to the slides.  
2.8.4 In Situ Hybridisation 
In Situ Hibridisation (ISH) was performed using RNA free equipment. Slides containing 
formalin fixed tissues were de-waxed in histoclear for 10 min and hydrated by two washes in 
99% ethanol (Sigma Alrich) for 3 min. Slides were then washed in 95% ethanol for 3 min and 
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washed twice in water for 3 min each. The ImmEdge hydrophobic barrier pen was used to 
draw circles around tissues, then the slides were covered in proteinase K (Sigma Alrich) 
(5µg/ml) in 50mM TRIS/HCL buffer (pH 7.6) for 30 min at 37°. Slides were then washed 
twice in water for 3 min and dehydrated by washing in 95% ethanol for 3 min, followed by 
99% ethanol for 3 min. Tissues were air dried before addition of the probe hybridisation 
solution (Vector). Coverslips were used to retain this solution whilst slides were incubated at 
55 °C for 90 min. Slides were subsequently washed three times in TBS 0.1% Triton-x-100 
(Sigma) for 3 min each. Tissue sections were blocked with rabbit serum (Dako) for 10 min 
before the addition of rabbit F(ab) anti FITC/AP (Vector) in TBS 3% BSA, 0.1% Triton-x-
100. Slides were incubated for 30 min at room temperature. Slides were washed twice in TBS 
for 3 min before the addition of enzyme substrate and inhibitor (levamisole)  (Vector) in 100 
mM Tris/HCI, 50 mM MgCI2, 100 mM NaCI (pH 9.0). Slides were incubated 
overnight at room temperature, in the dark. The following day, slides were washed in 
TBST followed by water for 5 min. Tissues were counterstained in fast red 
(Vector)for 2-3 min and then dehydrated in IMS for 15 min before being cleaned in 
histoclear for 10 min and mounted, using DPX.   
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2.9 Primer Tables 
Beckman 
Coulter  
(antibodies) 
IMGT 
nomenclature 
Sequence 5’ to 3’ 
TCR Vβ1 TRBV9*01  
TRBV9*02 
TRBV9*03 
CAACAGTTCCCTGACTTGCAC 
TCR Vβ2 TRBV20-1*03 
TRBV20-1*04 
TRBV20-1*05 
TRBV20-1*06 
TRBV20-1*07 
TCAACCATGCAAGCCTGACCT 
TCR Vβ3 TRBV28*01 TCTAGAGAGAAGAAGGAGCGC 
TCR Vβ4 TRBV29-1*01 
TRBV29-1*02 
TRBV29-1*03  
ACATATGAGAGTGGATTTGTCATT 
TCR Vβ5.1 TRBV5-1*01 
TRBV5-1*02 
CTTCAGTGAGACACAGAGAAAC 
TCR Vβ5.2 TRBV5-5*01 
TRBV5-5*02 
TRBV5-5*03 
TRBV5-6*01 
TRBV5-7*01  
CCTAACTATAGCTCTGAGCTG 
TCR Vβ6 TRBV7-3*04 
TRBV7-3*05 
TRBV7-8*01 
TRBV7-8*02 
TRBV7-8*03 
GGCCTGAGGGATCCGTCTC 
TCR Vβ7 TRBV4-2*02 
TRBV4-3*01 
TRBV4-3*02 
TRBV4-3*03 
TRBV4-3*04 
TGAATGCCCCAACAGCTCTC 
TCR Vβ8 TRBV12-3*01 
TRBV12-4*01 
TRBV12-4*02 
ATTTACTTTAACAACAACGTTCCG 
TCR Vβ9 TRBV3-1*01 AATCTCCAGACAAAGCTCAC 
TCR Vβ10 TRBV21-1*01 TCCAAAAACTCATCCTGTACCTT 
TCR Vβ11 TRBV25-1*01 ACCAGTCTCCAGAATAAGGACG 
TCR Vβ12 TRBV10-3*01 
TRBV10-3*02 
TRBV10-3*03 
TRBV10-3*04 
TGACAAAGGAGAAGTCTCAGAT 
TCR 
Vβ13.1 
TRBV6-5*01 GACCAAGGAGAAGTCCCCAAT 
TCR 
Vβ13.2 
TRBV6-2*01 
TRBV6-3*01 
TGGGTGAGGGTACAACTGCC 
TCR Vβ14 TRBV27*01 CTCTCGAAAAGAGAAGAGGAAT 
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TCR Vβ15 TRBV24-1*01 TCTCTCGACAGGCACAGGCT 
TCR Vβ16 TRBV14*01 AGAGTCTAAACAGGATGAGTCC 
TCR Vβ17 TRBV19*01 TCACAGATAGTAAATGACTTTCAG 
TCR Vβ18 TRBV18*01 GAGTCAGGAATGCCAAAGGAA 
TCR Vβ19 TRBV23-1*01 CCCCAAGAACGCACCCTGC 
TCR Vβ20 TRBV30*01 
TRBV30*02 
TRBV30*04 
TRBV30*05 
TGAGGTGCCCCAGAATCTC 
TCR Vβ21 TRBV11-2*03 TCCAACCTGCAAGGCTTGACGACT 
TCR Vβ22 TRBV2*01 
TRBV2*02 
TRBV2*03 
GAGAAGTCTGAAATATTCGATGATC 
TCR Vβ23 TRBV13*01 GCAGGGTCCAGGTCAGGACCCCCA 
TCR Vβ24 TRBV15*01 
TRBV15*02 
TRBV15*03 
CCCAGTTTGGAAAGCCAGTGACCC 
TCR Vβ 
constant 
 CGACCTCCTTCCCATTCACCCAC 
Table 2.1 Primer sequences used for PCR of the variable beta TCR chain. 
All sequences are written in the 5’ – 3’ orientation.  
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Primer Sequence 
C15 
Vα F 
GCGCGGCCGCACCATGAGGCAAGTGGCGAGAGTG 
C15 
Vα R 
GGGTCGGGGTTCTGGATGTTTGCTAAAACCTTCAGCCTGG 
 
C15 
Vβ F 
CGTGGAGGAAAACCCTGGCCCCATGAGAATCAGGCTCCT
GTGCTGTG 
C93 
Vα F 
GCGCGGCCGCACCATGAAGACATTTGCTGGATTTTCGTTC
C 
C93 
Vα R 
GGGTCGGGGTTCTGGATGTTTGGACTGACCAGAAGTCGG
G 
C93 
Vβ F 
GTGGAGGAAAACCCTGGCCCCATGAGCAACCAGGTGCTC
TGC 
Vβ R GAACACGTTCTTCAGGTCCTCTACAACTGTGAGTCTGGTG
CC 
C105 
Vα F 
GCGCGGCCGCACCATGGTGAAGATCCGGCAATTTTTG 
C105 
Vα R 
GGGTCGGGGTTCTGGATGTTTGGGTTGATAGTCAGCCTGG 
C105 
Vβ F 
GTGGAGGAAAACCCTGGCCCCATGATGCTCTGCTCTCTCC
TTG 
 
Cb F GAGGACCTGAAGAACGTGTTC 
Cb R GGGGATCCTCAGCCTCTGCTGTCCTTCCG 
Ca F AACATCCAGAACCCCGACCC 
Ca R GGGGCCAGGGTTTTCCTCCAC 
C140 
Vα F 
GCGCGGCCGCACCATGGCTCAGGAACTGGGAATG 
C140 
Vα R 
GGGGTCGGGGTTCTGGATGTATGGGTGTACAGCCAGCCT 
C140 
TRBV
30 F 
CGTGGAGGAAAACCCTGGCCCCATGATGCTCTGCTCTCTC
CTTG 
 
C140 
TRBV
30 R 
GAACACGTTCTTCAGGTCCTCTGTCACAGTGAGCCTGGTC 
Table 2.2 Primers used for TCR generation by sequence overlap extension. 
All primers written in 5’ to 3’ orientation.  
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2.10 Table of antibodies 
Antibody source Clone cat num concentrati
on used 
AmCyan conjugated anti-
human CD8 
BD Biosciences SK1 339188 0.5ug 
AmCyan conjugated anti-
human CD3 
BD Biosciences SK7 339186 0.5ug 
APC conjugated anti-
human TNFa 
Becton 
Dickinson 
6401.111 340534 62.5ug 
ECD conjugated anti-
human CD8 
Beckman 
Coulter 
SFCI21Thy2
D3 
737659 0.05ug 
ECD conjugated anti-
human CD4 
Beckman 
Coulter 
SFCI12T4D
11 
6604727 0.025ug 
APC-Cy7 conjugated 
anti-human CD3 
BD Biosciences SK7 557832 1ug 
Pacific Blue conjugated 
anti-human CD3 
BD Biosciences UCHT1 558117 0.2ug 
FITC conjugated anti-
human CD107a 
BD Biosciences H4A3 555800 0.25ug 
FITC conjugated anti-
human CD4 
BD Biosciences RPA-T4 555346 0.1ug 
FITC conjugated anti-
human CD3 
BD Pharmingen UCHT1  555332 0.025ug 
PE conjugated anti-
human CD4 
BD Pharmingen RPA-T4 555347 0.025ug 
PE conjugated anti-
human IL2 
BD Pharmingen MQ1-17H12 559334 7.5ng 
PE conjugated anti-
human CD3 
BD Biosciences UCHT1 555333 0.025ug 
PE conjugated anti-
human Vb17 
Beckman 
Coulter 
E17.5F3.15.
13 
PN-IM2048 
AmCyan conjugated anti-
human CD3 
BD Biosciences SK7 339186 0.5ug 
Alexa Fluor® 700 
conjugated anti-human 
DR 
BD Biosciences G46-6 560743 0.1ug 
FITC conjugated anti-
human CD83 
Biolegend HB15e 305306 0.25ug 
PE conjugated anti-
human CD86 
AbD Serotec  MCA1118PE 
PeCy5 conjugated anti-
human CD40  
BD Biosciences  555590 0.015ug 
FITC conjugated goat 
anti-mouse 
SIGMA - F2012 2ug 
mouse IgG1 isotype 
control 
R and D Systems 11711 MAB00
2 
assay 
dependent 
mouse IgG2b isotype 
control 
Dako - MCA69
1 
assay 
dependent 
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mouse anti EBV EA-R-
p17 
Millipore 5B11 MAB81
88 
1ng 
mouse anti EBV EA-D-
p52\50 
Millipore R3 MAB81
86 
1.6ug 
mouse anti EBV ZEBRA Santa Cruz BZ1 sc53904 2ug 
mouse anti EBNA1 AbD Serotec O211 4260-
0906 
10ug 
mouse anti EBNA2 Abcam PE2 ab90543 5ug 
sheep anti EBNA3a Abcam N/A ab16126 1.25ug 
mouse anti LMP1 Dako CS.1-4 M 0897 4.6ug 
rat anti EBV LMP2a Santa Cruz 1579 sc10131
5 
2ug 
mouse anti EBV VCA-
gp125 
Millipore N/A MAB81
84 
10ug 
mouse anti EBV BALF2 Kind gift of Jaap 
Middeldorp 
OT13N N/A 20ug 
 
Table 2.3 Descriptions of antibodies used 
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CHAPTER 3 
3 Selection of T-cells for TCR isolation 
3.1 Target selection 
3.1.1 Considerations for target selection 
There are a number of important criteria to meet when selecting an antigen to target 
therapeutically by TCR gene transfer. Firstly, the target must be present in the tumour being 
treated and absent in healthy cells. This prevents on-target off-tissue toxicity. With regard to 
PTLD, as the majority of cases are EBV associated, here we will target an EBV derived 
antigen. Viral antigens may not be solely expressed on tumour cells but they will be uniquely 
expressed in infected cells. Therefore targeting viral antigens should result in minimal to no 
on-target off tumour toxicities. In the case of EBV, it is thought that other than EBV-infected 
malignant B-cells, only 1 in 10,000 to 1 in 50,000 circulating B-cells are infected [242]. 
Furthermore, as viral antigens are foreign, they are immunogenic; highly avid T-cells will not 
be deleted during T-cell development. TCRs with high avidity can thus be isolated 
Additionally, as TCR gene transfer therapy is MHC restricted, it is advantageous to target an 
epitope presented through a common HLA allele so that the TCR could be used to treat many 
patients.  Furthermore, to enable direct recognition of tumour cells, that epitope should be 
presented on the tumour cell surface. MHC class II complexes classically present peptides 
from exogenous proteins, and intercellular transfer of antigen from virus-infected cells has 
been demonstrated for several EBV proteins [35, 188, 189]. It is now also widely accepted 
that some endogenous peptides can also access the MHC class II pathway, and this 
mechanism is used to process the viral protein EBNA1 [33, 243]. Through these mechanisms, 
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CD4+ T-cells are able to directly target infected cells provided sufficient levels of peptide-
MHC are expressed at the cell surface, and direct CD4+ T-cell recognition of LCL has now 
been described in the context of multiple EBV derived epitopes [189].  
3.1.2 PTLD protein expression 
PTLD is a heterogeneous disease; it has varied clinical presentations and histopathologies 
which are thought to be related to the time to PTLD onset. Due to the high degree of immune 
suppression, and consequent loss of T-cell control of the virus, early onset PTLD following 
SOT or HSCT is most often EBV associated. Here the tumours present as ‘early lesions’ or 
polymorphic lymphoproliferative disease (as defined by the WHO), and expresses an 
unrestricted EBV gene expression profile (latency III) [206, 207]. PTLD can also develop as 
late-onset (> 1 year post transplant), which is more common following SOT transplant as 
patients are given low level immunosuppression for life. Late-onset PTLD has been shown to 
express a more limited EBV gene expression profile, suggested to be caused in part by a 
degree of immune pressure, and as such are frequently monomorphic and often resemble HL 
[244]. Therefore, to successfully treat PTLD by selectively targeting specific EBV antigens, 
knowledge of viral gene expression is of paramount importance.  
Here we have analysed the expression of multiple EBV derived proteins in 17 PTLD cases, in 
order to select an EBV protein to target, for the treatment of PTLD. Although some analysis 
of EBV protein expression in PTLD has been performed by others, many of these studies 
were performed using outdated techniques and included limited numbers of patients. We 
have collected a larger data set that includes cases of PTLD after HSCT and SOT (6 biopsies 
for HSCT patients and 11 biopsies from SOT patients, from the University of Birmingham 
Human Tissue Biorepository and The University of Nottingham Tissue Biobank) [244-250]. 
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Additionally, we have collected data on the time between transplant and PTLD and so can 
compare EBV protein expression in early- and late-onset PTLD.  
3.1.3 IHC and ISH of EBV derived RNA and protein 
We have tested for the expression of EBERs by in situ hybridisation (ISH) and EBNA1, 
EBNA2, LMP1, BZLF1 and HLA DR at the protein level by immunohistochemistry (IHC). 
EBER staining was performed to determine the EBV status of the tumour. Although not all 
EBV positive tumour cells express EBV proteins, EBERs are constitutively expressed in all 
EBV positive cells [177]. This is therefore a reliable method of confirming the EBV status of 
the tumour. The EBER staining performed here matched with the EBER status previously 
determined by hospital laboratories, confirming that ISH was working as expected. EBER 
positivity was also confirmed by qPCR (data not shown).  
The specificity of the antibodies used in IHC was demonstrated in preliminary experiments 
and optimised using control cells that were known  to be EBV negative (tonsil samples) and 
EBV positive (Hodgkin’s lymphoma samples) (data not shown). Controls for EBNA1, 
EBNA2 and LMP1 staining were cytospins of B95.8 LCLs and T-cells, which were positive 
and negative for the three proteins , respectively. Induced EBV positive Akata cells were 
used as a positive control for BZLF1 staining, as this Burkitt’s lymphoma cell line can be 
induced by TPA into lytic cycle [251].   
Following antibody optimisation, the sections from the 17 PTLD cases were stained for 
EBER and protein expression. Figure 3.1 shows example ISH and IHC for EBER and all 
proteins investigated here, on one EBV negative case and one EBV positive case. In the cases 
shown, strong EBER staining can be seen in the EBV positive case, whereas the EBV 
negative case is clearly EBV negative, suggesting that staining is specific. Additionally, 
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specificity is implied as non-tumour cells within the PTLD section do not stain positively for 
EBER. Interestingly, EBER staining across the panel of cases showed that EBV positive 
tumour cells in PTLD biopsies can be diffuse or clustered. Whilst the stain in Figure 3.1 
shows clustered staining, many sections contained diffuse EBER positive cells.  
The EBV positive case showed clear nuclear staining of EBNA1, EBNA2 and BZLF1 in the 
tumour cells with no staining detected in the EBV negative control case. In the case of  
LMP1,  membrane staining was detected in the tumour cells and again the negative control 
case did not stain. Across the panel of cases, whilst EBNA1 appeared to be positive in 100% 
of tumour cells, this was not the case for EBNA2, LMP1 and BZLF1. EBNA2 is positive in 
the majority of tumour cells in all sections whilst LMP1 and BZLF1 are less frequently 
expressed. This is in line with published work in which PTLD biopsies have been stained for 
LMP1 and BZLF1 [245-247]. Furthermore BZLF1 is a lytic protein and as such would only 
be expected to be expressed in a small number of tumour cells, as only a small number of 
EBV infected cells undergo lytic replication at any given time [207].  
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Figure 3.1 In Situ Hybridisation and Immunohistochemistry of PTLD biopsies. 
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Examples of EBV negative and EBV positive cases of PTLD stained by ISH for EBER and 
with antibodies against EBNA1, EBNA2, LMP1 and BZLF1.   
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 Patient Transplant 
Type 
Time to 
PTLD onset 
(months) 
EBER EBNA1 EBNA2 LMP1 BZ1 HLA 
DR 
EB
V
 P
o
si
ti
ve
 
1-2 HSCT 2 + NT + NT - + 
1-3 HSCT 3 + NT - + + NT 
A2 SOT 4 + + + + + + 
1-5 HSCT 5 + + + + + + 
1-6 HSCT 5 + + NT + + + 
A SOT 7 NT + + + + + 
A1 SOT 7 NT + + + + + 
4 SOT 12 + + + + + + 
9 HSCT 12 + + + + + NT 
C1 SOT 18 NT + + + + NT 
5 SOT 60 + + + + + NT 
10 SOT 96 + + - + - NT 
11 SOT 132 + + - + NT - 
EB
V
 N
eg
at
iv
e 
1-4 HSCT 2 - - - - - + 
A5 SOT 72 - - - - - + 
3 SOT 96 - - - - - NT 
2 SOT 168 - - - - - + 
Table 3.1 Summarised IHC of PTLD biopsies. 
PTLD biopsies were analysed for expression of EBV genes and RNA by IHC and ISH, 
respectively. Gaps represent cases that were not stained for specific markers. Biopsies were 
analysed blind by a qualified pathologist. NT – not tested.  
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Table 1.1 shows a summary of the staining performed on all 17 cases, 13 EBV positive and 4 
EBV negative. Results show that in line with the literature, PTLD following HSCT usually 
occurs within one year of transplant (early-onset PTLD) and PTLD following SOT can be 
early- or late-onset. EBNA1 was present in all PTLD biopsies which stained positive for 
EBERs. LMP1 was also present in all biopsies that were EBER positive, but in a lower 
percentage of cells.  In the samples stained for EBNA2, the protein was present in 3/4 EBER 
positive HSCT samples and 6/8 EBER positive SOT samples. This suggests that 75% of 
samples have a latency III gene expression profile. Additionally, 4/5 and 6/8 EBV positive 
sections from PTLD following HSCT and SOT respectively were positive for BZLF1, 
suggesting that at least some cells within these tumours were able to enter lytic cycle. 
3.1.4 Target Selection 
Based on the expression in multiple PTLD samples as seen by IHC, we elected to targets 
derived from EBNA2 and BZLF1. Not only is EBNA2 expressed in PTLD, it is also 
expressed in AIDS- related lymphomas and a proportion (28-32%) of EBV positive 
DLBCL’s of the elderly. As such, a treatment based on targeting EBNA2 could be used to 
treat multiple malignancies [252, 253]. BZLF1 is the first immediate early lytic cycle protein 
which is expressed in lytic cycle. It is the transcription activator which mediates the switch 
the lytic gene expression. Like EBNA2, BZLF1 is expressed in the majority of PTLDs and 
has been shown by others to be a strong candidate for T-cell targeting [254]. 
We selected to target the EBNA2 derived peptide, “PRS” (full sequence 
PRSTVFYNIPPMPLPPSQL). It has been demonstrated that the PRS epitope is processed 
and presented through MHC class II following antigen transfer to neighbouring cells [35]. 
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This method of accessing the MHC class II pathway is efficient, and many antigens which 
access MHC class II via this route are presented at sufficiently high levels for direct CD4+ T-
cell recognition [35]. Crucially, our group has shown that CD4+ T-cell clones recognised 
PRS naturally processed and presented by HLA DR52b at much higher levels than any other 
CD4+ T-cell clones recognising other epitopes. This finding is not explained by a higher 
functional avidity of these clones but rather the data suggest that presentation of the PRS 
epitope on the cell surface is more efficient with HLA DR52b [189]. Furthermore, DR52b is 
a common allele, expressed in 27-40% of Caucasians and so many patients could be treated 
with a PRS- DR52b restricted TCR [255-257].  Whilst the PRS peptide is not present in type 
2 EBV due to sequence variation in EBNA2, type 1 EBV is the most common strain 
worldwide, and in the UK [258]. This target, presented through this HLA allele, is therefore 
an ideal candidate for immunotherapy.  
The BZLF1 derived peptide we have chosen to target is “LTA” (full sequence 
LTAYHVSTAPTGSW). LTA specific CD4+ T-cells have previously been isolated and 
shown to respond directly to unmanipulated LCL, in both effector and cytotoxic manners, 
again highlighting that this peptide is presented at high enough levels on LCLs for direct 
CD4+ T-cell recognition. In addition, LTA is also restricted through the common MHC 
allele, DR52b [188].  For these reasons, we chose to begin by targeting both peptides. Whilst 
I had been given a PRS specific clone (clone 93) by Dr Long, we sought to generate 
additional PRS clones, along with LTA clones, in order to determine which had the highest 
therapeutic potential.   
IHC has shown that not every cell within the tumour biopsy is EBNA2 or BZLF1 positive. 
Reasons for this are twofold. Firstly, these proteins may be present at levels below the 
detection limit for IHC. Secondly, some tumour cells may either not express these proteins, 
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or may not be expressing them at high enough levels to detect at the snapshot in time that the 
biopsies were taken. Brooks et al have identified cyclical expression of LMP1 in LCLs and so 
it is conceivable that tumour cells derived from PTLD patients could cyclically express other 
EBV genes [259]. 
Although this heterogeneity of protein expression in tumour cells could limit intercellular 
antigen transfer for peptide access to the MHC class II processing pathway, we hypothesise 
that CD4+ T-cells with redirected specificity towards these antigens would still be 
therapeutically useful. Firstly, tumour cells could uptake antigen in an autocrine fashion, 
thereby allowing access to MHC class II as exogenously derived antigen. Secondly, whilst 
intercellular antigen transfer is a proven route of entry into the class II processing pathway, a 
smaller contribution from intracellular access to this pathway, for example via autophagy, has 
not been ruled out. Cells that employ autophagy to present endogenously derived antigen in 
MHC class II do not need to be neighbouring other tumour cells and so could be directly 
targeted by specific CD4+ T-cells. Finally, if PRS and LTA cannot be directly presented to 
CD4+ T-cells on tumour cells, CD4+ T-cells could still function indirectly by helping CD8+ 
T-cells and stimulating a broad immune response.  
Although EBNA1 and LMP1 have been identified in 100% of PTLD biopsies studied here, 
physiological levels of epitopes presented on the infected cell surface cannot be efficiently 
recognised by CD4+ T-cells. For EBNA1 this is thought to be due to the mechanism of 
epitope access to the MHC class II processing pathway. EBNA1 has been shown not to be 
transferred between neighbouring cells to enter the class II pathway, but instead is solely 
processed (somewhat inefficiently) by autophagy [33, 191]. LMP1 is a poor T-cell target, and 
no commonly recognised CD4+ T-cell epitope derived from this protein has been identified 
to date [166].  
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3.2 Isolation and characterisation of PRS- and LTA- specific CD4+ 
T-cells from healthy donors 
3.2.1 Production of PRS-specific and LTA CD4+ T-cell clones 
In order to isolate PRS and LTA specific CD4+ T-cells, we performed IFNγ capture and 
limiting dilution cloning on peptide-stimulated cells, as described in Materials and Methods. 
Briefly, we isolated PBMCs from healthy, HLA-DR52b positive, EBV seropositive donors 
and removed CD8+ T-cells by negative selection with dynabeads. We then exposed PBMCs 
to PRS and LTA peptides together to reactivate epitope specific T-cells. One week later, we 
re-stimulated the PBMCs with both peptides and captured cells producing IFNγ with an IFNγ 
secretion assay. These cells were plated out by limiting dilution cloning at 0.3, 3 and 30 cells 
per well into wells containing peptide-loaded autologous LCLs and PHA-treated mixed 
allogeneic buffy coat feeder cells (both irradiated with 4000 rads).   
3.3 Characterisation of T-cell clones 
3.3.1 IFNγ production in response to target peptide 
The expanded T-cell cultures were screened for their specificity and functional capacity using 
several approaches to identify the clone with the highest therapeutic potential.  
After two weeks of expansion, we screened 154 growing cultures for their specificity towards 
PRS or LTA. Using an IFNγ ELISA, we co-cultured the T-cells with autologous LCLs pre-
exposed to PRS and LTA epitope peptides. 65 cultures produced IFNγ in response to peptide-
exposed LCL and so were re-stimulated and expanded as described. The remaining cultures 
did not secrete IFNγ in response to peptide exposed LCLs and so were deemed non-specific 
or exhausted T-cells and discarded.   
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Figure 3.2 IFNγ production in response to LTA- and PRS-exposed LCL.  
LCL was exposed to LTA or PRS epitope peptide and then co-cultured with T-cells for 16 
hours, before supernatant was analysed in an IFNγ ELISA. Background responses to LCL 
pre-incubated with the DMSO solvent have been subtracted. Red line indicates the clones 
picked for further analysis. 
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Responding cell lines that continued to grow well in culture were then tested a second time 
using the same assay to determine whether the cells were PRS or LTA specific. Here, we 
stimulated all T-cell cultures with PRS and LTA peptides separately. Results show that of the 
48 cultures screened, 30 produced IFNγ at high levels to either PRS or LTA (Figure 3.3). Of 
these, 24 were carried forward for further analysis. Cell lines that produced IFNγ in response 
to targets but were not carried forward did not continue to grow, suggesting the cell line may 
have been exhausted.
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Figure 3.3 IFNγ production in response to PRS or LTA.  
Selected T-cell cultures were analysed for specificity against LCLs pre-exposed to either PRS or LTA by IFNγ ELISA after 16 hours co-culture. 
Background responses of T-cells cultured with DMSO have been subtracted.  
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3.3.2 Determination of T-cell functional avidities 
To determine which T-cell cultures showed highest avidities for the PRS or LTA peptides, 
we determined T-cell functional avidity using a peptide titration assay, again measuring IFNγ 
release by ELISAs (Figure 3.4). Here, I compared the cell lines I had generated to a clone 
(clone 93) previously generated in the same manner by Dr. H. Long [189]. To remove 
complication by background recognition of the unmanipulated target lines, these assays used 
LCLs transformed with EBV lacking the relevant epitope sequences. Thus, PRS specific 
cultures were co-cultured with Ag876 LCLs, either pre-exposed to epitope peptide or not. 
Ag876 is an EBV type 2 strain that carries an EBNA2 gene with a number of sequence 
changes from the standard type 1 EBV stain, B95.8 [260]. Consequently, the PRS peptide 
sequence differs to the sequence present in B95.8 EBV, and as such ablates PRS-specific T-
cell recognition. LTA specific T-cell lines were co-cultured with LCLs which have 
previously been genetically engineered to prevent them from expressing the BZLF1 protein 
(BZLF1 knock out (K/O) LCL). As BZLF1 K/O LCLs do not express BZLF1, they do not 
present LTA unless loaded exogenously with the epitope peptide [261]. In these experiments, 
we defined functional avidity as the peptide concentration required to produce half the 
maximal response. The results in Figure 3.4 show that we have successfully isolated T-cell 
cultures specific for either LTA or PRS with a range of avidities from 1.3 to 19nM. This 
shows that the T-cell lines generated here have high avidities in comparison to other EBV 
specific CD4+ T-cells within the literature [189].  
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B) LTA-specific clones 
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Figure 3.4 Peptide titrations of T-cell cultures. 
 A) T-cell cultures that previously responded to PRS peptide were co-cultured for 16 hours 
with autologous Ag876 LCL pre-exposed to various concentrations of PRS peptide. B) T-cell 
cultures that previously responded to LTA peptide were co-cultured with LTA-exposed 
BZLF1 knock out LCL for 16 hours…as above. Both culture supernatants were then analysed 
by IFNγ ELISA. 
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3.3.3 Confirmation of T-cell HLA restrictions 
The HLA restriction of isolated T-cell cultures is important therapeutically, as we can only 
treat patients who share the same HLA allele that the T-cell is restricted by. Therefore, the 
isolated T-cells should ideally be restricted through common HLA antigens. Previously 
published work has identified that PRS is restricted through multiple HLA alleles, and can be 
presented in the context of DR1, DR7, DR16, DQ2, DQ7, DR52a, DR52b and DR52c [189, 
262]. LTA has been described previously as being DR52b restricted [188]. 
We aimed to isolate DR52b restricted TCRs, as this HLA allele is frequent in the population. 
We therefore isolated PBMCs from healthy donors who express DR52b and do not express 
other HLA alleles known to present PRS. As such, we hypothesised that the T-cell cultures 
we had isolated would be restricted through this HLA allele.  We validated the HLA 
restrictions of promising CD4+ T-cell cultures using a panel of LCLs which included the 
autologous LCL and a range of lines that were partially matched with the autologous donor at 
different class II alleles. Figure 3.5 shows the HLA restriction of the LCLs used. If the T-
cells were restricted through DR52b, they should respond to donors one, two and three which 
share the DR52b allele, and not produce IFNγ in response to donors four and five, which do 
not express DR52b.  All T-cell cultures tested produced IFNγ when co-cultured with DR52b+ 
LCLs. However, clone 23 and 13 produced some IFNγ in response to DR52b- LCLs, 
suggesting a possibility of oligoclonal T-cell cultures. For the other clones tested, a DR52b 
restriction was evident.  
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A) 
Donor HLA type 
 DR DQ 
1 11 13 52a 52b 6 7 
2 11   52b 6 7 
3  13  52b 6  
4   52a  6  
5      7 
*Donor 1 is autologous. Donors 2-5 are partially HLA matched and share some of the same 
class II HLA alleles as donor 1.  
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Figure 3.5 HLA restrictions of T-cells.  
5x104 T-cells/well were co-cultured with 1x105 LCLs of defined HLA type which had or had 
not been pre-exposed to epitope peptide. After 16 hours co-culture, supernatants were 
analysed for T-cell response by IFNγ ELISA. IFNγ produced by LCLs and T-cells alone was 
subtracted from results shown, although these levels were consistently low (below 1% of the 
amounts produced by co-cultures). 
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3.3.4 T-cell responses to naturally processed and presented target epitope 
The T-cell response to peptide-exposed targets is important as it confirms that the T-cell 
cultures isolated are capable of responding to their cognate antigen, and also determines their 
avidity. However, for these T-cell responses to be therapeutically relevant they must be 
capable of responding to levels of antigen that are naturally presented on the infected cell’s 
surface. To explore the ability of our T-cell cultures to respond to naturally processed and 
presented antigen we calculated the ‘efficacy’ of T-cell responses to LCL.  
The efficacy of the T-cell cultures was analysed by co-culturing the T-cells with DR52b 
positive LCL (carrying the B95.8 EBV strain) pre-exposed to the target peptide epitope (or to 
DMSO solvent only as a control), and DR52b positive Ag876 LCLs and BZLF K/O LCLs. 
DR52b negative B95.8 LCLs were also used as a further negative control. The efficacy with 
which the T-cell cultures recognised unmanipulated LCL was expressed as a percentage of 
maximal response seen against the same targets loaded with an optimal epitope peptide 
concentration (Figure 3.6).  
Efficacy was calculated as:   
pg/ml of IFNγ produced by  T-cells in response to LCL                                 
     X 100 
pg/ml of IFNγ produced by  T-cells in response to LCL pre-
exposed to peptide. 
 
Figure 3.6 shows three representative T-cell efficacy graphs. There was a range of efficacies 
amongst the T-cell lines tested and 7 cell lines tested had efficacies over 10%. There was no 
correlation between T-cell avidity and percentage efficacy of LCL recognition (correlation 
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efficient 0.09), indicating that at least for these cell lines, levels of peptide:MHC naturally 
presented on EBV-infected B cells were sufficient to fully stimulate the T-cells for IFNγ 
release regardless of the avidity of the T-cell culture. Clone 93 (c93) has previously been 
shown to respond to unmanipulated LCL well, producing 35% of the IFNγ that it produces in 
response to peptide exposed LCL (35% efficacy) [189].  
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Figure 3.6 T-cell efficacy.  
T-cells were co-cultured with targets for 16 hours and supernatants analysed by IFNγ ELISA. 
A) T-cell response using different T-cell input numbers to LCLs with or without peptide-
loading B) T-cell response to Ag876 LCL with 2500 T-cells/well. In all cases IFNγ release 
levels from T-cells alone have been subtracted. Blue boxes show efficacy of responding cells. 
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3.3.5 T-cell ability to bind soluble peptide-MHC 
To further investigate the specificity of our T-cell cultures at a single cell level, we stained 
the T-cells with soluble PRS-DR52b molecules which had been linked by streptavidin to 
generate tetramers and PE-conjugated to allow for identification (PRS-DR52b tetramers). 
Unlike IFNγ ELISAs, using p-MHC tetramers within flow cytometry provides information on 
the proportion of cells within the population that carry the correct TCR to bind to a given p-
MHC complex. Results showed that in T-cell lines 26, 13, 38 and 93, between 92.9% and 
98.7% of cells bound the tetramer, suggesting that they may be monoclonal populations. T-
cell line 6 is positive for tetramer staining; however two peaks suggests at least two separate 
PRS-specific T-cell clones with different abilities to bind the tetramer. This could be due to 
different levels of TCR expressed at the cell surface or different abilities of the TCRs present 
to bind tetramer. T-cell lines 30 and 23 show clear oligoclonal populations, as 73% of T-cell 
line 30 and 42% of T-cell line 23 bind to the tetramer. 
That only 42% of T-cells in line 23 express the DR52b restricted LTA TCR backs up the 
suggested oligoclonality observed in the HLA restriction assay (Figure 3.7). Here, the T-cell 
line responded to LCL 5, which did not express DR52b, along with all LCLs that did express 
DR52b (LCLs 1, 2 and 3). With a T-cell population where less than half of the cells express 
the desired TCR, cloning the correct TCR alpha and beta genes would prove difficult. As a 
consequence, this cell line was not investigated further. As clone 23 was the only LTA 
specific clone to survive and expand in vitro to sufficient levels for functional analysis, LTA 
specific TCR gene transfer was dropped at this point and following work was focused on 
PRS-specific TCRs. 
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Figure 3.7 Tetramer staining of T-cell cultures.  
T-cells were stained with PE-conjugated LTA- or PRS-DR52b tetramers, or empty tetramer 
negative controls. Cells were gated on lymphocytes then live cells. 
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3.3.6 Identification of T-cell variable beta genes 
Successful cloning of the required TCR genes is made much easier if the T-cell population is 
monoclonal, to reduce the chance of isolation of non-specific TCR genes from contaminating 
T-cells. Therefore, before attempting to clone the alpha and beta TCR genes, we identified 
which variable beta chains were expressed in the T-cell cultures. This allowed us to look 
further into the clonality of the T-cell lines.  
To determine which beta chains the T-cell cultures expressed we extracted cellular RNA, 
performed reverse transcription to generate cDNA and then conducted PCR reactions using a 
panel of primers specific for different V-beta alleles (primer sequences are described in 
materials and methods Table 2.1). Each T-cell can express one variable beta allele. There are 
24 variable beta families, with an estimated 57 variable beta alleles [263].  Our primer panel 
allowed us to test for 24 alleles. As such, this panel will not conclusively determine T-cell 
clonality, as there could be T-cells in the culture containing an allele that is not tested for 
here. Alternatively, two different T-cell clones in one culture may share the same beta allele. 
Nevertheless, in combination with tetramer staining, we can increase our chances of 
identifying a monoclonal T-cell population.  
As can be seen in Figure 3.8, cell lines 13 and 6 are positive for multiple Vβs and therefore 
were rejected. 
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Figure 3.8 PCR analysis of Vβ chain usage in T-cell clones. 
Shown regions are 200 to 300 base pairs (expected beta fragment size) and 500 base pairs (GAPDH size).  Red asterix highlights where bands 
were observed. 
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3.4 Summary of cloning and analysis 
From the collated T-cell analysis performed here, we decided to clone the T-cell receptor 
from c93. This clone appears monoclonal by Vβand tetramer analysis, has a high avidity and 
is restricted through the correct HLA allele. Importantly for therapy, it is also able to 
recognise and respond to LCLs presenting physiological levels of peptide, as is evident from 
it’s efficacy of 35%. 
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Clone T-cell 
avidity 
(nM) 
Functional 
Efficacy 
DR52b 
restricted 
Tetramer 
staining 
DR52b-
epitope MFI 
Vβ PCR 
bands 
26 1.9 31% Yes Single peak 1 
13 1.3 45% Yes Single peak 5 
38 10.2 27% Yes Single peak 0 
6 10.1 6% Yes Two peaks 1 
30 8.5 6% Yes Two peaks 2 
23 2.1 27% Yes Two peaks N/A 
93 3.8 35% Yes Single peak 1 
Table 3.2 Summary of results from T-cell clones with therapeutic potential. 
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3.5 T-cell Receptor Cloning 
To isolate the alpha and beta genes from c93, we used the Clontech SMART RACE cDNA 
Amplification Kit according to the manufacturer’s instructions. We first converted poly A+ 
RNA into cDNA, and then amplified both the  and  TCR genes using Rapid 
Amplification of cDNA Ends (RACE) PCR with specific alpha and beta primers (see 
materials and methods). 
 
Figure 3.9 c93 alpha and beta TCR chain PCR.  
Alpha and beta TCRs were amplified using alpha and beta gene specific primers and a 
universal primer mix. C93 α (-) and C93 β (-) are negative controls which do not 
contain DNA.  
 
Resulting DNA was run on an agarose gel, the appropriate bands extracted, and amplified 
through bacterial transformation. Alpha and beta TCR chains were then sequenced. The 
variable alpha allele used in this TCR was  TRAV5*01 (IMGT nomenclature), also known as 
Vα15.1 (Wei et al. nomenclature; used throughout this thesis) [264]. The joining region allele 
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used in this alpha TCR chain was TRAJ8*01. The beta chain used the TRBV19*01 variable 
allele (Vβ17) and the TRBJ1-1*01 joining allele.  
The isolated TCR alpha and beta chains were ligated into a pMP71 retroviral plasmid (kindly 
provided by C. Baum, Hannover, Germany). The plasmid that was used for these experiments 
had TCR genes already cloned into it and these genes and been codon optimised (by 
GeneArt) to enhance the efficacy of translation. The alpha and beta chains were separated by 
a 2A peptide linker from porcine Teschovirus. This ensured equimolar expression of both 
genes as at translation the ribosome ‘skips’ the 2A linker, preventing peptide bond formation 
and consequently cleaving the polypeptide chain [265].  Furthermore, the constant chains had 
previously been adapted to contain two extra cysteine residues which generate an additional 
disulphide bond to aid correct TCR chain pairing in transduced cells [235]. 
In order to insert alpha and beta variable, joining and diversity sequences into this plasmid 
(thereby replacing the existing variable, joining and diversity regions but retaining the codon 
optimised constant domains), primers were designed to extend the alpha and beta sequences 
of the TCR genes from c93 with correct nucleotides to allow for insertion (see Figure 3.10). 
The alpha chain was extended to include a 5’ Not1 restriction enzyme site followed by a 
Kozak sequence (CCACCATGG). The 3’ end of the alpha chain was extended to include a 
constant chain overlap to allow for PCR driven joining of alpha variable and joining regions 
to codon optimised constant domain. The beta chain was extended to include a 5’ overlap to 
the p2A linker and 3’overlap to allow for PCR driven joining of the beta variable joining and 
diversity regions to the beta constant domain. Finally, the beta constant domain was extended 
with a 3’ stop codon and BamH1 restriction site. 
After performing the multiple PCRs required to construct the TCR alpha-p2A linker-beta 
fragment, we inserted this into an MP71 retroviral vector by restriction enzyme digestion of 
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the parental MP71 vector to remove the original TCR, and subsequent ligation of the newly 
amplified TCR gene fragments. After amplification of the plasmid in bacteria and sequence 
confirmation of the new PRS-TCR retroviral vector, we proceeded to transduce and analyse 
healthy donor T-cells as described in Chapter 4.  
 
Figure 3.10 TCR cloning strategy 
Primer combinations 1 and 2, 3 and 4, 5 and 6 and 7 and 8 were used to generate the first 
fragments. The first two DNA products were then connected using primers [1 and 4] and the 
latter two using primers [5 and 8]. To get a final, linear DNA fragment, primers [1 and 8] 
were used. Primer 1 contained the Kozak sequence CCACCATGG and primer 8 contained 
the stop codon TGA. 
 
Sequencing of the construct confirmed that we had successfully cloned the correct TCR into 
the vector (see Figure 3.11). 
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Figure 3.11 Sequence of clone 93 TCR in pMP71 vector. Red font indicated variable regions. 
Purple font indicates joining regions. Blue font indicates constant regions. Yellow font 
indicates the GSG spacer and green font indicates the linker sequence.  
3.6 Discussion 
3.6.1 Overview 
Here, we have isolated and cloned  CD4+ T-cells from healthy donors against the PRS and 
LTA epitopes, derived from the proteins EBNA2 and BZLF1, respectively. Both EBNA2 and 
BZLF1 are expressed in multiple EBV associated malignancies including PTLD, AIDs 
related lymphoma and DLCBL [247, 266-271].We hypothesise that CD4+ T-cells that can 
recognise and respond to physiological levels of cognate antigen presented on the surface of 
EBV-infected B cells have therapeutic potential. Furthermore, such T-cells that directly 
interact with the target T-cell should have both direct effector and helper functions [188, 
ATGGAGACATTTGCTGGATTTTCGTTCCTGTTTTTGTGGCTGCAGCTGGACTGTATGAGTAGAGGAGAGGATG
TGGAGCAGAGTCTTTTCCTGAGTGTCCGAGAGGGAGACAGCTCCGTTATAAACTGCACTTACACAGACAGCTC
CTCCACCTACTTATACTGGTATAAGCAAGAACCTGGAGCAGGTCTCCAGTTGCTGACGTATATTTTTTCAAATA
TGGACATGAAACAAGACCAAAGACTCACTGTTCTATTGAATAAAAAGGATAAACATCTGTCTCTGCGCATTGC
AGACACCCAGACTGGGGACTCAGCTATCTACTTCTGTGCAGAGAAGGGAAGGAACACAGGCTTTCAGAAACT
TGTATTTGGAACTGGCACCCGACTTCTGGTCAGTCCAAACATCCAGAACCCCGACCCCGCCGTGTACCAGCTG
CGGGACAGCAAGAGCAGCGACAAGAGCGTGTGCCTGTTCACCGACTTCGACTCCCAGACCAACGTGTCCCAG
AGCAAGGACTCCGACGTGTACATCACCGACAAGTGCGTGCTGGACATGCGGAGCATGGACTTCAAGAGCAAC
AGCGCCGTGGCCTGGTCCAACAAGAGCGACTTCGCCTGCGCCAACGCCTTCAACAACAGCATCATCCCCGAGG
ACACCTTTTTCCCCAGCCCCGAGAGCAGCTGCGACGTGAAACTGGTGGAGAAGTCCTTCGAGACAGACACCA
ACCTGAACTTCCAGAACCTGAGCGTGATCGGCTTCAGAATCCTGCTGCTGAAAGTGGCTGGATTCAACCTGCT
GATGACCCTGCGGCTGTGGAGCAGCGGCAGCGGCGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACG
TGGAGGAAAACCCTGGCCCCATGGGCAACCAGGTGCTCTGCTGTGTGGTCCTTTGTCTCCTGGGAGCAAACAC
CGTGGATGGTGGAATCACTCAGTCCCCAAAGTACCTGTTCAGAAAGGAAGGACAGAATGTGACCCTGAGTTG
TGAACAGAATTTGAACCACGATGCCATGTACTGGTACCGACAGGACCCAGGGCAAGGGCTGAGATTGATCTA
CTACTCACAGATAGTAAATGACTTTCAGAAAGGAGATATAGCTGAAGGGTACAGCGTCTCTCGGGAGAAGAA
GGAATCCTTTCCTCTCACTGTGACATCGGCCCAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCCCTCC
CGGGACAGAGAAAGCTGAAGCTTTCTTTGGACAAGGCACCAGACTCACAGTTGTAGAGGACCTGAAGAACGT
GTTCCCCCCCGAGGTGGCCGTGTTCGAGCCCAGCGAGGCCGAGATCAGCCACACCCAGAAAGCCACCCTGGT
GTGCCTGGCCACCGGCTTCTACCCCGATCACGTGGAGCTGTCTTGGTGGGTGAACGGCAAAGAGGTGCACTC
CGGCGTCTGCACCGACCCTCAGCCCCTGAAAGAGCAGCCCGCCCTGAACGACAGCCGGTACTGCCTGTCCTCC
CGGCTGAGAGTGTCTGCTACATTCTGGCAGAATCCCCGGAACCACTTCCGGTGCCAGGTGCAGTTCTACGGCC
TGAGCGAGAACGACGAGTGGACCCAGGACAGAGCCAAGCCCGTGACCCAGATCGTGTCCGCCGAGGCCTGG
GGCAGAGCCGACTGCGGCTTCACCAGCGAGAGCTACCAGCAGGGCGTGCTGTCTGCCACCATCCTGTACGAG
ATCCTGCTGGGCAAGGCCACCCTGTACGCCGTGCTGGTGTCCGCCCTGGTGCTGATGGCCATGGTGAAGCGG
AAGGACAGCAGAGGCTGA 
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189]. As anti tumour responses are enhanced in the presence of both effector and helper 
activity, this could further increase their therapeutic efficacy [272]. 
3.6.2 Target Selection   
To select an EBV derived antigen to target, we analysed the expression of multiple EBV 
proteins on PTLD biopsies from 17 patients.   The panel included 6 biopsies from patients 
following HSCT and 11 biopsies from patients following SOT. We showed that EBNA1 and 
LMP1 were expressed in 100% of EBV positive biopsies and EBNA2 and BZLF1 were 
expressed in 75% and 77% of EBV positive biopsies, respectively. Whilst EBNA2 and 
BZLF1 were expressed less frequently that EBNA1 and LMP1, we selected to target antigens 
derived from these proteins. Reasons for this include that epitopes derived from EBNA1 and 
LMP1 are not presented at high enough frequencies on the surface of target T-cells in MHC 
class II complexes for direct CD4+ T-cell recognition. However, EBNA2 and BZLF1 are 
both well-presented and it has previously been demonstrated that T-cells that target antigens 
from these proteins can respond directly to physiological levels of antigen, by producing 
cytokines and cytotoxic responses [188, 189]. As the frequency of PTLDs positive for these 
two proteins is high, and the antigens are presented by common MHC alleles, a significant 
number patients would be able to benefit from TCR gene therapy against these epitopes.  
3.6.3 TCR selection 
One hundred and fifty four expanded T-cell cultures were sequentially subjected to a range of 
assays in order to determine which has the most potential to be used therapeutically. 
Selection was based on several assays that allowed us to investigate a range of T-cell 
functions. These included identifying PRS- and LTA- specific cultures that displayed high 
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avidity for their target antigen, identifying clones that were DR52b-restricted, and those that 
efficiently recognised EBV-infected B cells (a model for PTLD), and appear monoclonal.  
The functional readout used for much of this screening was IFNγ production. IFNγ has been 
shown to have a multitude of immunostimulatory effects, and therefore T-cells that produce 
IFNγ are considered clinically beneficial for cancer therapy. Moreover, IFNγ is a cytokine 
produced by Th1 and Th17 CD4+ T-cells, both of which have been shown to have anti-
tumour effects, and are capable of recruiting and promoting a larger immune response [273]. 
Nevertheless, this approach will have missed specific T-cells that responded to their target 
but without the release of this particular cytokine. Alternative selection of tetramer stained T-
cells can avoid this problem but does not provide a reliable functional readout to determine 
avidity. 
3.6.4 T-cell specificity 
We first performed peptide recognition studies to allow us to distinguish between cell 
cultures which responded to the target peptides and non-peptide-specific cell cultures that 
were captured by the IFN capture assay.  
Of 154 growing cultures, 65 cell lines produced peptide in response to peptide loaded LCLs. 
As all the cells were isolated using an IFNγ secretion assay, all isolated cells should produce 
IFNγ in response to peptide. The lack of IFNγ production by 89 of the 154 cultures may have 
been due to ‘background selection’ of non-responding T-cells, or isolation of cells that 
secreted IFNγ due to bystander activation. Alternatively, PRS and LTA specific effector T-
cells that produced IFNγ in the initial selection assay may have been highly differentiated 
effector cells that became exhausted after repeated stimulations [274]. This would have 
rendered the specific T-cells unable to produce cytokines and would have resulted in non-
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specific T-cells within the culture overgrowing the exhausted T-cells, which would not have 
proliferated.  
3.6.5 T-cell functional avidities 
The functional avidities of the epitope-specific T-cells seen here are high in comparison with 
those reported for other CD4+ T-cell clones in the literature. The T-cells studies here have 
avidities ranging between 1.3 and 19nM. Long et al. have investigated the avidities of a range 
of EBV specific CD4+ T-cell clones and report avidities ranging from 15-100nM, indicating 
that the T-cell avidities seen here are comparable to those of other viral specific TCRs [189]. 
Other EBV specific TCRs have been shown to have a high functional avidity, with a class I 
restricted TCR against an A2-restricted LMP2-derived peptide (CLGGLLTMV) having a 
functional avidity of 1nM when transduced into CD8+ T-cells and 10nM when transduced 
into CD4+ T-cells [237]. Interestingly, a number of CD8+  T-cell functional avidities against 
non-EBV viruses have been published, and a large range of avidities are noted, from 10pM to 
1µM [275-277]. Generally, T-cells specific to antigens overexpressed in cancers, such as the 
cancer testis antigen MART1 have much lower functional avidities than T-cells specific for 
virus derived antigens. Clinically tested T-cells that are specific to MART1 have a functional 
avidity of 0.1µM [278].  
High affinity TCRs are beneficial therapeutically, as the target T-cell could be recognised 
when expressing lower levels of antigen-MHC compared to what would be required for 
recognition by low affinity TCRs. Indeed, Adaptimmune, Oxford, UK, who focus on TCR 
gene transfer, use affinity maturation to enhance the affinity of tumour specific TCRs, 
highlighting the importance of this T-cell parameter.  
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Continuing this work with a high avidity T-cell could therefore show benefit in vivo. To 
further characterise our T-cell clones, we tested for their efficacy at recognising and 
responding to EBV-infected cells expressing physiological levels of their target antigens. 
3.6.6 T-cell response to physiological levels of target epitope 
We determined the efficacy of our cloned T-cells by calculating to what extent they were able 
to respond to LCL, in comparison to their maximal response (determined using LCLs 
exposed to an optimal concentration of peptide). As LCLs are EBV infected B-cells 
expressing a latency III profile they are a good model for PTLD, naturally processing and 
presenting the same antigens. Due to this similar gene expression, T-cells that are able to 
respond to naturally presented peptides on LCLs through HLA class II alleles have the best 
chance of therapeutic success for PTLD patients. Furthermore, T-cells that can recognise 
EBNA2 on LCLs could be therapeutically useful for the treatment of some AIDs related 
lymphomas and DLBCLs which express this EBV latent protein. Of the T-cell lines analysed 
here, 7 cell lines responded to physiological levels of antigen with efficiencies over 10%. 
Previous analysis of CD4+ T-cell clone efficacies towards EBV latent protein derived 
epitopes have identified 3 clones that could recognise more than 10% of the maximal IFNγ 
response (an EBNA211-30 GQT specific clone recognised unmanipulated LCL with an 
efficacy of 15%, a different EBNA2276-295 PRS specific clone had a 15% efficacy and the 
clone used here showed an efficacy of 35%). This shows that we have isolated a range of T-
cell lines which could potentially be used to treat EBNA2 expressing malignancies. 
3.6.7 T-cell clonality 
Having selected T-cell lines based on these functional tests, we moved on to check T-cell 
clonality. Clonality is important, as having a pure T-cell population of high avidity allows us 
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to clone a T-cell receptor with ensured high avidity. An oligoclonal population may result in 
cloning a TCR with a lower avidity, or alpha and beta chains from different clones. 
3.6.8 Final TCR selection 
Following all the screening tests, we selected clone (PRS-specific) for TCR cloning because 
it showed high avidity, restriction through the desired HLA allele and a good response to 
unmanipulated LCL. We isolated the TCR encoding genes from this clone, inserted them into 
a retroviral expression vector optimised for TCR transduction, and sequenced the construct to 
confirm correct TCR gene insertion. 
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CHAPTER 4 
4 In vitro functionality of PRS-TCR transduced T-cells 
With the intention of investigating the therapeutic potential of EBV-specific, class II-
restricted TCRs, I have isolated and cloned a high avidity TCR that recognises the EBNA2 
derived epitope PRS in the context of HLA-DR52b, as described in chapter 3. We 
hypothesise that this TCR will be useful in the treatment of EBV-associated tumours which 
express EBNA2. These include PTLD, AIDs related lymphoma and DLBCL.  Here, we 
proceeded to express the isolated TCR in PBMCs derived from healthy subjects and 
investigate it’s functionality through a range of in vitro assays.  
The direct recognition and cytotoxicity of EBV-specific CD4+ T-cell clones against EBV-
infected LCLs expressing physiological levels of their target antigens has previously been 
demonstrated [188, 189]. We have isolated a TCR against PRS, as this epitope is presented at 
high enough levels on the surface of LCLs to allow for direct CD4+ T-cell-mediated 
recognition and cytotoxicity. We therefore hypothesised that transduced T-cells would be 
similarly able to respond in an effector and helper manner in vitro, suggesting therapeutic 
potential in vivo. We have investigated the response of PRS-TCR transduced T-cells through 
a range of in vitro functional studies.   
4.1 Surface expression of exogenous TCR  
T-cells from healthy donors were activated in vitro with 30ng/ml Okt3, 30ng/ml anti-CD28 
and 600U/ml IL2 and transduced with a MP71 retroviral vector encoding the PRS-specific 
TCR from c93, as described in materials and methods. In order to function, the TCR genes 
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must be inserted into the genome, transcribed and translated correctly, and trafficked to the 
cell surface. In order to confirm surface expression of the introduced TCR and determine the 
efficacy of transduction, transduced cells were stained with an antibody against the specific 
TCR V beta variable chain and with a specific peptide-MHCII tetramer. 
As all T-cells express a native TCR prior to transduction, the introduced TCR is referred to as 
exogenous and the original TCR as endogenous.  We had previously determined, by both 
PCR and sequencing, that the β-chain of our PRS-specific TCR is Vβ17 (chapter 3). Herein, 
we therefore analysed the efficiency of every transduction using surface staining for Vβ17. 
Interestingly, both CD4+ and CD8+ T-cells were effectively transduced (Figure 4.1). In all 
transductions performed, there was a small level of Vβ17 staining in non-transduced (mock) 
populations. This represents the frequency of naturally occurring Vβ17 usage in the host’s 
TCR repertoire. Whilst different donors have been used throughout this work as a source of 
PBMCs, in each experiment we generated a control mock-transduced cell line from the same 
donor. Therefore, we were able to determine the percentage of engineered Vβ17+ T-cells 
within the transduced T-cell line by subtracting the percentage of naturally occurring Vβ17+ 
cells present in the mock-transduced line. 
The TCR used here has been modified to include an additional disulphide bond within the 
constant domains to promote correct pairing between the exogenous alpha and beta chains. 
However, mispairing between the exogenous and endogenous TCR chains remains a safety 
concern [279]. As described in the introduction, this could potentially lead to the formation of 
TCRs with novel, undefined specificities, which have not been subject to central tolerance 
mechanisms in the thymus and therefore have the potential to target self-antigens [280] . The 
adoptive transfer of such undetermined specificities could theoretically cause unwanted toxic 
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and even lethal side effects. We therefore explored the level of TCR chain mispairing within 
our transduced T-cells.  
To this end, we stained transduced and mock T-cell populations with the PRS-DR52b 
tetramer, and with the Vβ17 –specific antibody. Although the Vβ antibody will bind any TCR 
formed with this chain, the TCR must have both the correct alpha and beta chain in 
combination for the tetramer to bind. Our results showed that there are a small proportion of 
CD4+ and CD8+ T-cells in the natural T-cell repertoire which express Vβ17 and PRS-DR52b 
specific TCRs. The percentage of cells binding tetramer was almost identical to the frequency 
of Vβ17 positive cells, after mock Vβ17-positive cells has been subtracted (Figure 4.1), and 
this was true of every transduction in multiple donors. This strongly suggested that the 
exogenous Vβ17 chain was only pairing with the exogenous alpha chain to form functional 
TCRs expressed at the T-cell surface. Unfortunately, because antibodies to Vα5 are not 
available, it was not possible to determine whether the exogenous alpha chain was mispairing 
with endogenous beta chains. 
Note that the tetramer staining also demonstrates that the transduced T-cells have the same 
specificity as the parent clone, and target the PRS peptide presented through HLA DR52b.  
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Figure 4.1 Surface expression of transduced TCR.  
A) Transduced and mock T-cells were stained with anti-Vβ17 three days after transduction. 
B) Transduced and mock T-cells were stained with the PRS-DR52b tetramer three days after 
transduction. Cells were gated on live, CD3+ populations. Results are representative of four 
independent experiments. Percentage values shown represent the proportion of CD4 or CD8 
T-cells that express either Vβ17 or have bound the PRS-DR52b tetramer.  
 
The level of surface expression of the exogenous TCR on individual cells was more varied 
than that of the parent clone, as measured by the MFI of the tetramer staining of the 
transduced cells versus the parent c93 (Figure 4.2). This variance was likely reflective of 
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different transduction levels within different cells but could have also reflected different 
levels of competition for CD3 binding by the different endogenous TCRs [124]. T-cells with 
endogenous TCRs that bind CD3 weakly are more likely to express the exogenous TCR at 
the cell surface and vice versa [124]. Different endogenous TCR repertoires between donors 
may also explain the variation in staining intensity between donors.  
 
 
 
 
 
 
 
Figure 4.2 Tetramer staining of transduced cells and clone.  
Cells gated on lymphocytes, live, CD4 or CD8. Two different transductions with  
different donor PBMCs shown. 
4.2 The MHC CLASS II restricted TCR is functional in CD4+ and 
CD8+ T-cells. 
4.2.1 Functional Avidity 
The functional avidity of the transduced T-cells was defined as described in chapter 3 for the 
T-cell clones, as the concentration of peptide required to produce half a maximal response 
(Figure 4.3). Peptide titrations were performed by co-culturing 5x104  total cells from PRS 
specific transduced T-cell populations with 1x105 Ag876 LCLs, pre-loaded with titrating 
93 
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peptide concentrations. The PRS epitope sequence is mutated in this strain and so there 
should be no background recognition of the target T-cell alone [260]. Clone 93 was diluted 
by mock-transduced autologous T-cells to ensure the same number of PRS specific T-cells 
were in both T-cell populations.  Results showed that the transduced polyclonal T-cell line 
displayed a functional avidity of 4nM, which is very similar to though slightly lower than that 
of the parent clone (1nM) (Figure 4.3). The transduced population produced less total IFNγ 
than the clone, which could be due to some cells being exhausted after activation. 
Alternatively, it could be a consequence of the lower level of TCR on the T-cell surface when 
compared to the clone (see Figure 4.1). T-cells expressing low levels of surface TCR may not 
respond fully. 
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Figure 4.3 Functional avidities as determined by the concentration of peptide that 
produced half the maximal response.  
Transduced cells were compared with the parent clone. Both transduced and clone cells have 
5x104 Vβ17+ T-cells per well. The transduced cells contained  25% CD8+ T-cells and 60% 
CD4+ T-cells.  Results are representative of three experiments. 
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As the MHC class II restricted TCR was transduced into a total PBMC population, we 
separated the CD4+ and CD8+ T-cells to determine whether the TCR is functional in both 
subsets and if so, what their functional avidities against their target antigen are. Again, PRS 
was loaded onto B-cells infected with the type 2 EBV strain Ag876. After separating the two 
cell populations by negative selection with dynabeads, the resulting populations were stained 
with anti-CD4 and -CD8 antibodies to determine the efficiency of separation. As can be seen 
in Figure 4.4, separation was successful, with over 99% purity achieved here. In sorts that 
had over 1% contamination (containing cells which were depleted in the negative selections), 
controls were put in place (note, every sort had at least 98% purity). In those cases, mock 
cells were spiked with the equivalent frequency of contaminating transduced T-cells, to 
determine to what extant these contaminating populations produced Interferon gamma (IFNγ) 
in response to peptide loaded target T-cells. Any IFNγ produced from these control 
populations was subtracted from the results obtained with the sorted transduced T-cell 
subsets. 
The results in Figure 4.5 showed that CD4+ T-cells had a slightly higher functional avidity 
compared to CD8+ T-cells, yet both populations were able to produce IFNγ in response to 
peptide. The difference in the functional avidities was likely due to the lack of CD4 co-
receptor in CD8+ T-cells. As CD8+ T-cells have a functional avidity comparable to CD4+ T-
cells, we suggest that the introduced TCR can function in CD4-negative T-cells, however 
introducing the CD4 co-receptor may be required to achieve optimal CD8+ T-cell avidity 
[237]. 
Levels of IFNγ produced in the mock cells were consistently lower than transduced 
populations. However, the small amount of IFNγ detected in some experiments scan be 
attributed to the naturally occurring EBV specific T-cells within the mock population, as 
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EBV positive donors were used as PBMC sources for transduction.  As there was no IFNγ 
produced by mock or transduced cells alone, we have ruled out the possibility of background 
due to responses to fetal bovine serum and activation induced IFNγ production. Mock 
responses are shown here and then for clarity subtracted from every subsequent graph shown.  
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Figure 4.4 Negative sorting of CD4+ and CD8+ T-cells is efficient.  
Graphs show pre and post sorted mock and transduced T-cells. Graphs are gated on 
lymphocytes, live, CD3, CD4 or CD8. Percentages show the percentages of CD4+ and CD8+ 
cells in pre and post sorted populations. 
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Figure 4.5 CD4+ and CD8+ T-cell functional avidities.  
PBMCs were negatively sorted into CD4+ and CD8+ T-cell populations and tested. Vβ17+ 
percentage was normalised between the subsets, taking into consideration naturally 
occurring Vβ17+ cells seen in the mock population. Results are representative of three 
experiments. 
 
4.2.2 Recognition of endogenously processed antigen and HLA restriction 
To analyse the ability of transduced T-cells to recognise endogenously processed antigen, we 
performed an IFN-g ELISA with a panel of DR52b-matched and mismatched LCL targets, 
with each target pre-exposed to PRS-peptide or DMSO. By using a range of DR52b positive 
and negative LCL targets we were also able to confirm that PRS was being recognised 
exclusively in the context of DR52b in this panel of targets. As expected, transduced T-cells 
only produced IFNγ in response to DR52b positive LCLs, confirming that the response is 
restricted through this allele. The lack of response to a DR52b-matched LCL that carried the 
Ag876 EBV strain is consistent with this virus strain carrying a mutation in the PRS epitope 
sequence. Note however, that these cells, which are DR52b-positive, can be recognised when 
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coated with the PRS peptide sequence taken from the standard type I EBV strain B95.8. 
Crucially, the transduced T-cells produced IFNγ in response to DR52b+ LCLs even without 
pre-exposing the LCLs to the PRS peptide. This demonstrated that physiological levels of 
PRS naturally presented by EBV-infected B cells were able to sufficiently activate the T-
cells, suggesting that the transduced cells should be functional as direct effectors against 
virus-infected cells in vivo.  
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Figure 4.6 Recognition of EBV-transformed LCLs.  
Transduction efficacy of the T-cells used in this assay was 18%. Transduced T-cells were co-
cultured with DR52b positive or negative LCLs, pre-loaded with target PRS peptide or not. 
An IFNγ ELISA was performed on supernatant after 16 hour incubation. IFNγ produced by 
mock transduced cells and background IFNγ produced from T-cells alone has been 
subtracted. Results are representative of four experiments. All LCLs used here are infected 
with the EBV strain B95.8 unless otherwise stated.  
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4.2.3 Cytokine production in response to target T-cells 
An increased frequency of CD4+ T-cells with capacity for multifunctional cytokine 
production is associated with improved control of some infections, including HIV and CMV 
[281-284]. We therefore sought to determine if transduced T-cells are multifunctional by ICS, 
as multifunctionality may also improve responses to tumours. T-cells were co-cultured 
overnight with peptide-exposed or DMSO-exposed LCLs, in the presence of BFA. The 
following day T-cells were analysed for the production of Interleukin 2 (IL2), IFNγ and 
tumour necrosis factor alpha (TNFα) by flow cytometry.  
TNFα, as suggested by its name, is a cytokine with anti-tumour activity. It binds to TNF 
receptor (TNFR) 1 and 2 on target T-cells and induces downstream signalling pathways 
leading to apoptosis [285]. IL2 stimulates T-cell proliferation  and induces activation of B 
and NK cells by signalling through its receptor, CD25 [286]. IFNγ up-regulates MHC class II 
on target T-cells, promotes cytokine production from DCs, activates macrophages and 
synergises with TNFα to induce tumour cell senescence [62, 287, 288]. These cytokines have 
all been used clinically for the treatment of different cancers, highlighting their anti-tumour 
effects [285, 289, 290]. Production of these cytokines by transduced T-cells would therefore 
suggest that the T-cells could have anti-tumour effects in vivo. 
Intracellular staining allows us to look at multiple cytokines produced in any single cell. 
Logical gating strategies were applied to the flow cytometry results to identify cells that can 
produce one, two or three cytokines and these are described in materials and methods.  
Interestingly, both CD4+ and CD8+ transduced T-cells produced multiple cytokines in 
response to target T-cells. In Figure 4.7 we compared the frequency of cells producing one, 
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two or three cytokines, after the background from mock-transduced T-cells had been 
subtracted.   
The results showed that, taking into consideration the transduction efficiency of 20%, a high 
percentage of transduced cells can produce TNFα, IFNγ and/or IL2 in response to autologous 
PRS-exposed LCLs (assuming that any cells producing cytokine were PRS-specific and 
responded in a TCR specific manner). Note that it was not possible to co-stain for the TCR 
alongside the cytokines, as T-cell activation leads to down-regulation of TCR on the cell 
surface. . These cytokines are commonly produced by Th1 T-cells, and so we suggest that at 
least some of our transduced T-cells display a Th1 phenotype. However, we have not tested 
for cytokines associated with other CD4+ T-cell subsets (e.g. IL17 secreted by Th17 cells), 
and as such cannot exclude that they may also be produced. 
The majority of responding cells produced threat least two of these cytokines (Figure 4.7). 
Importantly, transduced T-cells also produced multiple cytokines when co-cultured with 
unmanipulated LCL. The percentage of cells producing one, two or three of these cytokines 
was greater in the CD4+ than CD8+ T-cells, which was likely attribuTable to the higher 
CD4+ T-cell functional avidity (Figure 4.5)  and the inherent cytokine producing function of 
CD4+ T-cells.  Indeed, increased cytokine production by CD4+ T-cells over antigen specific 
CD8+ counterparts has been observed not only by us but also by other groups [291]. CD4+ 
T-cells have also been shown to produce more cytokines that CD8+ T-cells when transduced 
with a MHC class I-restricted TCR [237].  
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Figure 4.7. IFNγ, TNFα and IL2 production by transduced T-cells.  
Transduced and mock transduced T-cells were co-incubated with LCLs, pre-exposed to 
epitope peptide or not, for 12 hour in the presence of BFAs. Cytokine production was 
measured by ICS following fixation and permeabilisation. Cells were gated on live, CD4+ or 
CD8+. Frequencies of mock transduced T-cells producing cytokines were subtracted .In the 
graph shown, the transduced CD4+ T-cells contain 20% more Vβ17+ cells than mock and the 
CD8+ T-cells are 23% Vβ17+ above mock. Results are representative of four experiments.  
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4.2.4 Proliferation Capacity 
In order to efficiently transduce T-cells with retrovirus they must first be activated. Our 
protocol involves activating T-cells with 30ng/ml anti-CD3, 30ng/ml CD28 and 600U/ml 
IL2, for 48 hours. As activation will push cells to a more terminally differentiated phenotype, 
we have sought to confirm that the transduced cells still have proliferative capacity [292]. 
Indeed, repeated activations when expanding TILs prior to infusion has been linked to poor 
T-cell persistence which correlates to a shortened telomere length [293]. Proliferation is a key 
requirement for an effective adoptive transfer therapy, with clonal expansion of tumour 
specific T-cells increasing the number of T-cells that are able to respond to the tumour [294, 
295].  
To analyse the proliferative potential of the transduced T-cells we performed CFSE dilution 
assays (Figure 4.8). CFSE-labelled T-cells were co-cultured with irradiated (4000 rads) 
autologous LCLs, pre-exposed to epitope peptide or not and analysed after five days 
incubation. Results showed that activated transduced cells, as indicating by their Vβ17 
expression, were able to proliferate in response to antigen in vitro, suggesting that they could 
proliferate in vivo. A proportion of Vβ17+ mock transduced cells also proliferated in 
response to LCLs, which we suggest is due to the presence of naturally occurring EBV 
specific T-cells within the population. Nonetheless, the proportion of proliferating cells is 
higher in transduced Vβ17+ cells. Almost all of the Vβ17+ T-cells in the transduced T-cell 
population proliferated in response to PRS-exposed LCL, and encouragingly, the proportion 
of these cells that proliferated to unmanipulated LCL was very similar.  
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Figure 4.8. Transduced T-cells proliferate more than mock cells in response to antigen. 
The graph shows T-cell proliferation in response to LCL and peptide epitope exposed LCL 
after 5 days co-culture. Results are representative of four experiments. Cells were gated on 
lymphocytes, live, cd4 or cd8, Vβ17.  In the graph shown, the transduced CD4+ T-cells 
contain 33% more Vβ17+ cells than mock and the CD8+ T-cells are 32% Vβ17+ above 
mock.  
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4.2.5 Transduced CD4+ T-cells have the capacity to mature DCs 
We have transduced T-cells with MHC class II restricted TCRs in order to harness the CD4+ 
response. Naturally occurring CD4+ T-cells are able to both orchestrate a broader immune 
response (including helping to promote and sustain CD8 T-cells) and mediate direct cytotoxic 
activity, making them very useful therapeutically. Therefore, our next experiments were 
designed to investigate whether the transduced T-cells have helper or effector functions, or 
both.  
One way that CD4+ T-cells ‘help’ the immune response is by maturing dendritic cells (DCs).  
Through this maturation process, DCs are licenced to prime CD8+ T-cells, thereby ensuring 
CD8+ T-cells are fully activated and able to respond optimally to their target [296].  
To assess the ability of the transduced CD4+ T-cells to mature DCs, CD8-depleted TCR 
transduced T-cell populations were co-cultured with immature DCs for two days. On day 
two, levels of surface CD86, CD40 and CD83 were measured on live, DC-SIGN+ cells 
(Figure 4.9). We observed that when iDCs were co-cultured with both mock and transduced 
T-cells, they upregulated CD83, CD86 and CD40, suggesting that the T-cells were capable of 
inducing a degree of maturation in the absence of peptide-MHC T-cell activation. This may 
have been due to T-cell activation prior to transduction, as activation up-regulates CD40L on 
T-cells [69].  When mock transduced T-cells were co-cultured with peptide exposed DCs a 
slight further increase in intensity of expression of the three maturation markers studied was 
always seen. This may be explained by naturally occurring PRS-specific T-cells within this 
mock-transduced T-cell population driving DC maturation in a peptide dependent manner. 
Importantly, transduced T-cells were much more efficient in maturing DCs in a peptide 
dependent manner than mock transduced T-cells. In fact, the intensity of expression of CD40 
CHAPTER 4                                    In Vitro functionality of PRS-specific TCR transduced T-cells 
162 
 
was higher than that of the positive control (namely DCs co-cultured with cytokines). CD83 
and CD86 were also raised on PRS-pulsed DCs cultured with transduced T-cells, to similar 
intensities of expression as DCs co-cultured with cytokines. These results highlight the 
efficiency of transduced T-cells to mature DCs presenting their epitope peptide. 
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Figure 4.9.  DC maturation is increased by TCR transduced CD4+ T-cells.  
DCs were gated on live, DC-SIGN+. CD4+ T-cells were 28% Vβ17+ above mock in the graph shown. Results are representative of three 
experiments. 
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4.2.6 Cytotoxicity of transduced T-cells 
After confirming that transduced CD4+ T-cells have retained their helper functions, we then 
went on to investigate the cytotoxic potential of transduced cells including both CD4+ and 
CD8+ subsets. CD4+ T-cells are able to induce tumour eradication by enhancing the immune 
response in a helper fashion (see introduction) but have also been shown to have direct 
effector functions including cytotoxicity. These direct effector functions can lead to 
eradication of tumours in immunocompromised mice, highlighting their therapeutic 
importance [76]. CD8+ T-cells are classical cytotoxic T-cells and are capable of eradicating 
tumours through this cytotoxic response [297].  
The cytotoxic activity of transduced T-cells was determined by chromium release assays. 
Transduced T-cells were co-cultured with a range of DR52b+ and DR52b- LCLs, pre-loaded 
with 51 Cr, in the presence and absence of the PRS peptide (Figure 4.10). Results here show a 
10:1 effector: target ratio after 5 hours co-culture. When DR52b+ LCLs were pre-loaded with 
PRS peptide, transduced T-cells induced high percentages of target T-cell lysis.  This 
cytotoxicity was not seen when transduced T-cells were cultured with DR52b- LCLs, 
whether pre-exposed to peptide or not, confirming again that the response is DR52b 
restricted. Crucially, even in this short co-culture time of 5 hours, transduced T-cells were 
able to kill LCL target T-cells in the absence of peptide exposure. This indicated that the 
transduced T-cells could exert a direct effector response against LCLs presenting 
physiological levels of PRS antigen. As DR52b-positive Ag876 LCLs were not killed unless 
pre-exposed to PRS peptide, the response was confirmed to be PRS peptide specific.  
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Figure 4.10. Killing of HLA matched or mismatched LCL targets, with or without 
peptide.  
Graph shows a 10:1 effector: target ratio after 5 hour incubation. Results are representative of 
four experiments. In the graph shown, the transduced CD4+ T-cells contain 48% more 
Vβ17+ than mock and the CD8+ T-cells are 59% Vβ17+ above mock. LCL donors are 
labelled in accordance with those used in Figure 4.6. All LCLs used here are infected with the 
EBV strain B95.8 unless otherwise stated. 
 
To establish which subset of T-cells were responsible for the cytotoxicity, in subsequent 
experiments we analysed the T-cells for expression of the de-granulation marker, CD107a, by 
flow cytometry. CD107a is a highly glycosylated membrane protein, that is used as a marker 
for de-granulation [298]. In resting cells, it is located within cytolytic vesicles, which contain 
perforin and granzyme [299]. When T-cells become activated, these cytolytic vesicles merge 
with the cell surface plasma membrane to release their cytotoxic granules and so CD107a that 
was originally located within vesicles now resides on the cell surface [300].  
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Results showed that after six hours CD107a was up-regulated in CD8+ transduced T-cells 
when co-cultured with autologous LCLs (either pre-exposed to PRS peptide or not) (Figure 
4.11).  A similar result was also seen in CD4+ Transduced T-cells, albeit at lower levels. This 
suggests that both CD4+ and CD8+ T-cell subsets mediate cytotoxic function in response to 
peptide-loaded LCLs but also in response to physiological levels of PRS peptide naturally 
expressed in an LCL.  
We show that transduced CD8+ T-cells were more cytotoxic than transduced CD4+ T-cells. 
This provided further evidence that functional differences could be due to the different T-cell 
types and further rationale for transducing a bulk population of T-cells.  
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Figure 4.11. CD107a staining of T-cells after six hours of co-culture with autologous 
LCL and peptide loaded autologous LCL.  
Cells are gated on live, CD3+. Results are representative of three independent experiments. 
In the graph shown, the transduced CD4+ T-cells contain 37% more Vβ17+ than mock and 
the CD8+ T-cells are 20% Vβ17+ above mock. 
 
To confirm whether the cytotoxic activity of transduced cells seen in chromium release 
assays was sufficient to control the outgrowth of EBV infected cells, we set up outgrowth 
assays. These experiments span four weeks and so give us the opportunity to look at tumour 
control over a longer period of time in vitro. Within these experiments we used PBMCs from 
EBV seronegative donors as a source of T-cells for transduction, to avoid the complication of 
reactivation of naturally occurring EBV-specific T-cells specific for the immunodominant 
EBNA 3 family of viral proteins. In duplicate, we set up a serial dilution of LCLs, pre-
exposed to PRS peptide or not, from 100,000 to 0 cells per well. To these we added either 
100,000 TCR- or mock-transduced T-cells per well. After four weeks, the plates were 
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observed for wells that contained growing cultures.  The results shown in Figure 4.12 
indicated that the transduced T-cells are capable of controlling the outgrowth of an 
autologous LCL, even in the absence of exogenously added peptide. This suggests that the 
transduced T-cells could effectively control the outgrowth of tumours in vivo, which is 
critical to therapeutic success.  
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Figure 4.12. TCR transduced T-cells can control the outgrowth of LCLs in a long 
term assay both in the presence and absence of peptide. 
 In the graph shown, the transduced CD4+ T-cells contain 30% more Vβ17+ than mock 
and the CD8+ T-cells are 16% Vβ17+ above mock.  Dots and squares represent the lowest 
input number of LCLs that resulted in growing colonies. Co-cultures were tested in 
duplicate and the black lines indicate the means. Results are representative of four 
independent experiments.  
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4.3 Discussion 
To our knowledge, this is the first description of TCR gene transfer for a class II-restricted 
EBV-specific TCR. This could provide a novel therapy for the treatment of EBNA2 positive 
malignancies. In order to determine if this TCR gene transfer could be effective at clearing 
EBNA2 positive tumours, we have characterised the functional responses of transduced T-
cells in vitro. We have transduced both CD4+ and CD8+ T-cells with this TCR and have 
investigated whether transduced T-cells act as helper and/or effector cells in response to 
target antigen.  
4.3.1 Surface Expression of exogenous TCR 
Our results show that the PRS-specific MHC class II -restricted TCR isolated during this 
work can be successfully expressed in both CD4+ and CD8+ T-cells to a similar level, and 
that at least the beta allele has paired correctly allowing functionality in both T-cell subsets. 
Here, we used constant chains which have been modified to include an additional cysteine 
residue on each TCR chain to allow for the formation of an additional disulphide bond. This 
has been shown to increase the exogenous TCR surface expression by increasing correct TCR 
pairing [301]. There are also other mechanisms available to reduce TCR mispairing, and each 
comes with both advantages and disadvantages. These include the use of murine constant 
domains, the removal of endogenous TCRs and generating single chain TCRs. However, to 
date, the optimal mechanism to reduce mispairing is still unknown, as to date there has not 
been a study directly comparing the different options.  
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4.3.2 TCR specificity 
Through a range of functional studies we have demonstrated that both CD4+ and CD8+ T-
cells transduced with our TCR can respond to target T-cells specifically, by p-MHC driven 
activation. This allows us to harness the functions of CD4+ and CD8+ T-cells against MHC 
class II restricted peptides. 
Transduced T-cell specificity towards the EBNA2 derived PRS peptide presented in the 
context of HLA-DR52b has been validated in numerous assays. Tetramer staining of the 
transduced T-cells indicates that they are capable of binding to PRS when in complex with 
DR52b. These PRS specific T-cells are low or absent in the mock population, indicating the 
majority of tetramer-specific T-cells are carrying the exogenous, transduced TCRs. 
Additionally, the functionality of the transduced T-cells against DR52b-presented PRS was 
confirmed against LCL targets. Thus unmanipulated DR52b-positive B95.8 LCLs were 
recognised, with recognition increasing upon peptide loading, whereas DR52b-positive 
Ag876 LCLs were only recognised when pre-loaded with exogenous peptide.   
4.3.3 TCR Cross Reactivity 
As many TCRs are capable of binding to more than one peptide, there is the theoretical 
possibility this TCR might target other MHC:peptide complexes [302]. The TCR was derived 
from a T-cell from a healthy EBV positive donor, so because of self-tolerance mechanisms it 
should not respond to self peptides presented through HLA alleles carried by this donor. We 
cannot, however, rule out cross reactivity towards other epitopes not present in self tissues 
from this donor, or epitopes presented through HLA alleles that the donor does not carry. 
Kumari et al. have generated an HLA-A2 restricted TCR and tested it against a panel of cell 
lines expressing HLA-A2 without cognate antigen [303] and a similar approach could allow 
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us to investigate whether our TCR can cross react with other DR52b-restricted peptides. 
However, the approach is limited by the range of self-antigens expressed in the panel of cell 
lines. Whilst such cross-reactivity is a risk carried by all TCR gene therapies, it remains a 
theoretical risk in the context of naturally occurring TCRs. However, affinity maturation of 
TCRs alters the original TCR that was originally subjected to tolerance mechanisms, and has 
led to mortalities [144]. This off target toxicity highlights the benefit of using viral specific 
TCRs as they are naturally of high avidity and so do not need affinity maturation to function 
efficiently. 
4.3.4 Avidities of transduced T-cells 
Although the parent clone and transduced cells show very similar functional avidities, a 
factor that will alter the functional avidity between the parent clone and the transduced cells 
is the frequency of TCRs on the cell surfaces. Transduced cells express less exogenous TCR 
on the cell surface when compared to the parent clone (Figure 4.1). T-cells expressing less 
surface TCR may be less sensitive and therefore less responsive.  
This reduced surface TCR expression could be a result of different gene expression levels in 
transduced cells. For instance, if the retrovirus integrates into a hypermethylated 
chromosomal area gene expression will be limited or shut off. Additionally, competition 
between endogenous and exogenous TCRs is also likely to be a factor that can lower T-cell 
avidity. To be expressed at the cell surface, the TCR must bind to the CD3 complex [304]. 
Therefore, the TCR with the highest CD3 affinity is more likely to be expressed at the cell 
surface.  
To overcome this problem (which is theoretical here, due to the similar functional avidities 
between the parent clone and transduced T-cells), it is possible to disrupt endogenous TCR 
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gene expression prior to transduction, therefore limiting their surface expression. Provasi et 
al. have done this using zinc finger nucleases, which are directed towards specific DNA 
sequences and introduce double strand breaks. The process of non-homologous end joining is 
error prone and consequently, incorrect DNA sequences result, therefore disrupting the 
endogenous TCR sequences and resulting in lack of protein expression [305].  Using this 
method,  T-cells that were pre-treated with zinc finger nucleases before transduction of TCR 
expressed more surface TCR and were superior in antigen recognition when compared to 
transduced T-cells without this treatment [125]. Alternatively, T-cells that have not yet 
developed endogenous TCRs can be transduced. Snauwaert et al. have successfully 
transduced postnatal thymus derived T-cells and adult hematopoietic progenitor cells for this 
purpose. These single TCR transduced T-cells effectively kill tumour cells in vitro [306]. 
Providing additional CD3 to transduced cells by co-transducing the CD3 complex could also 
overcome CD3 competition between endogenous and exogenous TCRs. This has been 
described to increase exogenous TCR expression up to ten fold [130]. 
Having taken these options into consideration, we decided to continue our studies with these 
T-cells, which have two different TCRs. We argue that the difference in avidity between the 
parent T-cell clone and transduced cells is relatively small, and the avidity of the transduced 
cells is still high in comparison to T-cell avidities that target self antigens, and is sufficient to 
mediate T-cell responses to EBV-transduced B cells in vitro. One of the main advantages of 
TCR gene therapy over other adoptive therapy techniques to target EBV positive lymphomas 
is its rapid T-cell preparation time. The methods described above to increase exogenous TCR 
surface expression all increase the time of T-cell preparation and the manufacturing cost. We 
therefore argue that these methods should only be considered if the benefits are substantial.  
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The lower avidity of transduced CD8+ T-cells when compared to CD4+ T-cells could be due 
to the lack of the CD4 co-receptor in CD8+ T-cells. Others have shown that when CD4+ T-
cells are transduced with an MHC class I-restricted TCR the functional avidity can be lower 
than that of CD8+ T-cells transduced with the same construct. This can be rescued by co-
transduction with a CD8 molecule, highlighting the requirement for the interaction of this 
molecule with MHC class I [307]. It is not, however, true in all cases, and it appears that 
some TCRs can function independently of their co-receptor, a phenomenon believed to be 
associated with high TCR affinity [308] [309]. The peptide titration assay performed here 
suggests that the transduced TCR has some CD4 dependency as transduced CD8+ T-cells 
have lower functional avidity than transduced CD4+ T-cells. To further investigate the co-
receptor dependency of our TCR, CD4 interaction with class II could be blocked using a 
specific antibody and the effect of this could be tested in functional studies using the parent 
clone. Furthermore, CD4 could be co-transduced into the transduced CD8+ T-cells, to 
determine if this increases the functional avidity of the transduced CD8+ T-cells. Co-
transduction of CD4 has been described by other groups and shown to improve cytotoxicity 
of CD8+ T-cells transduced with a class II restricted TCR [291]. 
4.3.5 Bystander activity 
When looking at intracellular cytokine production in response to peptide loaded LCLs in 
CD4+ populations, there are more T-cells responding than there are transduced T-cells in the 
culture. This phenomenon could be attributed to bystander activity of T-cells [310]. As T-
cells produce cytokines in response to target, they may activate other non-specific T-cells, as 
IFNγ, IL2 and TNFα are all immunostimulatory. These background responses may not be 
seen in non-transduced populations, as the majority of cells in culture there will not respond 
to LCLs, and it is conceivable that a threshold of cytokine production may be required to 
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activate non-specific T-cells.  Such “bystander” effects also seen with CD107a staining, when 
CD8+ T-cells are co-cultured with LCL pre-exposed to peptide antigen.   
In conclusion, transduced T-cells show helper effects in vitro. They can produce multiple 
cytokines in response to targets and mature DCs. Additionally transduced T-cells have shown 
effector responses in vitro. Transduced T-cells are capable of killing target T-cells as shown 
by chromium release assays, CD107a staining and long term outgrowth assays. All of these 
responses suggest that transduced T-cells have therapeutic potential.
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CHAPTER 5 
5 In vivo functionality of PRS-TCR transduced T-cells 
5.1 Introduction 
Work performed in chapters 3 and 4 has shown that PRS-TCR transduced T-cells can 
function effectively in vitro, with the ability to produce cytokines and kill target T-cells in 
response to physiological levels of antigen presented on virus-infected LCLs. These 
responses suggest that the transduced T-cells possess the functions required to control tumour 
growth, thereby indicating therapeutic potential.  In this chapter, we have performed assays to 
determine the ability of transduced T-cells to eliminate EBV positive tumours in vivo. 
5.1.1 Mouse model 
For these experiments we used non-obese diabetic (NOD)/ severe combined immunodeficient 
(SCID)/ IL2 receptor gammanull (NSG) mice. NSG mice have been developed over two 
decades, with SCID mice being bred first [311]. SCID mice have a loss of function mutation 
in the protein kinase, DNA activated, catalytic polypeptide (Prkdc) gene [312]. The Prkdc 
protein functions to resolve DNA strand breaks within V(D)J recombination of BCRs and 
TCRs [313]. Consequently, loss of function of this gene results in impaired lymphopoiesis 
and so SCID mice have very few B and T-cells. NOD mice were developed unintentionally 
through a breeding programme that aimed to generate cataract-prone subline mice. A mouse 
bred for this purpose was noted to have insulin dependent diabetes and further in-breeding 
from this strain resulted in mice which had high frequencies of insulin dependence [314]. It 
was later determined that NOD mice have polymorphisms at the insulin dependent diabetes 
loci 3. As the IL2 gene is located within this locus, IL2 expression is deregulated in NOD 
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mice [315, 316]. Consequently, this strain of mouse has impaired innate immunity, with 
reduced APC function, macrophage and NK cell activity and no complement system [317, 
318]. SCID mice were crossed with NOD mice to generate NOD-SCID mice which had more 
severe impairments in adaptive and innate immunity than either strain alone [318]. However 
residual innate immunity is witnessed in this mouse model. To overcome this, NOD-SCID 
mice have been subjected to targeted mutations at the IL2-receptor gamma chain locus 
(Il2rg). This is a common gamma chain that is required for the generation of functional 
receptors for multiple cytokines, including IL2, IL4, IL7, IL9, IL15 and IL21 [319]. Mice 
lacking functional Il2rg have no NK cells and do not develop functional B- and T-cells [320]. 
Consequently, NSG mice are immunodeficient, lacking B- and  T-cells. Additionally to this 
lack of adaptive immunity, NSGs have limited innate immunity, with no NK cells, reduced 
DC and macrophage functionality, and no complement systems [318].   
This strong immunodeficiency renders NSGs suiTable mice to study PTLD. Prior to 
transplant, patients are treated with high doses of immunosuppressive drugs, chemotherapy 
and irradiation to ablate their immune systems [321, 322]. Consequently, PTLD patients are 
usually in the early stages of immune reconstitution, with little adaptive immunity [94].  
By using NSG mice we are able to infuse human LCL and transduced T-cells without 
rejection. This is important because EBV does not establish infection in mouse B-cells. 
Additionally, NSG mice that are administered LCLs have been used widely as a model for 
PTLD and consequently this is an established model for testing therapeutic interventions for 
the disease [236, 323]. 
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5.1.2 Pilot studies of optimal tumour dose 
Firstly we set up a pilot experiment to determine the minimum amount of LCL required to 
generate consistent tumour growth and to produce palpable tumours by two weeks. This 
timescale was important because after the transfer of human T-cells there is a window of 
about four weeks to see an anti-tumour response, before the infused T-cells begin to cause 
GvHD, necessitating termination of the experiment [324]. Therefore we aimed to choose a 
dose of LCLs which would allow us to palpate tumours by two weeks or earlier, so that any 
anti-tumour responses could be determined by tumour size. 
In the pilot experiment, we injected 2.5x106 LCLs into three mice and 5x106 LCL into three 
mice, subcutaneously (SC). We used the SC method of tumour administration as this was the 
stated method of administration on the project licence and we are able to measure tumour 
growth easily, by caliper. Importantly, all the LCLs used in this chapter are DR52b positive 
and had been stably transduced with luciferase before injection, to ensure that they could be 
detected by bioluminescent imaging of the mice after the injection of luciferin. Mice were 
monitored three times a week for tumour size (manually, by calliper) and once a week for 
tumour size by intravital bioluminescence imaging. Additionally, mice were monitored three 
times a week for signs of distress, including; weight loss, piloerection, disinterest in 
surroundings, lethargy, poor body condition, hunched back, swollen cheeks, sunken eyes and 
skin colour.  
Mice were imaged by intravital bioluminescent imaging at day 7, 13 and 23, and then the 
experiment was ended due to tumour size limitations. No mice showed signs of distress.  
As expected, both groups of mice developed tumours that were detecTable by intravital 
bioluminescent imaging, and the group of mice that received 5x106 LCL had a larger mean 
CHAPTER 5  In vivo functionality of PRS-TCR transduced 
T-cells 
178 
 
tumour size at each imaging point (Figure 5.1). However, there was intra-group variability in 
tumour sizes, indicating that more mice need to be used to show statistically significant 
results (Figure 5.2). Alternatively, more tumour cells need to be administered to overcome 
inaccuracies associated with injecting small numbers of cells or small volumes. In 
conclusion, injecting LCLs subcutaneously results in variable tumour growth and so we 
changed the mode of LCL administration for following experiments.   
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Figure 5.1. Tumour size as monitored by bioluminescent imaging. 
 Intravital imaging of subcutaneous tumours shows that mice developed tumours of 
different sizes, which grew with different growth kinetics. Graph is showing mean 
and SEM. 
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Figure 5.2. An image of mice injected with LCL subcutaneously. 
In A) mice were injected with 2.5 million LCL. In B) mice were injected with 5 
million LCL. The image was taken 23 days post LCL injection.  
5.1.3 Testing intraperitoneal tumour administration  
We next injected LCLs intraperitoneally (IP). Injecting LCL IP gives a much more 
physiological model of PTLD, as tumour cells can circulate the body, thus modelling the 
human disease [325]. 
Here, we injected 3 groups of mice with 0.01x106, 0.1x106 and 1x106 LCL, IP, to determine 
the minimum amount of LCL that consistently resulted in tumour growth. Mice were 
monitored weekly for tumour growth by intravital bioluminescent imaging, and three times a 
week for the signs of distress previously mentioned.  
Results show that no group had consistent tumour growth (Figure 5.3). At least 1x106 LCL is 
required to visualise tumour development at time points before two weeks after tumour 
injection. At days 7, 11 and 14 tumours were undetecTable in mice which received 0.01x106 
LCL. Tumours were undetecTable at days 11 and 14 in mice which received 0.1x106 LCL. 
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The detection limit can be set by determining background photon counts in mouse tissue that 
does not contain tumour. Mice which received 0.01x106 or 0.1x106 LCL were culled on day 
21 as tumour was not consistently detected in these mice by this point and we were aiming to 
identify a dose of LCL which would produce visible tumours by day 14. At 28 days the 
experiment was ended, as we would not expect infused T-cells to be able to persist for longer 
than this time in mice without producing GvHD. No mice displayed any signs of distress 
during this time.  
 
4 5 6 7 8 9
1
0
1
1
1
2
1
3
1
4
1
5
1
6
1
7
1
8
1
9
2
0
2
1
2
2
2
3
2
4
2
5
2
6
2
7
2
8
1100 5
1100 6
1100 7
1100 8
1100 9
0.1x10(6)
1x10(6)
0.01x10(6)
p
h
o
to
n
s
Days since LCLinjection
 
Figure 5.3. Tumour growth in mice as measured by Intravital bioluminescent imaging. 
Graph is showing mean and SEM. 
The grey bar indicates the limits of detection.  
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Figure 5.4. Tumour growth as measured byintravital bioluminescent imaging. 
Here mice were injected with different numbers of LCL, inraperitoneally. Images 
were taken 21 days after LCL injection. A) shows mice which were injected with 
0.01 million LCL. B) shows mice which were injected with 0.1 million LCL. C) 
shows mice which were injected with 1 million LCL.  
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5.2 Anti-tumour capacity of transduced T-cells 
Next, we sought to determine the anti-tumour effect of transduced T-cells. The T-cells used 
throughout this chapter are from the same donor of the LCLs used, to avoid allogeneic 
responses against the LCL. Furthermore, the T-cells used are sourced from a healthy, EBV 
seronegative donor to avoid the possible complication of mock-transduced T-cells containing 
natural responses to EBV antigens (especially the immunodominant EBNA3 family of 
proteins).  
5.2.1 Transduced T-cell function in vivo 
We had previously shown that 1x106 LCL was enough to form tumours in mice, therefore for 
the next experiment we decided to inject the mice with 2x106 LCL, doubling the dose to 
hopefully improve consistency in tumour growth kinetics.  Additionally, group sizes were 
increased to six mice per condition for more accurate results.  All mice received LCLs, 
injected IP, on day 0. Six mice then received an IV injection of 1x107 mock transduced T-
cells, one hour after LCL injection, and six received 1x107 transduced T-cells at the same 
time point. Of note, IV injections were performed by trained technicians, within the animal 
house.  In this experiment, the transduced T-cells contained 27% more Vβ17 positive cells 
within the CD4+ subset, and 26% more Vβ17 positive cells within the CD8+ subset than 
mock transduced T-cells. As the transduced population consisted of 67% CD4+ T-cells and 
18% CD8+ T-cells, the total number of transduced cells that were administered into each 
mouse was 2.3 x106. 
Results showed a significant difference in tumour sizes in mice which received mock or 
transduced T-cells at day 7 (p = 0.02 using a two tailed Mann-Whitney U test which is used 
throughout this chapter). Mean tumour bioluminescence was 3.6 fold higher in mice which 
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received mock vs. transduced T-cells.  However, this was not maintained to day 14 (p = 0.41) 
(Figure 5.5). All mice were culled at day 16 when they showed signs of distress. These 
included lethargy, sunken eyes and low body condition scores. The reasons for the distress 
symptoms are unknown. GvHD is unlikely the cause of distress as it does not normally 
develop until three to four weeks after T-cell injection [324].  Additionally, distress was 
unlikely to be caused by cytokine storms or tumour lysis syndrome. These occur when T-
cells are so effective in killing target T-cells that the immune system is hyperactivated, 
causing heightened flu-like symptoms. As we did not see tumour control, this is unlikely the 
explanation.  One possibility is that either the LCL or T-cells may have carried a low level of 
infection before infusion. 
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Figure 5.5. Intravital bioluminescent imaging 
Imaging at day 7 and day 14 showed increase in tumour size over time, in mice which received 
both mock and transduced cells. Graph is showing mean and SEM. 
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Figure 5.6. Tumour growth after the administration of T-cells. 
Intravital imaging of mouse tumours 7 days after LCL injection. In A) mice were injected with 2 
million LCL and mock T-cells and in B) mice were injected with 2 million LCL and PRS-TCR 
transduced T-cells.  
 
5.2.2 Ex vivo LCL phenotype 
One possibility for the lack of continual tumour control is that surface MHC class II may 
have been selectively down regulated in LCLs when injected into the mice, as has been 
reported in another study using SCID mice [323]. To check if MHC class II is down 
regulated in the mouse models used here, we injected two NSG mice  with 1x108 LCLs (IP). 
On day 0 we gave one mouse an additional injection of 0.25mg/kg decitabine. This is a 
demethylating agent that is used in chemotherapy and was shown by Merlo et al. using a 
similar model to increase the expression of MHC class II on LCLs in vivo [323]. Injections 
were repeated twice on days 1, 2 and 3 in this mouse, to a total of 7 injections. The other 
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mouse received no drug. On day 4 both mice were culled and LCL was isolated from the 
peritoneum by peritoneal wash.  
Results showed that surface MHC class II expression is partially down regulated on LCLs in 
NSG mice after 4 days. The median fluorescent intensity (MFI) of MHC class II staining on 
LCLs that have been in vivo for 4 days is two-fold lower than LCLs which have been 
cultured in vitro, however the MFI is still relatively high (Figure 5.7). Clearly with only one 
mouse per group these results are preliminary and would need repeating with larger numbers 
of mice. Additionally, it would be beneficial to set up assays with ex vivo LCLs and PRS-
TCR transduced T-cells, to determine if the level of MHC class II down regulation seen 
reduces T-cell recognition, compared to recognition of the same LCL maintained in vitro. 
This lack of decitabine induced up-regulation of MHC class II clearly contrasts results 
published by Merlo et al [323]. It is plausible that decitabine can induce some level of MHC 
class II up-regulation, which is masked here by the low level of in vivo MHC class II down 
regulation.  
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Figure 5.7 MHC class II expression on LCL that has been cultured in vitro or in vivo, 
with or without decitabine. 
LCL was gated on lymphocytes, Live, MHC class I and HLA DR, after in vitro culture or 
isolation from mice post mortem. 
5.3 Anti tumour effects of transduced T-cells in vivo 
Due to time constraints a further experiment exploring the anti-tumour effect of PRS-TCR 
transduced T-cells was conducted in parallel with the previous decitabine experiment. 
Therefore it included the use of decitabine treatment in an attempt to restore MHC class II 
levels based on the published work of Merlo et al [323] (even though our preliminary data 
shown above suggests this was not necessary or effective).  2x106 LCLs were injected IP into 
14 NSG mice on day 0. All mice received a total of 7 injections of 0.25mg/kg decitabine, 
once on day 0 and twice on days 1, 2 and 3. On day 4, mice were intravitally imaged by 
bioluminescence imaging to determine tumour sizes. Mice were split into three groups; 2 
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control mice which would not receive T-cells, and two groups of six mice which would 
receive either PRS-TCR or mock transduced T-cells. The mice receiving T-cells were 
monitored at day 4 for tumour growth and split into two groups with similar tumour sizes. 
15x106 transduced or mock T-cells were then injected into each mouse IV. Of the infused T-
cells, 50% of the population were CD4+ and 29% of the population were CD8+. Both CD4+ 
and CD8+ transduced T-cells had 15% Vβ17 positive T-cells more than their non transduced 
counterparts. Therefore the group of mice that received the PRS-transduced T-cells received 
a total of 2.25x106 genetically engineered T-cells. Mice were monitored three times a week 
for signs of distress, as previously mentioned, and once or twice a week for tumour size by 
intravital bioluminescence imaging. Additionally, tail bleeds were performed once a week to 
investigate the persistence and/or expansion of adoptively transferred T-cells. 
5.3.1 T-cell persistence and expansion in vivo 
Results from the tail bleeds showed that adoptively transferred T-cells persisted in the 
peripheral blood of mice throughout the experiment (Figure 5.8). Between days 8 and 19 post 
LCL injection, both total CD4+ and CD8+ T-cells gradually proliferate in mice which 
received mock or transduced T-cells. CD4+ T-cell and CD8+ T-cell proliferation is 
exponential after this time point, which is a classical characteristic of GvHD. In particular, 
GvHD is characterised by a proliferation of CD8+ T-cells, which is observed here [326].  
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Figure 5.8 Total numbers of CD4+ and CD8 T-cells in mice. 
T-cells were gated on single cells, lymphocytes, live/dead, CD4+ or CD8+ T-cells. The 
number of cells per ml of blood was calculated by the administration of a known number of 
Flow Cytometer Cell Counting Beads to each sample prior to analysis on the BD LSR II 
flow cytometer. Graph is showing mean and SEM.  
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The T-cells from the peripheral blood were further analysed for surface expression of Vβ17, 
to identify whether transduced cells were selectively expanding, which would be an 
indication of anti-tumour responses. 
The percentage of Vβ17 positive cells was consistently higher in mice which received 
transduced T-cells, when compared to mice which received mock T-cells (Figure 5.9 b and 
d). This is expected, as the transduced T-cells contained more Vβ17 positive cells than the 
mock when analysed prior to infusion. The percentage of Vβ17 positive T-cells in mice 
which received transduced T-cells increases slightly between the time of T-cell injection and 
day 8, at which point the percentage drops until day 19. After this time point, the percentage 
of Vβ17 positive T-cells begins to increase slightly in both CD4+ and CD8+ T-cells. The loss 
of Vβ17 positive T-cells between day 8 and 19 in transduced CD4+ and CD8+ populations 
may reflect a greater tendency for successful transduction of more highly differentiated cells 
which are also more likely to succumb to senescence [327]. Alternatively, transduced cells 
could be selectively lost in peripheral blood because they are leaving the hematopoietic 
system to attack tumour cells in tissues. To determine if transduced T-cells were leaving the 
hematopoietic system, a reporter system such as the luciferase system used here could be 
used to track the T-cells. Had tumours been visible, solid masses, tumours could have been 
isolated and sections could have then been stained for the presence of human T-cells ex vivo.    
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Figure 5.9. The total number and percentage of Vb17 positive T-cells per ml of 
peripheral blood. Graph is showing mean and SEM.  
Figure 5.9 a) shows the total number of Vb17 positive CD8+ T-cells in mice which received 
mock or transduced T-cells. B) shows the percentage of total CD8+ T-cells which are Vb17 
positive in mock and transduced populations. The dashed line shows the percentage of Vb17 
positive T-cells in vitro, prior to injection. C) and D) show the same results but for CD4+ T-
cells. 
 
5.3.2 Tumour sizes  
Intravital imaging results showed that in this experiment, there was no statistical difference in 
the ability of the transduced T-cells to control tumour growth above the mock T-cells (p 
value of 0.17 when comparing tumour sizes between the groups at day 28 using a two tailed 
Mann-Whitney U test). Importantly, both groups of mice appear to show some level of 
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tumour control after day 11 (Figure 5.10). Mean tumour sizes appeared similar in both groups 
of mice between day 11 and day 18 and then tumours appear to shrink in both groups, but at a 
faster rate in mice which received PRS TCR T-cells. Interestingly, this correlates with the 
time point at which the percentage of Vβ17 positive T-cells begins to increase in the blood 
(Figure 5.9), and so could possibly have been the beginning of tumour control by transduced 
T-cells. This indication of anti-tumour response is not statistically significant in either group 
of mice, as the difference between tumour sizes at day 11 and 28 in mice which received 
mock and transduced T-cells, produced p values of 0.57 and 0.06, respectively. It is clear, 
however, that whilst significance was not quite reached, mice which received transduced T-
cells showed more tumour control than mice which received mock T-cells. This suggests a 
trend of tumour control by transduced but not mock T-cells.  
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Figure 5.10 Tumour sizes as measured by intravital imaging.  
Intravital bioluminescent imaging of mice which received LCL and mock or transduced T-
cells, at different time point since LCL injection. Graph is showing mean and SEM.  
 
Figure 5.11 Intravital imaging of mouse tumours. 
Mice were injected with 2 million LCL and multiple injections of decitabine followed by 
mock or transduced T-cells at day 4. This Intravital image shows tumour sizes 28 days after 
LCL injection. 
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Figure 5.11 shows intravital imaging of mice at day 28 and clearly shows that one mouse in 
the group which received transduced T-cells is an anomaly, with much larger tumour than all 
other mice in this group. Interestingly, when this mouse was removed from analysis, the 
difference in tumour control between the groups of mice is even more pronounced (Figure 
5.12). Statistical significance is very nearly reached between the groups of mice by the end of 
this experiment (p = 0.055). Further experiments could use larger groups of mice to 
determine if there is a statistical difference in tumour control.  
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Figure 5.12 Tumour sizes as measured by intravital imaging with anomaly removed 
Intravital bioluminescent imaging of mice which received LCL and mock or transduced T-
cells, at different time point since LCL injection. Here, the mouse with the largest tumour 
has been removed from the group of mice which received transduced T-cells. Graph is 
plotting the mean and SEM.  
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We ended the experiment at day 28 since the mice were showing signs of distress including 
piloerection, lethargy, disinterest in surroundings, swollen cheeks and face washing (likely 
due to GVHD). Therefore, unfortunately, we could not monitor the tumour sizes after day 28 
to determine if transduced T-cells are capable of controlling tumour over a longer time 
period.  
5.3.3 Ex vivo LCL phenotype 
After termination of the experiment, LCLs were recovered from the peritoneum post-mortem 
to investigate their phenotype after in vivo growth in the presence of T-cells. We were 
interested to test the hypothesis that transduced, PRS-specific T-cells could have selectively 
eliminated LCLs which retained sufficient surface levels of MHC class II but LCLs that 
might have lost class II expression would still have grown in these mice. Ex vivo staining 
showed that LCLs from mice which received mock or transduced T-cells had similar levels of 
surface MHC class II (Figure 5.12) indicating that there was no selective killing of MHC 
CLASS II+ LCL by the engineered T-cells.  
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Figure 5.13 HLA DR expression on LCLs restored from mice post-mortem. 
LCL was gated on lymphocytes, Live, MHC class I and HLA DR, after ex vivo growth in the 
presence of mock or transduced T-cells. The negative control was unstained LCL which was 
cultured in vitro and the positive control was stained LCL which was cultured in vitro.  
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5.4 Discussion 
This chapter focused on assessing the potential in vivo anti-tumour effects of T-cells 
transduced with the PRS-TCR, using NSG mice injected with EBV-transformed LCLs as a 
model for PTLD. This is important because control of tumour outgrowth in such pre-clinical 
models can indicate the therapeutic potential of transduced T-cells. The earlier in vitro assays 
had shown the therapeutic potential of PRS-TCR transduced T-cells, through their cytokine 
production and cytotoxicity against target T-cells. Additionally, transduced CD4+ T-cells 
maintained a helper function, as shown by their ability to mature DCs. We therefore 
hypothesised that transduced T-cells with such functions would show some control over 
tumour growth in vivo.  
5.4.1 Tumour control by transduced T-cells 
Results obtained here give an indication that T-cells genetically engineered to express the 
PRS specific TCR may be able to control tumour growth in vivo better than activated, 
unmodified T-cells. Work performed by others has shown that naturally occurring EBV 
specific T-cells can control LCL growth in vivo, in immunocompromised mice. However in 
these experiments EBV specific T-cells were administered the same day as LCL injection 
[236, 325]. Consequently these experiments were testing the ability of T-cells to control 
tumour growth, rather than to eliminate established tumours. Here we have begun preliminary 
work to investigate the ability of EBV specific T-cells to control tumours 4 days after they 
were injected.  
Although there was not a clearly significant effect on tumour growth, both experiments which 
included T-cell administration showed a trend towards better tumour control using transduced 
rather than mock T-cells. It is possible that transduced T-cells did not have a long lasting 
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anti-tumour effect because the tumour microenvironment suppressed immune responses. 
Some EBV positive PTLDs have been shown to be PD-L1 positive by IHC (19/26 cases) 
[328]. It is therefore not inconceivable that PD-L1 was expressed here and suppressed T-cell 
responses during the experiment. Post Mortem analysis of LCLs for PD-L1 expression could 
be investigated in future experiments. 
Figure 5.10 shows that the tumour size increased in mice which received mock or transduced 
T-cells until day 11, at which point tumours begin to shrink in both groups of mice. Two 
mice in this experiment received LCL and decitabine but no T-cells , and tumours in these 
mice did not shrink. In addition, previous assays (injecting differing numbers of LCLs) have 
never shown spontaneous tumour reduction. This suggests that the tumour could be being 
controlled to different extents by both mock and transduced T-cells, rather than shrinking 
spontaneously. 
The possible low level of control of tumour by mock T-cells in the final experiment was 
unexpected, especially considering that mock responses to LCL in short term in vitro assays, 
with T-cells from the donor used here, were consistently low. There are multiple possible 
explanations for this which could be further investigated. Firstly, it is possible that the T-cell 
donor has seroconverted recently and now carries EBV. The last EBV serology testing for 
this donor was performed a year before these experiments and so this could be possible. If so, 
mock T-cells which are reactive towards EBV antigens could have expanded over time in 
vivo and controlled tumour growth. Note that if this was the case, transduced T-cells should 
also contain these naturally occurring EBV specific T-cells with additional PRS specific 
engineered T-cells, and so should produce greater tumour control.  
Alternatively, mock T-cells could have been responding non-specifically, due to activation 
with anti CD3 and anti CD28. Mock T-cells could also have been responding to cellular 
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antigens, upregulated in B-cells after transformation. LCLs have previously been shown to be 
targeted by CD4+ T-cell clones which do not recognise EBV derived antigens [329]. Again, 
if this was occurring I would expect to see the same non-specific activation or cellular 
antigen derived responses from transduced T-cells. As transduced T-cells additionally have 
PRS specificity, anti-tumour responses should be greater in this T-cell population.  
Importantly, the difference in tumour sizes in mice which received mock and transduced T-
cells increased from day 11 onwards. The last intravital image at day 28 showed that tumours 
were smaller in mice which received transduced T-cells, as can be seen clearly in Figure 5.11. 
Additionally, when one anomaly was removed, statistically significance was very nearly 
reached (p = 0.055 when tumour sizes were compared at day 28 between mice which 
received mock and transduced cells). This trend for greater tumour control by transduced T-
cells that increases with time implies that had the experiment ran for longer, statistically 
significant differences in tumour sizes would have been observed.    
5.4.2 Limitations of model 
There are certain limitations that are recognised with mouse models, and these need to be 
taken into consideration when interpreting results. Firstly, there are inaccuracies with 
injection of cells. IV injection of material is technically challenging; If any of the sample is 
not injected into the vein the mice will receive a reduced dose of T-cells, which could affect 
the results [330]. Similarly, IP injections need to be accurate, to prevent injected cells 
entering the intestine or the bladder [331]. If this happens injected cells would be excreted, 
leaving mice with different T-cell numbers. For the work performed here highly experienced 
technicians were employed to inject T-cells IV and I injected LCLs IP only after sufficient 
training and practise.  
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Intravital bioluminescent imaging is a useful tool in the analysis of cells in mice. As cells 
transduced with luciferase emit light after the introduction of luciferin, signals can be 
quantified. This is less subjective than measuring tumour sizes by caliper. However, the depth 
of the tumour must be taken into consideration. Mouse tissues quench bioluminescent 
emission signals from luciferase transduced cells and so the same signal can appear stronger 
if the cells are closer to the skin and weaker if the cells are more internal [332].  However, 
signal increases or reductions can be compared accurately in the same mouse at different time 
points. 
5.4.3 Future work 
As time constraints only allowed for preliminary in vivo work, there are many future 
experiments that could be performed here to gain a better understanding of the function of 
PRS-TCR transduced T-cells in vivo.  
Firstly, it would be beneficial to perform a dose escalation study to determine if anti-tumour 
effects could be seen if more genetically engineered T-cells were administered. In the final 
experiment performed here which looked at the anti-tumour response of PRS-TCR 
transduced T-cells, a total of 2.25x106 transduced T-cells were infused. Many clinical trials 
aim to infuse between 1010-1011 T-cells, which equates to approximately 2x107 for a 20g 
mouse. Therefore we could perform a dose escalation study, increasing the number of infused 
genetically engineered T-cells nearly tenfold. However because the transduction efficacy in 
this experiment was 15%, to do this here we would have needed to infuse many more than 
2x107 T-cells per mouse to reach this number of PRS-TCR transduced T-cells. This would 
make GvHD more likely and could results in GvHD occurring quicker.  
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To overcome this, we would need to use cells that are more efficiently transduced. Previously 
we have had transduction efficiencies of 35%, which would be beneficial here. Alternatively,  
transduced T-cells could be sorted to obtain a pure population, using an anti-Vβ17 antibody 
followed by magnetic separation or fluorescence activated cell sorting (FACS).  
In this experiment we were also limited by the amount of blood that we had available as a 
source of T-cells; we were only able to take up to 200ml of blood from a healthy donor. To 
obtain more T-cells, buffy coats could be used, which often contain more than a billion T-
cells.  However the disadvantage of this is that many products would need to be collected and 
tested to find one which is DR52b positive and EBV negative, and then LCLs from that cone 
would need to be generated and transduced with luciferase. This would be a time consuming 
process, and was not possible here due to time constraints. 
Additional future work to evaluate the longer-term anti-tumour effect of PRS-TCR 
transduced T-cells against LCL targets could use a mouse model   that is not limited by 
GvHD, such as humanised mice. New-born NSG mice can be injected with human HSCs 
from DR52b positive donors, which develop in the mice to produce humanised immune 
systems. T-cells could be isolated from spleens of humanised mice such as these to use as a 
transduction source. This would prevent GvHD, as the T-cells have been tolerised to mouse 
proteins during development [333].  Figure 5.10 shows that transduced T-cells have superior 
anti-tumour responses over mock T-cells.  By using a humanised mouse model the 
experiment could be extended to test the hypothesis that this anti-tumour effect would reach 
significance with extended time. 
It would be interesting to track the infused T-cells in vivo using, for example, T-cells 
transduced with a luciferase construct. Luciferase is derived from multiple sources such as 
fireflies, sea pansies or bacteria. Different sources emit different bioluminescent lights and so 
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could be used in combination within one mouse to track both T-cells and tumour cells [334]. 
It would be interesting to see if the infused T-cells contact the tumour. 
Finally, the differentiation status of transduced T-cells could be investigated. It is possible 
that transduced T-cells are more efficiently activated during the transduction procedure than 
non-transduced T-cells and therefore could enter a replicative senescent state quickly in vivo, 
limiting tumour control. Indeed, more differentiated effector T-cells have been shown to be 
less effective at tumour control in vivo [335]. Transduced T-cells could be phenotypically 
characterised in vitro before infusion into mice and during the experiment by isolating T-cells 
from tail bleeds. If transduced T-cells were characterised as terminally differentiated effector 
cells, efforts to reverse this phenotype could be employed. T-cells cultured in vitro in media 
containing IL7, IL12 and IL21 have been shown to revert to a less differentiated phenotype 
[336]. Therefore these cytokines could be utilised in culture prior to T-cell infusion to delay 
terminal effector differentiation. Johannessen et al. have investigated the use of IL7 and IL15 
in culture media prior to the infusion of EBV-CTLs into SCID mice which have been injected 
with LCLs. The group demonstrated that mice which received CTLs cultured in this media 
survived longer than mice which received CTLs cultured in media which contained IL2 alone 
[325]. However the phenotype of the T-cells was not investigated, nor was the reason for the 
increased survival.  
5.4.4 Conclusion 
In conclusion, preliminary in vivo work performed here indicates that there may be tumour 
control by PRS-TCR transduced T-cells. These experiments require repeating and further 
optimisation, ideally infusing more engineered T-cells per mouse, to determine if the PRS-
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specific TCR is capable of producing effective T-cell responses to control tumour outgrowth 
in vivo. 
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6 Discussion 
TCR gene transfer is a form of immunotherapy that produces a specific immune response 
against a known target antigen. It has been designed for the treatment of multiple cancers and 
has shown promise in clinical trials [117, 139, 141]. This thesis focuses on TCR gene transfer 
for the treatment of EBV associated malignancies. As EBNA2 was identified in the majority 
of PTLD biopsies analysed here, and the EBNA2 derived epitope PRS is presented at high 
levels by MHC class II, TCRs against this epitope were isolated. A highly avid PRS-specific 
TCR was cloned, transduced into PBMCs and these transduced cells were shown to have 
therapeutic promise in vitro. This ‘therapeutic promise’ was demonstrated by the ability of 
the transduced T-cells to recognise and respond to target T-cells in a variety of assays. 
Preliminary in vivo studies showed that transduced T-cells most likely function to control 
tumour growth, however future work needs to be performed to optimise experiments in order 
to confirm this.  
Here I will discuss the advantages of harnessing the CD4+ T-cell response for cancer therapy 
and in particular, the advantages of using MHC class II restricted TCRs in this T-cell subset.  
Additionally I will discuss further optimisation of TCR gene transfer therapy in the context of 
EBV associated malignancies. Finally, I will consider how TCR gene transfer therapy is 
likely to progress in the future. 
6.1 PTLD treatment options 
PTLD is a life threatening consequence of both HSCT and SOT. The current standard of care 
is Rituximab. As previously described, rituximab depletes all mature B-cells by targeting 
CD20. Response rates to this therapy are between 42%-70%, and so it is clear there are a 
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number of patients who do not respond. Furthermore, responders often relapse and this is 
associated with a high rate of mortality [213, 214, 218].  To overcome this, EBV specific 
CTLs are being investigated for the treatment of PTLD patients, with 51-67% overall 
response rates across a number of clinical trials [228]. Production of donor derived EBV-
CTLs is time consuming and consequently third party EBV-CTLs are being generated, stored 
and given to partially HLA matched PTLD patients.  
As not every patient will respond to Rituximab or EBV specific CTLs, other forms of salvage 
therapy are required. Transducing T-cells with an EBV specific TCR not only provides an 
additional therapeutic option for PTLD patients but it could do so cheaper than the EBV 
specific CTL alternative. Currently CTLs are generated and stored for long periods of time. 
This is costly and labour intensive and TCR gene therapy could overcome this. In addition, 
TCR gene transfer is an autologous therapy and so negates the risk of GvHD that is 
associated with adoptive transfer of third party EBV specific CTLs.   
6.2 The anti tumour responses of CD4+ T-cells 
CD4+ T-cells have been shown to be important in anti-tumour immunity. In a trial using 
EBV specific-CTL for the treatment of PTLD, a positive correlation was observed between 
clinical response and the frequency of CD4+ T-cells in the infused product [229]. 
Additionally, a T-cells product generated from TILs of which 95% of cells were CD4+ T-
cells specific for a patient tumour-specific mutation resulted in tumour regression [81].  
Furthermore, Merlo et al. have investigated the anti tumour effects of CD4+ versus CD8+ 
EBV specific-CTLs in a mouse model of human PTLD. Here, they found that CD4+ T-cells 
have therapeutic activity, even in the absence of CD8+ T-cells [323]. This CD8 independent 
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effect could be due to recruitment of other immune cell types, or could be a result of direct 
effector function of the CD4+ T-cells against the tumour. 
As CD4+ T-cells can orchestrate a broad immune response and be directly cytotoxic, 
harnessing the response from this T-cell subset could be therapeutically beneficial. 
Harnessing the CD4+ T-cell response to EBV derived antigens is particularly useful, as 
CD4+ T-cells can directly recognise infected B-cells. This is due to endogenous viral 
antigens accessing the MHC class II pathway by mechanisms including autophagy, 
intercellular antigen transfer and other, as yet undefined pathways [33, 35].  We have shown 
here that CD4+ T-cells are capable of recognising physiological levels of antigen and 
responding by producing multiple cytokines, proliferating, maturing DCs and by killing 
target T-cells. These responses are all indicative of anti-tumour effects. 
6.3 Transducing CD4+ T-cells with MHC class II restricted TCRs 
6.3.1 Targeting MHC class II restricted antigens 
one advantage of targeting MHC class II presented epitopes, is that tumours that have 
selectively down-regulated MHC class I as a form of immune evasion could be treated. It has 
been reported that 40-90% of human tumours down-regulate MHC class I, with the total 
number of MHC class  I negative tumour cells within one biopsy being as high as 90% [57, 
337, 338]. MHC class I loss can be reversible or irreversible, depending on the cause of the 
down-regulation. For example, loss of heterozygosity results in irreversible MHC class I loss 
whilst epigenetic modifications are reversible and can be treated with immunomodulatory 
cytokines such as IFNγ  [57, 339, 340].  
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6.3.2 EBV-associated down-regulation of antigen presenting machinery 
EBV has been associated with down regulation of several genes involved in MHC class I 
antigen presentation in NPC [341]. Although the EBV protein responsible for the loss of 
MHC class I antigen presentation genes in the context of NPC has not been elucidated, 
certain lytic proteins have been described as disrupting MHC class I antigen presentation.  
The late lytic protein BNLF2a has been described as preventing antigen presentation through 
MHC class I. BNLF2a  prevents binding of peptides to TAP, which results in the inhibition of 
T-cell responses to immediate early and early lytic stage proteins [342]. Viral IL10 down-
regulates TAP, reducing the quantity of peptides which are transported into the ER [343]. 
BGLF5 is an exonuclease which degrades host cell mRNA. As MHC class I and TAP 
transcripts are degraded, fewer MHC class 1 molecules are produced [344, 345]. BILF1 
enhances MHC class I endocytosis and subsequent lysosomal degradation [346]. As many 
MHC class I restricted CD8+ T-cells are specific for immediate early and early EBV lytic 
antigens, EBV infected cells become protected from some CD8+ T-cell recognition[153]. 
There is limited evidence that EBV down-regulates MHC class II. LMP2a and BZLF1 have 
been reported to be able to down-regulate MHC CLASS II [347, 348]. However both LMP2a 
and BZLF1 are expressed (constitutively and sporadically, respectively) in LCLs, and CD4+ 
T-cells are able to respond to LCLs [153]. This suggests that any MHC class II down 
regulation by EBV is not sufficient to completely prevent T-cell responses. In addition, 
Stopeck et al. and Merlo et al. have shown that 94% of DLBCL cases (n=71) and 100% of 
PTLD cases (n=12) were MHC class II positive, respectively [323, 349]. Importantly, the 
results we have from PTLD biopsy staining suggest that MHC class II is still expressed on 
tumour cells when BZLF1 is expressed. Where studied, EBV associated malignancies 
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maintain MHC class II and therefore immune evasion from CD4+ T-cells by this method is 
unlikely.  
6.3.3 Limitations of transducing MHC class I restricted TCRs into CD4+ 
T-cells 
Transducing CD4+ T-cells with an MHC class II restricted TCR not only provides a 
therapeutic option for the treatment of tumours which have down-regulated MHC class I, but 
could also result in superior CD4+ T-cell responses, compared to if CD4+ T-cells were 
transduced with an MHC class I restricted TCR.  
Although MHC class I restricted TCRs have been shown to be functional in CD4+ T-cells, 
producing IL2 and IFNγ in response to target T-cells, the functional avidity is often lower 
than that of CD8+ T-cells transduced with the same TCR, suggesting a level of CD8 
dependence [237]. Here we have observed that CD8+ T-cells have a lower functional avidity 
than CD4+ T-cells when transduced with the same, MHC class II restricted TCR, supporting 
this concept of co-receptor dependence.  
Co-transduction to express the CD8 molecule has been performed to rescue the lower 
functional avidity of CD4 + T-cells transduced with a MHC I restricted TCR [237]. However, 
due to the limitations of the amount of DNA which can be incorporated into one recombinant 
viral vector, co-receptors have to date been engineered into separate vectors [237]. GMP 
grade vectors are costly and therefore the addition of another vector to therapy would be 
expensive. Another consideration is that many more cells would need to be transduced to 
achieve the required number of co-transduced cells as the process will be less efficient. 
Furthermore there are already a number of other gene modifications proposed to improve 
safety and/or efficacy and so co-transductions may be better ‘reserved’ for these genes. 
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Transducing CD4 T-cells with a class II-restricted TCR overcomes this problem. Transducing 
CD4+ T-cells with an MHC CLASS II restricted TCR harnesses the optimal CD4+ T-cell 
response to tumours, whilst providing additional, MHC class II restricted targets.  
6.4 Target Selection 
6.4.1 Viral Antigens 
Currently, identifying good epitope targets is limiting TCR gene therapy. Finding a target that 
is a) specifically expressed on tumour cells, b) shared between patients and c) required for 
cell survival and/ or proliferation and so unlikely to be ‘lost’ in order to escape immune 
destruction is a huge challenge.  
Targeting viral antigens minimises on target off tumour toxicity as only EBV infected cells 
will express the target antigen, and these are infrequent, with only 1 in 10,000-50,000 
circulating mature B-cells are infected [242].Therefore treating EBV associated malignancies 
by TCR gene transfer would remove the toxicities related with the current standard of care, 
Rituximab. Rituximab targets CD20, and consequently results in the destruction of all B-
cells, regardless of their EBV status.  
Additionally, viral epitope specific T-cells often have high avidity TCRs as they are not 
deleted during thymic tolerance. TCRs specific for shared tumour specific “self”-antigens are 
generally of weak avidity [350]. Whilst the avidity of these self-antigen-specific TCRs can be 
enhanced, for example by affinity maturation, there are safety concerns regarding the 
specificity of such manipulated TCRs [144].  
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6.4.2 EBNA2 
One of the advantages of TCR gene transfer therapy is that it can be used in an ‘off the shelf’ 
manner, once TCRs against specific epitopes have been isolated. In order for such ‘off the 
shelf’ therapy to be clinically useful, it must have the ability to treat multiple patients. 
Therefore, epitope targets that are shared between patients must be identified. More than 
200,000 cancers per annum are EBV associated and as such, EBV proteins are ideal targets 
for TCR gene transfer [351]. What’s more, many EBV proteins are very immunogenic and as 
such, highly avid TCRs can be isolated. Specifically, EBNA2 is expressed in 75% of PTLDs 
tested here, 44% of AIDs related lymphomas and 28-32% of EBV positive DLBCLs, which 
are all MHC class II positive [247, 252, 267, 323, 349, 352]. Importantly, EBV has recently 
been identified as being present in malignancies previously thought to be EBV negative. 
These include up to 10% of gastric and an as yet an undefined percentage of breast cancers 
[353, 354]. Although the expression of EBNA2 is as yet unknown in these cancers, it is 
conceivable that in the future further EBV-associated tumours such as these may be identified 
that might be targeted.  
6.4.3 Alternate MHC class II restricted antigen targets for the treatment of 
PTLD  
As we have shown through immunohistochemistry, most PTLDs express EBNA2. Therefore 
many PTLD patients would benefit from a TCR gene transfer therapy that targets EBNA2 
derived antigens. The PRS epitope is an ideal immunotherapy target as it is expressed at high 
enough levels on tumour cells for direct recognition by CD4+ T-cells [189].  Additionally, it 
is presented through a common HLA allele and so the number of patients that can be treated 
with this TCR is wide ranging.  
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However not all PTLD patients express EBNA2 and expression is limited in DLBCL and 
AIDs related lymphomas. Therefore targeting additional EBV proteins would provide a 
therapeutic option for a wider range of patients. Additionally, patients with the type 2 strain 
of EBV, Ag876, would not be able to be treated with this PRS-specific TCR, as this epitope 
is not present in this EBV strain. Although type 1 EBV is most common worldwide, the 
Ag876 EBV strain is just as common in sub-Saharan Africa [258]. Furthermore, as DR52b is 
present in approximately 40% of the Caucasian population, it would be beneficial to isolate a 
TCR against an epitope presented through a different HLA allele, in order to increase the 
percentage of patients who could be treated. 
Currently there are few known MHC class II restricted antigens in comparison with those 
which are MHC class I restricted. However the importance of this T-cell subset in anti-
tumour immunity is beginning to be realised, and efforts are currently on-going to identify 
more MHC class II restricted targets.    
Several EBV latent protein derived epitopes that are presented through common class II HLA 
alleles have now been identified, including the EBNA1 epitope (TSL), the EBNA3c epitope 
(SDD) and the EBNA2 epitope (PAQ) [189]. T-cells against these targets have been shown to 
directly recognise naturally infected B-cells and therefore these are candidate epitopes for 
further analysis. They are presented through HLA DR103, HLA DQ5 and HLA DR14, 
respectively [189]. The www.allelefrequencies.net  website shows that DR103 is present in 
low frequencies in the majority of world populations studied. DQ5 is present in over 50% of 
Chinese and Serbian populations and high in other populations. DR14 is present in a low 
frequency of the majority of the world populations investigated but is present in a high 
percentage of the Taiwanese population. Therefore cloning these TCRs could be particularly 
useful for different populations. 
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Additionally, epitopes derived from EBV lytic proteins have been shown to be recognised by 
CD4+ T-cell clones. Although lytic cycle protein expression is sporadic, these antigens are 
transferred between neighbouring cells to be presented through MHC class II. Therefore 
antigen negative tumour cells can be targeted for destruction by CD4+ T-cells when antigen 
is transferred from tumour cells expressing lytic proteins [188]. As we have shown in the 
PTLD biopsies analysed here, BZLF1 is expressed in some tumour cells, and so work could 
be continued on the isolation of BZLF1 specific TCRs for the treatment of PTLD.  
Interestingly, Long et al have described CD4+ T-cell clones isolated from EBV seronegative 
people, which respond to LCLs and a range of tumour cell lines. The clones produce IFNγ in 
response to target T-cell lines and also have direct effector responses, killing target T-cells in 
both short and long term assays. Recognised tumour cell lines include HLs, BLs, follicular 
lymphoma, T-lymphoma and multiple myeloma. The target epitopes were not from EBV lytic 
or latent proteins and so considered to be of cellular origin.  Whilst the specific target 
epitopes of these T-cells are still under investigation, the clones did not respond to a panel of 
autologous non-transformed cell lines (activated B-and T-cells and DCs), indicating that the 
target epitopes may be up-regulated or only expressed in transformed cells [329]. Similarly, 
Linnerbaur et al have identified CD4+ T-cell clones with unknown specificities [236]. They 
too found CD4+ T-cell clones which produced cytokines and cytolytic responses towards 
LCLs and did not appear to be restricted to any EBV antigens. If the epitopes are identified 
and shown to be not expressed in other healthy tissues, TCR gene transfer with the TCRs 
from these clones could provide a therapy for the treatment of a wide range of lymphomas. 
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6.5 Future MHC class II restricted TCR gene transfer targets 
(general) 
For MHC class II restricted target selection of a broader range of tumours, Sahin et al have 
used next generation sequencing of tumours to identify patient specific neo-antigens, which 
are predicted to be processed and presented in MHC class I and II. Neo antigens were 
identified in all cancers analysed; namely melanoma, colon and breast cancer. Interestingly, 
80-90% of predicted neo-antigens were recognised by CD4+ T-cells [355]. In mouse studies, 
vaccinating against neo-antigens present in melanoma, colon and breast cancer cell lines 
show that CD4+ T-cells are capable of controlling tumours and prolonging mouse survival. 
Through epitope spreading, this CD4+ T-cell response can also lead to induction of CD8+ T-
cell responses. Not only does this work highlight the anti-tumour effects of CD4+ T-cells but 
it provides evidence that there are a large number of MHC class II restricted antigens which 
could in the future be used for TCR gene transfer therapy.  
Shared mutations would need to be identified for TCR gene transfer therapy at present; 
however the future may provide the technological advancements needed to treat patients 
individually, according to their specific neo-antigens. 
6.6 TCR gene transfer optimisation to treat EBV associated 
malignancies 
TCR gene transfer has shown clinical success in some settings. There has however, been 
much work to further optimise this approach. Here I will discuss ways in which TCR gene 
transfer for the treatment of EBV associated malignancies could be further improved.  
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6.6.1 Resistance to Immunosuppression 
In the context of transplant patients, it would be beneficial to engineer T-cells to render them 
resistant to immunosuppression. Transplant patients receive immunosuppression to prevent 
graft rejection, and this treatment could inactivate or delete infused T-cells, preventing 
therapeutic effects. Generating immunosuppression resistant T-cells has been achieved in 
pre-clinical studies. Riciardelli et al have shown that T-cells can be successfully engineered 
with a calcineurin mutant to render them resistant to the immunosuppressive drug tacrolimus 
[232]. By engineering T-cells in this manner, transplant patients could be administered T-
cells without compromising the levels of immunosuppression given. As reduced 
immunosuppression often results in graft rejection, this could be prevented. The group have 
developed a strategy to rapidly engineer EBV-CTLs to be tacrolimus resistant and this 
therapy will be tested in a clinical trial [231, 232].  
6.7 General TCR gene transfer optimisation 
6.7.1 T-cell differentiation  
The differentiation status of infused T-cells has been shown to have an effect on anti-tumour 
responses. Conventionally, T-cell based immunotherapies have relied upon in vitro expansion 
of antigen specific target T-cells, or T-cell activation for successful transduction. Activating 
and expanding T-cells drives their differentiation into a terminal differentiated effector 
phenotype. These cells have been shown to have limited persistence, limiting their 
therapeutic effectiveness. Therefore efforts have gone into determining the ideal T-cell 
phenotype for immunotherapy and the generation and/or maintenance of such phenotype.  
Naive T-cells have been shown to have great therapeutic potential, as they have a high 
proliferative capacity and have a survival advantage over effector cells [356]. Frumento et 
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al. have used cord blood T-cells as a source of naïve T-cells and report that cord blood 
derived T-cells transduced with an EBV specific TCR maintained a less differentiated 
phenotype and longer telomeres than transduced T-cells derived from adult blood [241]. 
The limitation of this approach is that cord blood T-cells are not autologous and so could 
theoretically cause GvHD. 
The functional benefit of adoptively transferring stem cell memory T-cells (Tscm) has been 
demonstrated. In animal studies Tscm have been shown to expand better than any other T-
cell subtype and persist even in the absence of antigen [357, 358]. Interestingly, 
experienced T-cells can be reverted back to Tscm cells. Telomere lengths in these reverted 
T-cells have been shown to be long, and the cells can expand better than effector cells, do 
not express exhaustion markers and are more cytotoxic [359]. It is likely that future trials 
with adoptively transferred T-cells will aim to induce Tscm phenotypes. 
Whilst transduction of multiple genes is required to generate induced Tscm T-cells, the 
generation of other T-cell phenotypes is much simpler [359]. The in vitro conditions in which 
T-cells are cultured affect the T-cell differentiation status. IL15 and IL7 have been proven to 
enhance T-cell survival by maintaining a more naive phenotype, and IL21 has been used in 
combination with IL15, and has been shown to synergistically enhance T-cell effector 
functions [360, 361].   
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6.7.2 Combinational therapy 
The clinical successes of checkpoint blockade inhibitors, including anti-PD1 and anti-CTLA4 
monoclonal antibodies, has taught the field much about anti-tumour responses. Firstly, 
success of these therapies highlights the power of the immune system when inhibition is 
removed. Secondly, as the types of tumours which are treated with these therapies are 
constantly increasing, they have emphasised how many tumours employ such immune 
suppressive techniques. Interestingly, the biggest successes with these therapies occur in 
tumours with high mutational loads, such as melanoma and NSCLC [362, 363].  This shows 
that many patients with these tumours have T-cells which are able to target them; however 
they are not able to function in the face of such suppression. Combination therapy of PD1 
blockade and TCR gene transfer therapy may be advantageous to enhance activity of the 
transferred T-cells in immunosuppressive tumours. 
Indeed, by combining PD-L1 blockade with adoptive T-cell therapy in a mouse squamous 
cell carcinoma model, Strome et al have demonstrated a synergistic effect, with a survival 
advantage observed in mice which received both T-cells and anti PD-L1 [364]. In addition, it 
has been shown that by blocking PD1, T-cells have enhanced ability to migrate to the tumour 
in a chemokine dependent mechanism [365]. Most importantly, Abate-Daga et al have 
analysed the phenotypes of T-cells that have been transduced with tumour specific TCRs and 
administered to patients with melanoma. T-cells were isolated from peripheral blood samples 
one month after infusion and a gene array was performed, to compare the phenotype of these 
T-cells with the pre-infusion product. Results showed that of 511 immune related genes 
analysed, 156 were differentially expressed following infusion. Specifically, PD1 was up-
regulated. This up-regulation correlated with reduced IFNγ production when cells were co-
cultured with PD-L1 positive target T-cells, compared to  the response observed from pre-
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infusion T-cells [366]. There is currently a trial on-going which will look at the combination 
of anti-CTLA4 blockade and autologous tumour specific CD8+ T-cells for the treatment of 
metastatic melanoma (NCT02027935). 
In the context of PTLD, some EBV positive cases have been shown to be PD-L1 positive by 
IHC (19/26 cases) [328]. Additionally, 27-100%  EBV+ DLBCL samples have been shown 
by IHC to express PD-L1 and 28% AIDs related lymphomas [367, 368]. Together, this 
suggests that at least some patients with these malignancies may benefit from combinational 
therapy combining TCR gene transfer and PD1 or PD-L1 blockade.  
Further combination therapies are being investigated in pre-clinical and clinical studies, with 
emphasis on combining chemotherapy with immunotherapy. Chemotherapy is used routinely 
prior to adoptive T-cell therapy for lymphodepletion. This creates ‘space’ in the 
hematopoietic system for expansion of transferred T-cells by homeostatic proliferation, 
increasing the amount of activatory cytokines available to the transferred T-cells and 
removing suppressive T-cells  [369].  
Other than creating a T-cell proliferative environment, chemotherapy has been shown to 
enhance T-cell responses through additional mechanisms. For example, consistently giving a 
low dose of cyclophosphamide  to end stage, chemotherapy resistant patients, selectively 
suppresses and depletes Tregs without affecting other immune cells [370]. Through this 
action, T-cells and NK cells proliferate and function more effectively [371]. In addition, 
gemcitabine can eliminate immunosuppressive myeloid derived suppressor cells (MDSCs), 
without inhibiting other immune cells [372]. Importantly for CD4+ T-cell mediated 
immunotherapy, Ding et al have highlighted the effects of chemotherapy on this T-cell 
subtype. The group administered a single dose of cyclophosphamide to B-cell lymphoma 
bearing mice, before transferring tumour specific CD4+ T-cells. This pre-treatment prevented 
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PD1 expression on CD4+ T-cells and resulted in improved cytokine production, proliferation 
and anti-tumour immunity, compared to control mice [373]. As some PTLDs have been 
shown to express PD-L1, combination therapy of chemotherapy and TCR gene transfer to 
target PTLD could be beneficial.  
Finally, as TCR gene transfer provides T-cell responses against individual epitopes, 
combining TCR gene transfer therapies could be investigated. This would reduce the risk of 
the therapy failing due to epitope loss. EBNA3b has been reported to be mutated in a patient 
following EBV-CTL infusion for the treatment of PTLD. The mutation was a deletion, of 
which the deleted region contained two CTL epitopes. As these two epitopes were the 
predominant target of the infused T-cells in this patient, the CTLs were less responsive to the 
tumour. The result of this deletion was that EBNA3b mutated tumour cells continued to 
proliferate and tumour progression resulted in patient death [374]. We have not investigated 
epitope loss as part of this work but future work could address this. If any tumours remain in 
mice after treatment with PRS-TCR transduced T-cells, they could be resected and analysed 
by IHC for EBNA2 expression in the tumour cells. This could be compared to results 
obtained from mice treated with mock transduced T-cells to demonstrate if antigen loss 
occurred. Ex vivo tumours could also be sequenced to determine if the PRS epitope is present 
in the tumour sample, or if, like the case of EBNA3b mutation, this critical region is lost in 
order to escape immune response. 
Additionally, by combining MHC class I and MHC class II TCR gene transfer therapies, 
optimal CD4+ and CD8+ T-cell responses could be harnessed. Our group has previously 
generated a HLA A11 restricted LMP2 TCR that was shown to function effectively in vitro 
and in vivo, producing cytokines and cytotoxic responses to target T-cells [235]. This could 
be used in combination with the TCR described here to investigate if targeting epitopes from 
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different proteins with different HLA restrictions results in an improved anti-tumour 
response. It has been noted by others that when anti-tumour CD4+ T-cells are functional in 
vivo, they mediate epitope spreading [355]. If CD4+ T-cells transduced with a PRS specific 
TCR could mediate epitope spreading, non-transduced T-cells could be activated and aid 
tumour clearance, even in the face of epitope loss.  
6.8 Future Developments in TCR gene transfer therapy 
6.8.1 Targeting non-hematopoietic tumours with MHC class II restricted 
TCRs 
MHC CLASS II is constitutively expressed in professional APCs.  MHC class II can be 
conditionally expressed in other cell types. As such, MHC class II restricted TCRs may in the 
future be used to treat tumours which are classically MHC CLASS II negative. MHC class II 
expression can be induced with IFNγ [375-377]. However all patients treated systemically 
with IFNs have suffered fever, chills, tachycardia, malaise and headaches. In addition, 
gastrointestinal symptoms, neurotoxicities and hematologic toxicities are common [378]. 
Therefore several ways to limit these toxicities have been explored. 
Zhang et al have transduced TIL products with a plasmid containing an inducible cytokine, 
IL12 [379]. Expression of these cytokines is dependent upon NFAT signalling, as NFAT 
response elements are contained within the promoter. When transduced cells are activated 
through TCR signalling, NFAT is expressed and the expression of the co-transduced cytokine 
is induced. This selective cytokine expression overcomes the limitations of systemic cytokine 
administration. A phase I clinical trial treated metastatic melanoma patients with TILs 
transduced with this construct has shown that 10/16 patients achieved short lived objective 
responses [380]. However, at doses greater than 3x109 cells, serious adverse events were 
CHAPTER 5  Discussion 
219 
 
recorded. Toxicities included liver dysfunction, fever and hemodynamic instability.  As T-
cells are being administered to patients pre-conditioned by chemotherapy and irradiation, 
there is space for T-cell homeostatic proliferation. NFAT drives T-cell proliferation, and so it 
is conceivable that NFAT is activated during homeostatic proliferation, leading to systemic 
expression of IL12 [381, 382]. 
An alternative method to selectively up-regulate cytokines in the microenvironment of solid 
tumours would be to induce expression in hypoxic regions. Due to disrupted angiogenesis in 
solid tumours, hypoxia is common [383]. This hypoxia could be harnessed therapeutically by 
generating a construct which contains a cytokine that is expressed when HIF is up-regulated, 
by engineering HRE repeats into the promoter. HRE driven gene expression has been 
performed by Dachs et al and shown to work effectively [384]. As part of this thesis I 
commenced work to generate such construct to drive the expression of IFNγ and other 
cytokines, after confirming by western blot that HIF is up-regulated in T-cells in hypoxic 
conditions. However, due to technical challenges and time limitations, this work was 
discontinued. 
6.9 Large Scale Production of T-cell products 
Engineering of T-cells has shown unprecedented success in phase I clinical trials, with 
clinical responses observed in advanced cases that have failed conventional treatments. 
Nevertheless, current approaches are complex and costly to deliver. Therefore, there is 
currently much interest in making this approach more widely available. Importantly, 
technological advancements have allowed for widespread use of cell products for HSC 
transplants and so there is no reason why advancements within T-cell therapy will not happen 
over the next few years. Indeed, much technological advancement in T-cell manufacturing 
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has already occurred. That pharmaceutical industries are showing interest in CARs hints that 
genetically engineering T-cells for adoptive therapy is now considered feasible and likely to 
enter mainstream cancer therapy. 
6.9.1 T-cell manufacturing 
To minimise the amount of handling of T-cells, G-REX flasks and WAVE bioreactors are 
now commonly used for generating T-cells to treat patients [385]. These flasks allow for 
rapid expansion of T-cells and media is continually perfused in a closed environment, 
complying with Good Manufacturing Practice (GMP) regulations [386]. T-cells are still ficoll 
separated from PBMCs in open systems, and so a process in which T-cells can be obtained 
from peripheral blood and cultured ex vivo in a fully closed system is desirable.   
If gamma retroviruses are being used, sTable virus producing cell lines are amplified in bulk 
and one virus stock can be harvested for up to three days. On the other hand, lentivirus 
production is more complicated, as sTable lentivirus producing cell lines are difficult to 
generate. Additionally, the removal of cellular contaminants after virus production and the 
concentration of virus whilst maintaining potency is complicated[387].   
To minimise the number of highly skilled workers and specialised laboratory facilities 
required to generate these T-cell products it is more efficient to use specialised centres for 
manufacturing and then ship the T-cell product to the patient. A similar approach has already 
been used successfully with third party EBV-CTLs for the treatment of partially HLA 
matched PTLD patients [212, 230, 388].  
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6.9.2 Universal T-cells 
TCR gene transfer is complicated by the need to use patients own T-cells, as isolating 
individual patient T-cells is labour intensive.  In an attempt to generate an ‘off the shelf’ 
approach, ‘Universal T-cells’ are currently under investigation. Like 3rd party EBV-CTLs, 
these would be generated and stored for use in an allogeneic recipient. As well as negating 
the need to isolate T-cells from each patient, universal T-cells could be prepared in bulk, 
removing the complexity of individual T-cell preparation and reducing waiting times for 
therapy. This would make the T-cell preparation and manufacturing process cheaper and 
simpler. Endogenous TCRs are knocked down by zinc finger nucleases in  ‘Universal T-cells’ 
to prevent GvHD and improve exogenous TCR expression and pairing [389]. Furthermore, 
HLA genes are being knocked down to prevent poor T-cell persistence due to graft rejection 
[390].  Such HLA negative T-cell could generate NK responses, and so to overcome this, non 
classical HLA expression could be enforced in these cells [391].  
6.9.3 Cost 
A significant barrier to the wider application of T-cell therapies is cost. As discussed, 
preparation of therapeutic cell products is complex and cell products are currently produced 
as patient-specific products. This will clearly result in high preparation costs, but whether 
these costs are higher than the costs of conventionally generated molecular products is 
questionable. The cost of TCR gene transfer therapy has been estimated to be $15,000 - 
$25,000 per patient [392]. Whilst this estimation does not include overhead and rental costs, 
it is clearly much less than some FDA approved monoclonal antibodies. For example, 
Ipilumumab costs over $100,000 per year per patient, and has shown limited responses [393].  
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Costs could be reduced in the future by transducing cells by non-viral means rather than with 
retro-or lentiviruses. The DNA plasmid Transposon-transposase systems such as Sleeping 
Beauty are electroporated into target T-cells require GMP grade plasmids rather than viruses 
and can accordingly be produced and purified easily and relatively cheaply [136]. Also they 
can carry up to 10 kilo-base pairs of DNA. This is far more than a virus could carry and as 
such, these transposon systems could transfer multiple genes in one plasmid [136]. This 
would make significant cost savings by avoiding the need for multiple vectors.  However at 
present transduction is inefficient using these systems so further development is required 
before they replace virus-based systems [138]. 
6.10 Conclusion 
This thesis investigates the therapeutic potential of MHC class II restricted TCR gene transfer 
for the treatment of PTLD and other EBV associated malignancies which express EBNA2. 
CD4+ T-cells which recognised the EBNA2 derived antigen PRS, or the BZLF1 derived 
antigen LTA, through the common MHC class II allele, DR52b, were isolated and cloned. 
Clones were subjected to a range of assays to determine which had the greatest potential to be 
effective therapeutically. After testing CD4+ T-cell clones for their response to epitope 
peptide and target T-cells expressing naturally processed and presented antigen, promising 
clones were selected for further analysis. The clone with the highest functional avidity that 
was confirmed to be restricted through DR52b and proven to be monoclonal was selected for 
TCR isolation. Here, BZLF1 specific TCRs were dropped as no T-cell clone identified in this 
body of work was suiTable for continuation. Specifically, only one LTA specific clone 
expanded to sufficient levels for in vitro functional analysis, and this was shown to be 
oligoclonal by DR52b-LTA tetramer staining.  
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Focus thus shifted onto the therapeutic potential of the PRS specific TCR which was isolated 
from the selected CD4+ T-cell clone (clone 93) and transduced into healthy donor PBMCs. In 
vitro functional studies of transduced CD4+ and CD8+ T-cells showed that the TCR genes 
were translated, alpha and beta chains paired correctly and the introduced TCR complex was 
efficiently trafficked to the cell surface.  Transduced cells had a high functional avidity, 
which was similar to the functional avidity of the parent clone. Interestingly, CD4+ T-cells 
had a higher functional avidity than CD8+ T-cells, suggesting a degree of CD4 co-receptor 
dependency. CD4+ T-cells maintained their helper function, as was evident by their ability to 
mature DCs. Most importantly, transduced T-cells were able to recognise target T-cells 
expressing physiological levels of antigen and responded by proliferating, producing multiple 
cytokines and killing.  
In vitro functional studies suggested that the transduced T-cells would be able to control 
tumour in vivo. A mouse model of PTLD was established which comprised of 
immunocompromised mice which were administered LCLs. After four days, mice were 
treated with transduced or mock T-cells. Results hinted that the transduced T-cells have some 
control over tumour growth, yet statistical significance was not consistently reached in these 
preliminary experiments. Unfortunately time constraints limited the in vivo work performed 
here, however future experiments could be set up to more fully investigate the function of  T-
cells transduced with an MHC class II restricted PRS TCR in vivo. 
Finally, the work performed here provides evidence that the transfer of MHC class II 
restricted TCRs is viable and effective. Whilst this work could be continued to prepare such 
therapy for clinical trial for the treatment of PTLD, it also acts as a model for harnessing 
CD4+ T-cell responses. The lessons learned in this system could be applied to any other 
model where stimulating CD4+ T-cell responses would be advantageous.   
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